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Abstract 
Nitric oxide (NO) is a free radical, gaseous molecule that is involved in a vast range of 
biological signalling processes including long term memory formation, neurogenesis, 
vasodilation and inflammation. The molecule is produced by a family of enzymes called 
nitric oxide synthases (NOS). There are three major isoforms of these NO producing 
enzymes, endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS). eNOS is 
constitutively expressed in the circulatory system, while iNOS is inducibly expressed in 
response to cellular invasion by a pathogen. nNOS, which was the isoform targeted in this 
work, is constitutively expressed in the brain and central nervous system, where the NO it 
produces regulates many neurogenic pathways. 
Over activation of nNOS leads to elevated levels of NO in the brain. This has been 
implicated in an array of serious physiological conditions including schizophrenia, 
Alzheimer’s and Parkinson’s disease. Modulation of nNOS over activation therefore 
represents a potential therapeutic avenue for treatment of a variety of debilitating and life 
threatening conditions. 
The field of nNOS inhibition currently focuses almost exclusively on the arginine binding 
site of the rat nNOS isoform of the enzyme. The arginine binding site in rat nNOS does 
differ from that of human nNOS, and as such is not an ideal system with which to study 
human nNOS inhibition. Therefore, this work incorporated computational studies to model 
and examine the binding sites of human nNOS. These included construction and 
verification of a human nNOS homology model. This offered the best option for a detailed 
examination of the protein as no crystal structure of human nNOS was initially available. 
The model was used to screen for novel and selective human nNOS inhibitors. This 
structure based approach was complimented by the use of a ligand based design approach. 
To do this, a pharmacophore was constructed and used for high throughput screening for 
the identification of novel inhibitory compounds. The pharmacokinetic properties of the hit 
compounds were considered, as was their potential selectivity for human nNOS over 
human eNOS and human iNOS. Over 20 million compounds from the Maybridge and Zinc 
databases were screened with the various computational methods, and 72 were chosen for 
biological evaluation. This high throughput in silico screening approach has not been widely 
utilised in the search for human nNOS inhibitors, with only one such study reported. This 
publication did not attempt to biologically evaluate the potential nNOS inhibitors.  
 
 
xv 
 
A functional assay was required to test the compounds identified from the in silico screens. 
This necessitated the recombinant expression of human nNOS, iNOS and eNOS proteins. 
The literature routinely reports rat nNOS, murine iNOS and bovine eNOS to test inhibitory 
compounds, so the establishment of an all human high throughput assay system 
represented a major step forward in the field. Bacterial cells were transformed with the 
DNA sequences for all three human NOS isoforms. The proteins were recombinantly 
expressed and purified from the resulting E. coli lysate. The procedure for human nNOS 
expression was optimised, and the co-expression of human nNOS with human calmodulin 
was achieved. Calmodulin is a vital co-factor for the production of NO from NOS and its co-
expression with human nNOS has not previously been reported. The same approach was 
applied to eNOS and iNOS. The expressed human NOS proteins were then used to establish 
a functional, high throughput NOS assay using the Griess reaction.  
Once established, the assay was used to screen the computationally derived hits for human 
nNOS inhibitory activity. Some hits could be purchased, but many had to be synthesised. 
The synthesised compounds were loosely classified into three classes, i) piperazine 
containing compounds, ii) urea containing compounds and iii) modified arginines and 
thioethers. The high throughput expression/assay system for human nNOS worked well, 
and although no novel inhibitory compounds were identified, it allowed for the testing of 
72 in silico derived compounds. The assay system also allowed for determination of the IC50 
of the non-selective NOS inhibitor, L-NNA.  
This work represents a valuable contribution to the field of nNOS inhibition as it is among 
the first projects to attempt large scale screening for human nNOS inhibitory compounds. 
The projects also succeed in the expression of all three human NOS proteins with human 
calmodulin, and a high throughput expression/assay system was established for human 
nNOS inhibition. Novel compounds were successfully synthesised, characterised and 
evaluated. This work provides a useful roadmap for the future development of human 
nNOS inhibitory compounds, as well as providing an established computational screening 
methodology and a high throughput functional human nNOS assays/expression system.  
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1.1 Nitric Oxide Synthase enzymes: Structure and function 
 
Nitric oxide synthases (NOS) are a family of enzymes that produce the key signalling 
molecule nitric oxide (NO) from L-arginine and molecular oxygen via an N-hydroxy-L-
arginine (L-NOHA) intermediate (Scheme 1.1).1 
 
 
Scheme 1.1 Production of NO from L-arginine and molecular oxygen. 
 
There are three mammalian isoforms of the NOS enzyme, endothelial NOS (eNOS), 
neuronal NOS (nNOS), and inducible NOS (iNOS).2 Endothelial NOS produces NO for use in 
the vascular system where it regulates vasodilation and vascular pressure.3 eNOS has also 
been observed in the lungs and trachea where it modulates ciliary motility and smooth 
muscle relaxation.3 nNOS is localized primarily in the brain and central nervous system 
(CNS). The NO produced by this isoform is used for neurogenesis and regulation of the 
cholinergic, dopaminergic and glutaminergic signalling pathways, among others.4 iNOS 
produces NO in response to infection of host cells by bacteria or other pathogens. This NO 
has been observed to have both pro and anti-inflammatory effects and also some tumour 
suppression activity.5  
All three isoforms exist as homodimeric enzymes, with each monomer consisting of an N-
terminus oxygenase domain and a C-terminus reductase domain.2 These domains are 
connected by a calmodulin binding region (CBR). The oxygenase domain contains a non-
catalytic zinc, tetrahydrobiopterin (BH4) and the catalytic active site, which binds L-arginine 
and a heme moiety. The reductase domain employs nicotinamide adenine dinucleotide 
phosphate (NADPH), flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) to 
shuttle electrons from the reductase domain to the iron at the centre of the heme co-
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factor in the catalytic active site.1 In the active site, L-arginine then becomes oxidised to L-
citrulline and NO is produced.6 The zinc ion in the oxygenase domain, while not directly 
participating in the catalytic cycle, provides a co-ordination site for four symmetry related 
cysteine residues, two from each monomer. This tetrahedral coordination sphere is an 
integral part of the dimer interface of NOS enzymes.7–9  
Activation of eNOS and nNOS is dependent on calmodulin (CaM) binding.10 This binding 
event is controlled by calcium levels where an increase in cellular calcium concentration 
facilitates formation of the NOS/CaM complex. Without CaM the enzymes are far less 
efficient at electron transfer and activity notably decreases.11 This system offers a 
regulatory mechanism for the constitutively expressed eNOS and nNOS. In contrast, CaM is 
bound to iNOS even at very low cellular calcium concentrations. This isoform is inducibly 
expressed and is therefore regulated at the transcriptional level, rather than by calcium 
binding events.12  
The mechanism of NO production is conserved across all three isoforms, with the heme 
iron in the arginine binding site playing a central role in the catalytic cycle. Although some 
of the specifics of this pathway have yet to be elucidated, a proposed cycle is provided in 
Scheme 1.2 adapted from the literature.12–14 The exact nature of the oxidative species is 
still unclear.13   
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Scheme 1.2. Proposed NOS catalytic cycle, (Por=porphoryin).
15
 
 
The proposed cycle begins with the heme iron in the resting (III) oxidation state. An 
electron, transferred from the reductase domain, reduces the heme iron to the (II) 
oxidation state. Molecular oxygen binds to the iron and subsequent electron transfer from 
tetrahydrobiopterin (BH4) and protonation generates an iron peroxy complex. Protonation, 
electron transfer (from the porphoryin ring) and loss of water generates the iron (IV) 
complex with a doubly bound oxygen atom.10,13 The iron (IV) complex then reacts with L -
arginine to form the intermediate L-NOHA and iron (III) is regenerated. A similar sequence 
of steps is then repeated, starting with the transfer of an electron from the reductase 
domain, reducing the heme iron to the (II) oxidation state. Once the iron (III) peroxy species 
is generated it reacts with L-NOHA to produce L-citrulline and an iron (III) nitrosyl species. In 
the final steps, the NO radical is formed and released along with the regeneration of iron 
(III) to restart the cycle.  
 
Chapter One                                                                                                                    Introduction 
  
 
5 
 
1.2 Biological role of NO 
 
As briefly alluded to above, NO is involved in a range of biological signalling processes. To 
exert these effects NO stimulates guanylate cyclase (GC), an enzyme which catalyses the 
production of cyclic guanosine 3’,5’-monophosphate (cGMP) from guanosine triphosphate 
(GTP) (Figure 1.1).   
 
 
Figure 1.1. Production of cGMP from GTP, catalysed by guanylate cyclase. 
 
cGMP then binds to allosteric sites on protein kinase G (PKG). The binding of cGMP to PKG 
results in a 3-10 fold increase in the phosphotransferase activity of PKG.16 PKG then 
phosphorylates a huge range of sites on a myriad of proteins, resulting in a diverse range of 
biological effects.17–20 These effects include neuronal signal transduction, vasodilation, 
increased pain perception and calcium release events.16 The effects of NO production on 
physiological function are clearly wide ranging and of vital importance. The malfunction of 
the NOS enzymes will therefore have serious and potentially fatal implications. This is of 
particular importance for nNOS owing to its key role in neurological signalling.  
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1.3 Disease states relating to nNOS  
 
Malfunction of nNOS has been linked to a range of disease states. Over activation of nNOS 
leads to elevated levels of NO in the brain and CNS. This has been associated with chronic 
neurological conditions including Alzheimer’s, Parkinson’s and Huntington’s diseases.21–24 
Post mortem brain tissue of schizophrenia sufferers was also reported to have double the 
levels of NO metabolites when compared to the tissue of patients not affected by the 
condition.25   
Over active nNOS can also lead to an increase in the levels of damaging oxidative species in 
the brain. This may be compounded by the uncoupling of the electron transport chain of 
nNOS as shown in Scheme 1.2. This uncoupling can occur in the absence of BH4, resulting in 
the production of reactive oxygen species (ROS) such as superoxide O2
-. This superoxide can 
further react to generate reactive nitrogen species (RNS), such as peroxynitrite (ONOO-
).6,14,26 Both of these species can inflict oxidative stress on cells, resulting in translation 
errors and protein aggregation.27 
Due to the number of disease states that NO is implicated in, over active nNOS represents 
an attractive therapeutic target. Partial inhibition of the protein may reduce the levels of 
NO, ROS and RNS in the brain and go some way to addressing the debilitating conditions 
outlined above. However, targeting of nNOS is not without its challenges. The protein is 
localised mainly in the brain, and so any potential inhibitor must have the ability to cross 
the blood brain barrier (BBB). Also, as the NO produced by nNOS is involved in a vast array 
of normal biological functions, any inhibitory effects must be partial and transient.  
The third issue which must be confronted for nNOS inhibition is that the iNOS and eNOS 
isoforms have similar binding sites and mechanisms of action to that of nNOS. Any 
inhibitory molecule must therefore selectively target nNOS, while leaving iNOS and eNOS 
unaffected. The current literature for nNOS inhibition has explored both the selectivity and 
efficacy of a number of compound classes, which have been targeted at four key sites in 
the NOS enzymes. These four binding sites, and the compounds used to inhibit them, will 
be outlined in the following sections.  
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1.4 NOS binding sites and inhibitory compounds 
 
To date several families of small molecule inhibitors have been developed to partially 
inhibit overactive nNOS. These inhibitors have been targeted at four potential therapeutic 
target sites. These sites are:  
1. The tetrahydrobiopterin (BH4) binding site, located in the oxygenase domain.  
2. The CaM binding site, which sits between the oxygenase and reductase domains.  
3. The NADPH binding site, which is located in the reductase domain. 
4. The catalytic active site, which is located in the oxygenase domain and binds 
arginine for production of NO.  
Of these four sites, the arginine binding site is by far the most studied, and is the most 
popular target for nNOS inhibition. The other three sites, and the compounds used to 
inhibit them will be briefly discussed, followed by a more detailed discussion of the arginine 
binding site, which was the target of this work. The nNOS isoform will be the focus of the 
discussion and, where appropriate, some comments will be made on the selectivity profile 
of the literature compounds. 
 
1.4.1 BH4 binding site 
 
Tetrahydrobiopterin, BH4 (Figure 1.2) is a pterin ring containing prosthetic group which is 
crucial for NOS function. It participates in electron transfer during NO production, and also 
plays a role in NOS dimer formation and stabilisation, which is necessary for enzyme 
activation.28 
 
Figure 1.2. Tetrahydrobiopterin with numbered positions. 
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An image of BH4 in the rat nNOS binding site is shown in Figure 1.3.
29 The strongest 
interaction between the binding site and BH4 was identified as a π stacking interaction with 
the primary amine substituted ring and the side chain of Trp678 (see Appendix, Table 8.1, 
for all amino acid one and three letter codes and Figure 8.1 for side chain structures).  An 
extensive network of hydrogen bond (HB) interactions was also identified.29 N-3 of BH4 
forms a direct HB with the carboxylate of the heme moiety and a solvent mediated 
interaction also exists between the same propionate group and the C-4 carbonyl. This 
carbonyl group also directly HBs with Arg596. The primary amine at C-2 interacts with the 
heme propionate and HBs with Trp678. The N-8 hydrogen interacts with Val677, and the 
BH4 dihydroxypropyl chain extends into the pocket formed by side chains of Trp(B)306, 
Met336 and TrpB676. The dihydroxypropyl chain also interacts with Ser334 and Phe(B)691 
carbonyl oxygens and with His(B)692 via structural water.29 
 
 
Figure 1.3. Rat nNOS BH4 binding site with BH4 bound (PDB: 4D2Y).
29 BH4 is shown in blue, heme in 
green and key resides in yellow. Waters removed for clarity. All images generated with pymol.30 
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A small number of inhibitors have been designed to target this site in an attempt to 
decrease over activation of nNOS.29 The most successful of these to date is a modified BH4 
compound, 1, shown in Figure 1.4. This had an IC50 of 3.68 µM against human nNOS, with a 
58.20 and 8.62 fold selectivity over human eNOS and human iNOS respectively.29  
 
Figure 1.4. Human nNOS inhibitory compound which targets BH4 binding site.
29
 (1) 
While this compound was not crystallised in the human nNOS BH4 binding site, the key 
interactions between it and the binding site were computationally predicted. The predicted 
interactions were similar to those observed for the natural substrate in the binding site as 
described above. The primary amine group HBs to the heme carboxylate and also to the 
Trp678 residue. The hydrogen on N-8 interacts with Val677. The C-4 carbonyl of BH4 is 
replaced by a C-4 NH in 1, which breaks the HB interaction with Arg596. The large p-
chlorophenyl group is accommodated by a pocket formed by TrpB306, Met336 TrpB676 
and Glu694. This pocket plays a key role in the selectivity of 1 for nNOS over eNOS and 
iNOS.  Replacement of Met336 with a valine (as in eNOS) resulted in lower binding affinity 
for 1.31  
 
1.4.2 Calmodulin binding site 
 
The second potential site for nNOS inhibition is the calmodulin binding site of the enzyme. 
CaM binding to NOS enzymes is an integral part of their function. The CBR of the enzymes 
is a ~25 amino acid sequence located between the oxygenase and reductase domain.32 
CaM binding allows a 70 Å conformational change to occur in the NOS proteins, as 
determined by nuclear magnetic resonance (NMR) spectroscopy and hydrogen deuterium 
exchange mass spectrometry.33,34 This conformational change facilitates the transfer of an 
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electron from the final reductase partner, FMN, to the heme moiety in the oxygenase 
domain of another NOS monomer as illustrated in the schematic (Figure 1.5).11 
 
 
Figure 1.5. CaM mediated hinge of NOS proteins. The NOS protein is shown in its dimeric form, with 
one monomer in grey and the other in white.
15
 
 
Some compounds have been developed which bind to the CBR site of nNOS and inhibit 
CaM interaction with the NOS enzyme. This prevents the “hinge” mechanism as shown 
above and reduces NO production. These compounds include monobutyltin trichloride and 
the breast cancer treatment tamoxifen, 2 (Figure 1.6), which was shown to reduce nNOS 
activity by 10-30%.32  
 
 
Figure 1.6. Tamoxifen, 2, which was used for nNOS calmodulin inhibition studies.
32
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The CBR of nNOS has not been as extensively studied as other sites such as the arginine 
binding site for nNOS inhibition. One of the key challenges associated with targeting the 
CBR region of nNOS is generating significant isoform selectivity. CaM binds to all three NOS 
isoforms using a 1-5-8-14 binding pattern. This binding motif is common for proteins that 
interact with calmodulin.35,36 The CBR of the three human isoforms, and the residues which 
are used to interact with CaM, are shown in Table 1.1. The 1-5-8-14 residue motif is 
conserved precisely in human nNOS and eNOS, while there are two residue changes in the 
iNOS motif. The iNOS sequence contains more hydrophobic residues than either of the 
constitutive isoforms, which may explain the higher affinity of iNOS for CaM.37 
 
Table 1.1. CBR of three human NOS isoforms, 1-5-8-14 residues highlighted in bold 
Isoform (residues) Alignment 
Human iNOS (412-431) REIPLKVLVKAVLFACMLMR 
Human eNOS (493-512) RKKTFKEVANAVKISASLMG 
Human nNOS (732-751) RAIGFKKLAEAVKFSAKLMG 
 
Another potential challenge with targeting the CBR region of nNOS is that the design of 
compounds to disrupt protein-protein interactions is often difficult no matter what the 
target.38 This is due to the fact that the binding sites for protein-protein interactions are 
often solvent exposed and are not amenable to formation of strong interactions with 
potential inhibitors.  
 
1.4.3 NADPH binding site 
 
NOS catalysis is driven by the reduction of NADPH, which binds to the reductase domain of 
NOS enzymes. The NADPH binding site therefore offers a potential intervention point at 
which the NOS catalytic cycle could be halted, thus inhibiting enzyme activity. The 
compounds which have been explored for this purpose have involved the coupling of an 
NADPH mimicking moiety with a chromophore, such as 3 shown in Figure 1.7. 39 
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Figure 1.7. 3 which was designed to target the NADPH binding site of the NOS proteins. The right 
portion of the molecule was designed to bind the NADPH site, while the left portion acts to capture 
electrons.39  
 
3 was designed to trap electrons and block the electron flow in the NOS electron transport 
chain. The predicted interactions between 3 and the NADPH binding site of the NOS 
enzymes all involved conserved arginine residues (Arg1400, Arg1314, Arg1284 and 
Arg1010).39 3 was reported to bind to nNOS, however this approach to nNOS inhibition 
struggled to generate selective inhibitors. There is also the possibility that 3 will interact 
with the NADPH binding site of other enzymes not related to NOS. This may result in 
serious off target effects. As such, 3 is one of only four compounds that have been 
designed to target the NADPH binding site of nNOS.39,40 
 
1.4.4 Arginine binding site 
 
The vast majority of nNOS inhibition studies are focused on the arginine binding site of the 
enzyme.27,41,42 This site facilitates the binding of L-arginine, the natural substrate for nNOS. 
Blocking of the site with a small molecule inhibitor has the potential to address the over 
activation of nNOS enzymes, and to aid in the treatment of the conditions discussed in 
section 1.3. The inhibitory compounds that have been explored for this purpose can be 
divided into two main categories. The first category is modified arginine compounds. These 
compounds attempt to mimic the binding of the natural substrate in the nNOS catalytic 
active site, and act as competitive inhibitors of L-arginine. The second class of inhibitors are 
2-aminopyridine containing compounds. These also act as competitive inhibitors of the L-
arginine binding site, but have demonstrated some unexpected binding poses.  
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1.4.4.1 Modified arginines 
 
One of the earliest compounds developed for nNOS inhibition was Nω-nitro-L-arginine (L-
NNA), 4.43 This compound has a very similar structure to arginine, differing only in the 
inclusion of a nitro group on the end of the guanidinium side chain (Figure 1.8). 
 
 
Figure 1.8. L-NNA, 4, one of the earliest arginine mimics studied for nNOS inhibition.43 
 
This compound was crystallised in the rat nNOS binding site (PDB 1K2R: reported in PDB 
only, not in the literature) to examine the key interactions between inhibitor and active 
site.  An image of L-NNA in the rat nNOS binding site is shown in Figure 1.9. 
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Figure 1.9. Rat nNOS arginine binding site with L-NNA (orange) bound (PDB: 1K2R). Heme is shown in 
green, residues in yellow. Hydrogens, waters and BH4 have been omitted for clarity. 
 
Glu592 was observed to form several HB interactions with the nitro guanidino group of the 
L-NNA inhibitor. Asp597 was also involved in binding via water mediated electrostatic 
interactions with the primary α amino group of the inhibitor. The C terminus carboxamide 
of L-NNA  formed HBs with Gln478, Arg481 and  Ser477 while the side chain amino group 
interacts via a water molecule with the heme propionate.44 
While L-NNA was seen to be an effective rat nNOS inhibitor, with an IC50 of 6 µM, it was 
also found to target bovine eNOS, making it a non-selective inhibitor.45 Attempts were 
made to improve its selectivity by synthesising a range of analogues such as those shown in 
Figure 1.10, 5, 6 and 7. These were observed to have Ki values of 0.13 µM, 0.12 µM and 
0.07 µM for rat nNOS, and 200 µM, 300 µM and 130 µM for bovine eNOS.44   
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Figure 1.10.. Modified L-NNA analogues, 5, 6 and 7, designed to study and improve inhibitor 
selectivity for nNOS over eNOS.
44
  
 
7 was crystallised in the bovine eNOS and rat nNOS binding site in an attempt to elucidate 
the reasons for its nearly 2000 fold selectivity for nNOS over eNOS. In the rat nNOS site the 
guanidine group made a bifurcated HB with Glu592. The nitro group made an additional HB 
with the protein backbone, strengthening the interaction of the inhibitors with the binding 
site. In bovine eNOS the inhibitors made the same interactions with the equivalent 
glutamic acid, Glu363. In eNOS, either the guanidine to Glu bond, or the nitro to backbone 
HB was stretched slightly (~3.2 Å), which partly explains the selectivity of the compounds.44  
The most important difference between eNOS and nNOS however was thought to be the 
replacement of Asp597 in nNOS with Asn368 in eNOS. It was hypothesised that the 
presence of the negatively charged residue in nNOS encouraged the inhibitors to adopt a 
curled configuration. This allowed the α amino group on the inhibitors to be stabilised by 
both Asp597 and Glu592 in nNOS. In eNOS, this dual stabilisation was not possible as the 
aspartic acid was replaced by an asparagine.44 The extended binding conformation of 7 in 
bovine eNOS and its curled binding conformation in rat nNOS are shown in Figure 1.11. 
Notice the proximity of the primary amine of the inhibitor to E592 in rat nNOS (2.8 Å), 
while the equivalent primary amine is further removed from E363 in bovine eNOS (5 Å).44 
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Figure 1.11. Bovine eNOS with 7 bound in extended conformation (PDB: 1P6N) vs rat nNOS with 7 
bound in curled conformation (PDB:1P6J).
44
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Further analysis of the precise binding modes of the arginine inhibitors using molecular 
docking has been reported. A selection of nNOS inhibitory arginine mimics, including 5, 6 
and 7, were flexibly docked into the arginine binding site of rat nNOS, human iNOS and 
bovine eNOS.46 This resulted in the identification of four “sub-pockets” within the rat nNOS 
arginine binding sites that could potentially be used to guide the design of inhibitors. The 
four pockets were termed S, M, C1 and C2.46 The S pocket is found above the heme ring 
and is comprised of residues Phe584, Val567 and Pro565. The M pocket is located between 
the substrate catalytic site and the substrate access channel. This pocket includes the 
residues Asp597, Ser477, Ser568, Gln478, Arg481, Asn569 and Arg603. The C1 and C2 
pockets are a little removed from the substrate binding cavity and constitute the substrate 
access channel. The C1 pocket contains Met336, L337, Glu307, Asn601 and Ser602 while 
the C2 pocket contains Pro708, Asp709, Pro710 and Gln500 (Figure 1.12). 
 
 
Figure 1.12. Sub pockets of the rat nNOS arginine active site with L-NNA bound.
46
 (PDB:1K2R) 
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The S pocket (with the exception of the Asn370Ser difference in iNOS) is identical in the 
three NOS isoforms used in this study, (rat nNOS, bovine eNOS and human iNOS). As such, 
it is difficult to explain the selectivity exhibited by some L-arginine analogues when only 
considering binding in the S pocket. 
The M pocket is defined by residues Ser477 and Ser568 in rat nNOS or Ala262 and Ala353 in 
human iNOS, which are postulated to be responsible for selectivity between the two 
isoforms. Alternatively, introduction of a positively charged functional group on inhibitory 
ligands would be unfavourable for eNOS binding in the M pocket. The nNOS M pocket is a 
more negative environment than the eNOS M pocket, with rat nNOS residue Asp597 being 
replaced by Asn368 in the bovine eNOS M pocket. This highlighted the significance of the M 
pocket in the design of isoform selective ligands.  
The C1 pocket differs among the NOS isoforms (rat nNOS, bovine eNOS and human iNOS) 
at five residues. Two selective regions were found, the first at residues Met336 and Leu337 
of rat nNOS and another at residues Glu307, Asn601 and Ser602 of rat nNOS. A histidine 
residue, His342 in human nNOS, (equivalent to Met336 in rat nNOS), could potentially be 
used to guide selective ligand design in this pocket. 
There are four residues in the C2 pocket that differ across the NOS isoforms (rat nNOS, 
bovine eNOS and human iNOS). The most important residues determined for selectivity are 
at the rat nNOS Asp709/human iNOS Glu494 positions. The authors postulated that 
inhibitors with a positively charged functional group positioned near the Asp709 of rat 
nNOS should be selective towards nNOS.46 
 
1.4.4.2 2-Aminopyridines 
 
The other main class of nNOS inhibitor is 2-aminopyridine containing compounds. 
Compounds such as 8 had been observed to have non-specific NOS inhibitory properties.47 
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Figure 1.13. Substituted 2-aminopyridine, 8, that was observed to have non-specific NOS inhibitory 
activity.
47
 
8 had an IC50 of 0.075 µM for nNOS, 0.072 µM for eNOS and 0.17 µM for iNOS. The species 
isoforms used for testing were not described in the publication.  
In an attempt to improve the selectivity and efficacy of the 2-aminopyridines, Ji et al. made 
use of a de novo design approach that focused on the “minimal pharmacophoric element” 
that was required for inhibition in each NOS isoform.48 This study made use of the “sub 
pockets” of the rat nNOS arginine binding site as described in Figure 1.12. It was proposed, 
for nNOS selective inhibition, that compounds should have an aminidino group positioned 
close to the Glu592, and a nitrogen atom should be near Asp597. This should allow 
selectivity over eNOS, which has a Asn in place of the Asp as previously discussed.48 It was 
also suggested that placing nitrogen atoms on potential inhibitors close to the heme 
propionate groups should facilitate formation of charge-charge interactions and HBs. The S 
pocket, meanwhile, was thought to facilitate hydrophobic and/or steric interactions. 
Based on this analysis and fragment docking studies, 9 in Figure 1.14 was developed.48 This 
exhibited low nano-molar rat nNOS inhibitory potency, and a 1,000 fold rat nNOS 
selectivity over bovine eNOS.48  
 
 
Figure 1.14. 2-aminopyridine containing compound developed from fragment screening, 9. This was 
screened as a mixture of enantiomers.
48
 
 
To improve the efficacy and selectivity of 9, further computational refinement was carried 
out by Ji et al.49  This resulted in the development of 10, shown in Figure 1.15. This had a Ki 
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of 0.014 μM for rat nNOS inhibition and a 2,000 fold selectivity over bovine eNOS and 290 
fold over murine iNOS. The 2-aminopyridine 10 was initially tested as a mixture of 
diastereomers.49 The four stereoisomers were subsequently resolved.50 
 
 
Figure 1.15. Unresolved aminopyridine 10 and the subsequently resolved stereoisomers.49,50 The 
3S,4S (10 S,S) and the 3R, 4R (10 R,R) stereoisomers had Ki values of 52.2 nM and 5.3 nM 
respectively for rat nNOS.  
 
Crystallographic studies revealed that compound 10 S,S interacted with the rat nNOS 
arginine binding site via HBs between the conserved Glu592 and the 2-aminopyridine on 
the inhibitor. Water mediated HBs formed with Asp597 and the 2-aminopyridine formed a 
pi-pi interaction with the heme. The flourophenyl arm was located in the hydrophobic 
pocket formed by Met336 and Leu337 (Figure 1.12). This is referred to as the “normal” 
binding mode of nNOS inhibitors by the authors, with the 2-aminopyiridine interacting with 
Glu592. Interestingly, the R configured inhibitor (10 R,R), adopted a different and novel 
binding mode with rat nNOS. This “flipped” binding mode saw the flourophenyl group 
orientated above the heme moiety. This then formed a π stacking interaction with the 
porphoryin ring. The 2-aminopyridine motif extended away from the heme moiety and 
induced a conformational shift in Tyr706. The aminopyridine then formed a bifurcated salt 
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bridge with the heme propionate A, as well as a π stacking interaction with the Tyr706. HB 
interactions were also observed between the pyrrolidine ring and the heme propionate B.  
The R,R stereoisomer possesses remarkable selectivity, with the rat nNOS Ki value being 
3,800 and 700 times lower than Ki value for  bovine eNOS and murine iNOS respectively. In 
rat nNOS, the 4 methyl group is accommodated by a hydrophobic pocket comprised of 
Met336, Leu337 and Trp306. This pocket is not available in iNOS, hence the selectivity over 
this isoform. The eNOS selectivity is more difficult to explain as the crystal structure studies 
suggest that the binding mode for 10 R,R in eNOS and nNOS is the same.50 Some selectivity 
differences between the two isoforms can be explained by residue differences between the 
eNOS and nNOS arginine binding pockets, with Asp597 in nNOS becoming Asn in eNOS and 
Met336 in nNOS becoming Val in eNOS. However mutation studies indicated that these 
residue differences were not the only contributory factors for selectivity.50 Mutation 
studies also indicated that the flexible Tyr706 contributes significantly to binding in nNOS, 
while contributing very little to binding in eNOS. Therefore, targeting the Tyr706 site with 
these new flipped binding mode compounds offers the potential of highly selective and 
efficacious nNOS inhibitors.  
Compounds such as 10 S,S and 10 R,R have great potential as nNOS inhibitors. However, 
their development was hampered by their somewhat poor “drug-like” properties as both 
10 S,S and 10 R,R have a large number of rotatable bonds and contain several ionisable 
groups. Attempts have been made to improve the drug-like features of these compounds 
and to make them more pharmacokinetically and pharmacodynamically favourable, while 
retaining the nNOS selective “flipped” binding modes as described above.51 These studies 
resulted in compounds such as 11 and 12, shown in Figure 1.16. 
 
 
Figure 1.16. Modified 2-aminopyridines designed to improve the pharmacokinetic profile of the 2-
aminopyridine family of nNOS inhibitors, 11 and 12.51 
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11 has a Ki of 7 nM for rat nNOS, 2,667 fold selectivity over bovine eNOS and 806 fold 
selectivity over murine iNOS.51 This is the most efficacious rat nNOS inhibitor reported to 
date. 11 was shown to adopt the flipped mode of binding (Figure 1.17), as previously 
described, where the 2-aminopyridine interacts with Tyr706 to improve the binding affinity 
for nNOS.52 As before, inverting both stereocenters (12) resulted in a switching of binding 
mode to the “normal” mode (Figure 1.18), with the aminopyridine positioned to interact 
with the heme ring. This indicates the crucial role stereochemical considerations must play 
in nNOS inhibitor design. 12 has a Ki of 220 nM for rat nNOS, 270 fold selectivity over 
bovine eNOS and 60 fold selectivity over murine iNOS.53 
 
 
 
Figure 1.17. The flipped binding mode of 11 (PDB:3NLM).
52
 Note how Y706 is orientated to interact 
with the 2 aminopyridine ring. 
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Figure 1.18. The normal binding mode of 12 (PDB:3NLK).
52
 Note how the Y706 does not position 
itself to interact with the flourophenyl ring.  
Compounds with two 2-aminopyridine rings joined together by a linker have also been 
developed for nNOS inhibition.54 An example of such an inhibitor, 13, is shown in Figure 
1.19. This compound has a Ki of 25 nM for rat nNOS and a 107 fold and 58 fold selectivity 
over bovine eNOS and murine iNOS respectively.54  
 
 
Figure 1.19. Two 2-aminopyridine rings joined by a central linker which demonstrated moderate 
selectivity for nNOS (13).54   
 
One of the most interesting features of 13 was its binding mode as determined by 
crystallization of 13 with rat nNOS (Figure 1.20).55 It was observed, as expected, that 13 
used one of the 2-aminopyridine moieties to form a network of HBs with Glu592 and 
Chapter One                                                                                                                    Introduction 
  
 
24 
 
Trp587. The second 2-aminopyridine moiety formed HB interactions with one of the heme 
propionates as well as a pi-pi interaction with Tyr706. Unexpectedly, a second molecule of 
13 bound to the BH4 binding site by using the central pyridine nitrogen to interact with the 
zinc atom present in the BH4 site. This resulted in the displacement of the BH4 and a 
rearrangement of several residues, in particular Arg596, which moved to interact with 
Glu592 and Asp600 of the substrate binding site. This movement opened a second zinc 
binding site in nNOS. The binding of a second zinc atom resulted in a tightening of the 
dimer interface in nNOS. This opening of a second zinc binding site was not observed in 
eNOS, potentially due to the tighter dimer interface of this enzyme. This may explain the 
selectivity of 13 for nNOS over eNOS. 
 
 
Figure 1.20. 13 interacting with both the arginine and BH4 binding sites of rat nNOS (PDB 3N5W).
55
 
 
 
Chapter One                                                                                                                    Introduction 
  
 
25 
 
1.4.4.3 Other scaffolds 
 
Some studies have examined alternate scaffolds to the two discussed above. These studies 
have been limited to thiophene and imidazole containing classes. The thiophene based 
scaffolds, such as 14 shown in Figure 1.21, bind to the rat nNOS arginine pocket by forming 
HBs with Glu592 and the heme propionate.56 The chlorophenyl ring of 14 is accommodated 
by the hydrophobic pocket consisting of Leu337 and Met336, and the interaction is further 
stabilised by π stacking with the Tyr706 side chain. 14 has IC50 values of 0.035 µM, 3.5 µM 
and 5 µM against rat nNOS, human eNOS and murine iNOS respectively.56 
 
 
Figure 1.21. A thiophene based inhibitor with an IC50 of 0.035 µM for rat nNOS, 14.
56 
 
Modification of one of the secondary amines to an alcohol substituted piperidine ring 
resulted in 15, Figure 1.22. This was observed to have superior inhibitory properties against 
rat nNOS, with an IC50 of 17 nM and a 1664 fold selectivity for rat nNOS over bovine 
eNOS.74 
 
 
Figure 1.22. Modified thiophene based inhibitor with an IC50 of 17 nM against rat nNOS, 15.
74
 
 
The imidazole based scaffolds adopt a different binding mode within the nNOS arginine 
active site. These compounds co-ordinate to the Fe at the centre of the heme moiety in the 
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active site via one of the imidazole nitrogens. Imidazole itself is a weak inhibitor of nNOS, 
with an IC50 of 290.6 µM.
57
 Various substituents have been added to imidazole in an 
attempt to improve its efficacy as a nNOS inhibitor. These substituents include phenyl rings 
(16) and various amino acids (17), Figure 1.23.54,55,58,59 
 
 
Figure 1.23. Phenyl and amino acid substituted imidazoles, 16 and 17, with nNOS IC50 values of 25 
µM and 19 µM respectively.
58,59
 
 
Recently, the field has begun to examine the applicability of the imidazole containing 
inhibitors for inhibition of human nNOS. The most efficacious compound developed was 
18, shown in Figure 1.24. This had an Ki of 0.125 µM against human nNOS, with a 202 fold 
selectivity over bovine eNOS and a 33 fold selectivity over murine iNOS.60 The nitrogen of 
the pyridine ring of 18 was reported to make a HB with His342 in the human nNOS binding 
site and was also seen to have a favourable PK profile in a CYP3A4 inhibition assay.   
 
 
Figure 1.24. 18 that was seen to be active against human nNOS.
60
  
 
The potential of the Fe co-ordinating binding modes observed for imidazole containing 
compounds was further explored through the development of thioester modified arginines, 
such as 19, Figure 1.25.61 This compound co-ordinates with the Fe using the sulphur atom, 
and also forms the HB interactions with Glu592 that has been previously observed for the 
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modified arginine inhibitor class of compounds. The terminal ethyl group of 19 fits into the 
hydrophobic pocket created by Pro565, Val567 and Phe584 in rat nNOS. The Fe-S distance 
is 2.5-2.6 Å (Figure 1.26).  
 
 
Figure 1.25 AN Fe co-ordinating compound, 19, that also forms some of the ""classic" modified 
arginine scaffold interactions with the rat nNOS binding site.
61
 
 
 
Figure 1.26. 19 co-crystallised with rat nNOS (PDB: 3JT4). The Fe-S distance was 2.6 Å.
61
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1.5 Current challenges in the field of NOS inhibition 
 
While the above compounds demonstrate that there has been some success in the field of 
nNOS inhibition, there remain several significant challenges in this area of research. The 
first issue that needs to be addressed is the lack of a uniform assay system based on the 
human isoform of nNOS. Almost all of the compounds described above were tested for 
their nNOS inhibitor activity against the rat isoform of the enzyme. This does not represent 
an ideal system when attempting to address and study the over activation of human nNOS. 
Furthermore, the specificity tests for inhibitory compounds are conducted using mixed 
species isoforms, most commonly rat nNOS, bovine eNOS and murine iNOS. This again does 
not provide a reliable and accurate system for determination of the selectivity of 
compounds for human nNOS over human eNOS and iNOS. The comparison of inhibitory 
compounds across publications is made all the more difficult due to the use of a variety of 
assay system for testing nNOS activity, these include radiolabelled arginine assays, whole 
cell assays, Griess assays and hemeoglobin conversion assays.  
The second weakness in the field is the over reliance on the modified arginine and 2-
aminopyridine based scaffolds for nNOS inhibition. While these scaffolds have provided 
some promising compounds, selectivity and efficacy issues remain. Movement of the field 
towards a more diverse scaffold set has the potential to improve the activity of nNOS 
inhibitory compounds. The currently reported inhibitory compounds also suffer from poor 
“drug-like” characteristics. While some efforts have been made to address this issue, 
particularly with the chiral 2-aminopyridine, there remains scope for development in this 
area.    
The third issue for human nNOS inhibition is the lack of application of modern in silico 
screening tools. Some computational studies have been conducted; however these have 
focused on the precise binding modes of already known active compounds, and not on the 
search for novel inhibitory scaffolds. The power and potential of large scale in silico screens 
for identifying potential inhibitors could make a significant contribution to the field of 
human nNOS inhibition.   
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1.6 Aims of the project  
 
The overall aim of this project is to design a novel, selective and druggable human nNOS 
inhibitor. To achieve this, the challenges in the field as outlined above will need to be 
addressed in turn. The first of these challenges to be tackled will be the lack of 
computational screens to identify human nNOS inhibitors. No human nNOS crystal 
structure was initially available at the beginning of this work; hence the construction of a 
human homology model will be attempted. This will then be screened with large 
compound databases with the aim of identifying a novel inhibitory scaffold for human 
nNOS. Ligand based drug design will also be employed through use of pharmacophore 
construction and screening. A particular emphasis will be placed on the pharmacokinetic 
properties of any potential human nNOS inhibitors. 
Work will also be conducted on advancing the contemporary assay systems for nNOS 
inhibition from the current standard of rat nNOS, bovine eNOS and murine iNOS. The 
project aims to move to an all human NOS assay system. This would make any successful 
inhibitory more “druggable”, and would represent a major advancement in the field. This 
will be done through the use of recombinant expression of the three human NOS proteins 
using a bacterial host, and purification using affinity chromatography. These isolated 
proteins will then be used to establish a functional assay system for testing of the in silico 
derived novel nNOS inhibitory scaffolds. Co-expression with human calmodulin will also be 
attempted. This approach has yet to be reported for human nNOS, and should yield 
maximally functional NOS proteins. It is hoped that the assay system will be high 
throughput, cost effective and transferable to allow other research groups to study human 
nNOS inhibition.   
The project will also focus on synthetic organic chemistry, and its use to access some of the 
compounds that will result from the in silico screen. While some of the screened 
compounds will be commercially available, many will have to be synthesised. The use of 
synthetic techniques to access novel scaffolds from the screens will therefore be of critical 
importance. These techniques should also allow the synthesis of a variety of scaffolds 
which will advance the field of human nNOS inhibition beyond the two favoured families of 
compounds which are reported in the literature.  
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2 Computational Studies 
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2.1 Introduction 
 
The field of nNOS inhibition is currently focused on the modification and testing of two 
ligand scaffolds and predominantly uses rat nNOS for inhibitor testing. These scaffolds are 
based on the natural NOS substrate, L-arginine, and on substituted 2-aminopyridines (see 
chapter one, section 1.4.4). This project departs from these much explored ligand families, 
as well as from the use of rat nNOS for inhibitor testing, and instead seeks to identify novel 
ligand scaffolds using the human nNOS enzyme. To achieve this, a high throughput 
screening approach will be employed using both structure based and ligand based design 
techniques.  
This type of approach has been attempted only once before in the field of nNOS inhibition. 
This publication is recent, and does not attempt to biologically evaluate the effectiveness of 
the proposed inhibitors.62 This project will employee a more extensive in silico examination 
of the human nNOS binding site, and also aims to biologically evaluate the hit compounds.  
Other groups in the field have regularly utilised in silico techniques for visualisation and 
representation of known rat nNOS inhibitors in their binding sites.27,63–65 These compounds 
were not derived from high throughput screening. The work presented in the following 
chapter therefore represents a novel and innovative method of screening for human nNOS 
inhibitors that has not yet been exploited.  
 
2.2 Structure based design overview 
 
The structure based design methodologies used during this project are outlined in Figure 
2.1.   
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Figure 2.1. Structure based drug design overview. 
 
The workings of each of these steps will be outlined briefly in the following sections.  
 
2.2.1 Building a homology model 
 
Sequencing technology has become increasingly sophisticated over the past decade and as 
a result protein amino acid sequences are readily accessible. However, publication of 
crystal structures to match these sequences has not been as rapid. On the 22nd of October 
2015 Uniprot, a repository for protein amino acid sequences, had 5,278,3601 entries, while 
the PDB had only 113,130 entries, demonstrating the gulf between sequence and 
crystallization data. 
Chapter Two                                                                                                     Computational Studies                                                                                                                     
 
 
33 
 
Crystallization of proteins is often difficult and time consuming and so 3-D structures of 
many fully sequenced proteins are not yet available. In cases where the sequence of a 
protein is known, but its 3-D structure is not, a homology model is necessary for carrying 
out structure based design.  
Homology modelling is based on two major observations: 
i) The structure of a protein is determined by its amino acid sequence. Knowing 
the sequence of the protein should therefore make it possible to predict its 
structure. 147 
ii) Proteins with similar amino acid structures should adopt similar structures. 
Therefore, if two proteins have similar amino acid sequences then they will 
have similar structures. 147 
The 3-D structure to be developed is known as the target structure, which has a 
corresponding (known) target sequence. The other partner in the homology modelling 
protocol is the template, which has known sequence and structure. The target sequence 
can be used to search databases of potential template sequences to identify homologous 
templates. The level of sequence homology between template and target is directly 
proportional to the level of structural homology. In this way, an unknown protein structure 
can be developed from a known protein sequence. There are several general methods for 
homology model construction, such as rigid body assembly and satisfaction of spatial 
restraints. All of these methods make use of the same generic steps for model generation, 
which will now be briefly outlined. 
Step one is to search for structures related to the target sequence. This is best achieved 
using a sequence alignment searching tool that is linked to the PDB. This search will return 
the known protein structures which bear some degree of sequence similarity to the target. 
These structures form the list of potential templates. Step two is to select which template 
is most suitable for model construction. Of key importance is the sequence similarity 
between target and template. The higher this similarity the more accurate the target 
structure will be. If the target and the template have a similarity of 40% or higher the 
model which results should be accurate. Lower similarity scores between the two 
sequences may result in a poor model.148 A template structure with high resolution is also 
desirable. Additionally, it is useful if the template structure has all known co-factors co 
crystallized with it, particularly if they are known to influence ligand protein interactions.148 
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Some modelling programs allow input of several templates. This can be of particular 
benefit in cases of low target-template sequence homology.  
Once the template has been selected the next step is to build the model. Biovia’s Discovery 
Studio program uses the Modeller algorithm for homology model construction.149 Modeller 
constructs models using a process called “satisfaction of spatial restraints”. This approach 
uses distance geometry or optimization techniques to satisfy a set of spatial restraints in 
the target structure. In Modeller these restraints are derived from two sources. Firstly, 
restraints for the target are derived from restraints observed in the template. For example, 
if it is observed that the residues at position 100-110 in the template and target sequences 
are the same, the dihedral side chain and main chain angels and N, O distances can be 
taken directly from the template structure. In areas where the template and target 
sequence differ, the geometry and bonding angles of the residues are calculated using the 
CHARMm force field by  calculating a series of probability density functions (pdfs) for each 
residue. For example, a glutamic acid is unlikely to have its side chain orientated towards 
another acidic residue due to the charge repulsions involved. This type of side chain 
arrangement therefore receives a low probability score. By moving the side chains away 
from each other the charge repulsion may be reduced, but the side chain bond angle may 
then become more unfavourable. Several variations are trialled and each is assigned a 
probability based on the score generated using CHARMm. The final model is then 
constructed by combinations of the pdfs into a discrete optimised protein energy (DOPE) 
score for each model.150 The model which is most probable will score best, while models 
with improbable geometries will score poorly.   
Once the model is built the final step is to check for potential model errors. It is often 
beneficial to generate more than one model, particularly if the sequence alignment 
required manual adjustment. Once generated the homology models must be structurally 
and functionally validated. 
 
2.2.2 Structural verification of model 
 
Errat is a system that analyses the non-bonded interaction energies between carbon, 
nitrogen and oxygen atoms within a protein structure.72 The calculated energies are 
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compared to a set of reference non-bonded interaction energies. A sample output is shown 
below (Figure 2.2). 
 
Figure 2.2. Sample Errat plot.  
 
It is expected that 95% of residues of a robust protein structure should be below the 95% 
error limit.72  Areas of the protein which are mis folded will move outside this error limit as 
the heavy atoms are either too close together (causing steric clashes) or too far apart 
(causing unusually long bond lengths).  
Procheck analyses the backbone angles of all crystal structure and generates a 
Ramachandran plot.68 The plot is split into a most favoured region (red), an additionally 
allowed region (brown), a generously allowed region (yellow) and a disallowed region 
(white) (Figure 2.3). 
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Figure 2.3. Sample Ramachandran plot.  
 
The phi (φ) axis represents the peptide bond angle and psi (ψ) represents the carbon-
carbon bond angle in the backbone.  
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Figure 2.4. Phi and psi angles in a protein backbone.
143
 φ represents the N-Cα angle, while ψ 
represents the C-Cα angle.  
 
It is expected for a good quality structure that 90% of the residues will fall into the allowed 
regions of the Ramachandran plot. However, two residues can appear in the disallowed 
regions of the plot, these are glycine and proline. These residues are exceptional due to the 
nature of their side chains which affects the backbone angles they can adopt. These appear 
as triangles on the graph, while all other residues appear as squares.   
Verify 3-D examines how closely the 3-D coordinates of the crystal structure model match 
the 3-D profile as calculated from the protein’s amino acid sequence.  The 3-D profile of a 
residue is calculated based on how deeply buried the residue is, the fraction of polar atoms 
in the side chain and the local secondary structure. If the 3-D profile and the 3-D structure 
of the model match closely (>80% matching), the structure passes the test. 71 
 
2.2.3 Functional validation of model 
 
The three tools above are useful for structural validation of the protein models. Functional 
tests of the docking protocol using the structure must also be carried out. The simplest of 
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these tests is to examine how well binding poses of co crystallized inhibitors can be 
reproduced by the docking program. The inhibitor is removed from the protein binding site 
and a conformer ensemble of the inhibitor is docked into the binding site. The original, 
crystallised pose is compared to the re docked pose using root mean standard derivatives, 
RMSDs. 
Equation 1. RMSD equation.
133
  
𝑹𝑴𝑺𝑫 = √
∑ 𝒅𝒊
𝟐𝑵𝒂𝒕𝒐𝒎𝒔
𝒊=𝟏
𝑵𝒂𝒕𝒐𝒎𝒔
 
 
Where Natoms is the number of atoms over which the RMSD is measured and di is the 
distance between the coordinates of atom i in the two structures (original and re docked) 
when they are overlaid. An RMSD score of less than 2 Å is widely accepted as distinguishing 
between success and failure in re producing known binding poses.75 
  
The second functional test is to measure how well a small test set can be docked into the 
binding site of the protein. This is done using a relatively small collection of ligands (~1000) 
called a test set. Some of the ligands in the test set are experimentally validated binders of 
the target site of the crystal structure (actives), while some of the ligands are deliberately 
chosen as they are known not to bind to the target site (decoys). The decoys may have 
similar physico chemical properties to the actives in order to ensure a robust test of the 
model and the docking procedure.  
 
The most common ratio of decoys to actives is 33:1.139 Actives are chosen based on a low 
IC50 value against the target of interest. The value for a “low” IC50 is target dependent. The 
decoys can be molecules randomly taken from a commercial database such as Maybridge 
or Zinc, or they can be compounds specifically chosen as they are known not to act against 
the target of interest. The Chembl website (https://www.ebi.ac.uk/chembl/) is a useful 
source for the building of these test sets. Targets can be searched, for example nNOS, and 
the inhibitory compounds are then sorted based on IC50 values. The most active can then 
be chosen and suitable decoys are also readily accessible. 
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Once the test set has been constructed its conformers are generated (section 2.2.4.1) and 
docked into the crystal structure. Docking scores are returned and are analysed using 
Receiver Operator Characteristics (ROCS). This scores how well the docking program can 
pick the active compounds out of the test  set, while discarding the decoys.144 Active 
compounds should score better than the decoy compounds if the model is accurate. Two 
sample ROC graphs are shown in Figure 2.5. (For docking scoring functions see Section 
2.3.1) 
 
 
Figure 2.5. Sample ROCS tables.  
 
ROC curves plot the true positive rate (sensitivity, y-axis) against the false positive rate (1-
specificity, x-axis).145 ROC scores run between zero and one based on the area under the 
ROC curve. The closer the ROC score is to one, the more accurate the docking protocol is at 
distinguishing between actives and decoys.146 If molecules are randomly assigned as actives 
or decoys a ROC score of 0.5 is returned. Such a protocol is not useful for identifying active 
compounds. The left panel in Figure 2.5 represents this scenario. The right panel in Figure 
2.5 represents a more accurate docking protocol, scoring 0.871 and is classed as a good 
model 
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2.2.4 Conformers of database 
 
A single molecule can have many binding poses for one target site. It is therefore necessary 
to analyse as many of these binding poses as is computationally practical to determine the 
likely bioactive conformation. To achieve this, several conformations of the target molecule 
are generated. This can be done in either a systematic or a stochastic manner. Systematic 
conformer generation involves generating all possible conformers of a given molecule. This 
is usually not possible due to a phenomenon called the combinatorial explosion. As the 
number of rotatable bonds in a molecule increases the possible number of conformers 
increases exponentially.133 If large numbers of compounds are being docked into one target 
site this becomes a considerable computational task.  
Stochastic conformer generation is widely used to avoid the combinatorial explosion. This 
essentially involves random generation of conformers and minimization of the resulting 
structures. The process is outlined in Figure 2.6. 
 
 
Figure 2.6. Flowchart for stochastic conformer generation. 
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Openeye’s Omega is a popular stochastic conformer generation program.139 Omega uses a 
variation of stochastic conformer generation that avoids the energy minimization step. The 
energy minimization can often lead to highly compact structures that do not accurately 
reflect the structure of species in solution. Owing to its importance for this work Omega 
will be discussed in more detail in the Section 2.2.4.1. 
 
2.2.4.1 Omega  
 
Rigid docking programmes (eg FRED, discussed in section 2.3) hold both the ligand and 
protein in a fixed conformation throughout the docking process. However, a degree of 
flexibility can be conferred on the ligands by docking a conformer ensemble of each 
molecule.74 The collections of conformers can be generated using the Openeye program, 
Omega. This program takes an input molecule and constructs conformers of it using five 
steps. The first two steps are pre-programmed while the remaining three are molecule 
specific and are completed at run time. Omega makes use of the Merck Molecular Force 
Field (MMFF94).140 This is a computationally derived molecular mechanics and dynamics 
force field. It describes and tries to predict what forces will act on atoms when they are 
combined and how these forces will affect the geometry of the molecule.140   
The first step in Omega is compilation of a fragment database. A large commercial database 
of molecules (e.g. Zinc) is fragmented into continuous rings and small linear linkers.141 One 
or more 3-D conformations for each fragment are then constructed by embedding each 
atom of each fragment in a random position in space and ensuring that these atoms are 
still connected in a logical way. Electrostatic and Van der Waals forces are removed from 
each fragment. This process is repeatedly applied and the lowest energy conformers that 
are unique in root mean square deviation (RMSD) space are retained.139 This ensures 
duplicated fragments are avoided.  
The second pre-programmed step is generation of a torsion sampling dictionary. Torsion is 
the twisting of an object due to applied force. In this case, the objects which are being 
twisted are atomic bonds and the forces acting on these bonds include kinetic energy and 
steric interactions. A list of torsions for bonds in small molecules is constructed using 
samples derived from the protein data bank, PDB, and energy scans of torsions against the 
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MMFF94. This list defines at what angles torsions should be sampled for particular bonds. 
Common torsions must obey very strict rules which are unique for that torsion. More 
unusual torsions are subject to more generic rules and repeated sampling. This torsion 
sampling directory is applied to the target molecule in step four of the Omega process.139 
The third step is the first of the molecule specific operations, the 3-D structure generation. 
The input molecule is fragmented and the possible structures of each fragment are taken 
from the fragment database, which was described in step one. If there is no entry in the 
database corresponding to one of the generated molecular fragments, the algorithm from 
step one is applied. The parent molecule conformers are then assembled by over lapping 
the fragments in accordance with geometric and chemical rules.139    
Step four is torsion driving. All the rotatable bonds of all the conformers are compared to 
the torsion library from step two and the correct torsion angles are applied. Several 
torsions are applied to eacHB to build up a large data base. Torsions which result in severe 
atom clashes or duplication are removed.139 
Finally, the data set generated from the first four steps is sampled. The conformer with the 
lowest overall energy is taken as the first molecule in the output sample set. Higher energy 
conformers are then added to this sample set until the user defined sample size is 
obtained. At no stage in this process is a minimization of the conformers conducted.  
 
2.2.5 Tautomer and stereoisomer generation 
 
Different conformations of molecules are possible due to the flexibility of bonds which 
allows them to rotate. There are other ways in which one molecule can adopt a variety of 
forms, most notably tautomers and stereoisomers.  
Tautomerism most often occurs by movement of a hydrogen from one atom to another, 
and rearrangement of double bonds along its path of travel eg keto-enol tautomerism 
(Figure 2.7). 
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Figure 2.7. Keto/enol tautomerism. 
 
Tautomers can be generated by a variety of methods in silico. The software used in this 
work was Biovia’s Discovery Studio which deals with tautomers by generation of the 
canonical, or most favourable, tautomer. Another tautomer generation method is 
enumerating all possible tautomers, although this can contribute to the combinatorial 
explosion phenomenon as previously described. 
Canonical tautomer generation involves first constructing a list of all possible tautomers of 
the query molecule. There are a variety of set rules which can be applied for this process 
depending on the exact structure of the query molecule.142 Once all the tautomers have 
been enumerated the canonical, or most likely, tautomer is decided based on another set 
of scoring rules. Each tautomer is scored based on what types of structures it contains. 
Examining the keto/enol example, the keto form is the chemically more favoured form; 
therefore that tautomeric form would be given a higher score than the enol form, which is 
less favoured.142 This process is repeated for all tautomerisable portions of the molecule 
until the overall most favoured tautomer is decided on.  
A final consideration for molecular structure is the stereoisomeric forms which the 
molecules can adopt. Biovia’s software enumerates all possible stereoisomers up to a user 
set cut off. This addresses both chiral centres to generate the R and S enantiomers at each 
stereocentre and also double bond geometry to generate the E and Z forms of the 
molecules. Stereoisomer generation is followed by a coordinate “clean up” to ensure that 
no atom overlaps or clashes occurred during the isomer generation. 
Following generation of stereoisomers, tautomers and conformers the ligands are ready for 
docking into the active site of the protein of interest.  
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2.3 Docking 
 
2.3.1 Fast Rigid Exhaustive Docking (FRED) 
 
Openeye’s Fast Rigid Exhaustive Docking (FRED) fits a conformer library a target site of the 
user’s choice.74,151 For this project the databases were sets of conformers generated by 
Omega. FRED scores how well each ligand fits into the target based on ligand size and 
shape. Those that fit best are given the most negative scores. FRED does this in two steps. 
The first step is the exhaustive search function. This analyses and docks all possible 
rotations and translations of each ligand being docked into the binding site. Any 
conformations which do not fit within the defined binding site are discarded and the 
remaining ligands are given a preliminary score.  
The second step is optimization. The ligands which were not discarded in the first step are 
moved around the binding site in very small movements to determine the exact best 
position for the small molecule in the binding site. The poses are then scored again and the 
number of poses defined by the user are retained and saved, the rest are discarded.152 In 
this way, the best orientations of ligands in the binding site are deduced. 
FRED Version 2.2.5 applies seven force field based scoring functions to rank ligand and 
binding site interactions. These are Chemgauss2, Chemgauss3, Chemscore, Consensus, 
PLP_docked, Screenscore and Shapegauss.74  
As implied by the name, Shapegauss represents all the atoms in the system as smooth 
Gaussian functions, and relies solely on the shape of the ligand to assess its binding 
affinity.153 The scoring function measures to what degree various Gaussian functions in the 
system overlap. If there is a large degree of overlap between atoms of the binding site and 
atoms of the ligand a high score is awarded.151 Chemgauss2 and Chemgauss3 operate on 
the same Gaussian principles but also take into account the position of HBing and aromatic 
groups.153 
Piecewise Linear Potential (PLP) incorporates HBing interactions as well as steric 
interactions due to carbon, nitrogen, sulphur, fluorine, oxygen and iodine atoms.76 
Screenscore takes several different parameters into account when scoring a binding pose; 
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these include steric interactions, HBs, metal atom interactions, aromatic interactions and 
penalties for clashes and the number of rotatable ligand bonds.153  
The consensus function attempts to collate the binding information from all of the scoring 
functions into one ranked list. For each scoring function a list of the binding poses of each 
molecule is created ordered by rank. Each pose is then assigned a consensus structure 
score equal to the sum of that pose’s rank in each list. The best scoring pose is retained, 
while all others are discarded. 154 
Chemscore was developed based on work previously conducted by Böhm.155 It scores poses 
using four different terms, namely HBing interactions, lipophilic interactions, ligand-metal 
interactions and a final term that considers contributions from rotatable bonds which are 
frozen because of contact with the receptor.156  
Certain scoring functions may perform better depending on the exact nature of the protein 
and ligand partners whose interactions are being examined.157 Prediction of which scoring 
function will perform best is difficult and as a result it is necessary to test all scoring 
functions with the test set. The performance of each scoring function with the test set is 
scored using ROCS and the best performing one can then be used for database screening.  
The FRED docking protocol was updated during the course of this project and was 
employed in some of the later docking studies. FRED 3.0.0 outputs only one docking 
function, Chemgauss4. This has improved HB detection relative to previous chemgauss 
scoring functions and also accounts for HB network effects.158 Similar to older iterations of 
the chemgauss functions, chemgauss4 scores a range of interactions including sterics, HB 
donors and acceptors, co-ordinating groups, metals, lone pairs, polar hydrogens and 
chelator co-ordinating groups. 159 
 
2.3.2 Flexible docking 
 
FRED docking is powerful as it can be used to examine a large number of potential binding 
poses in extensive databases. Large numbers of molecules can be handled as the binding 
site into which they are docked is held in a fixed orientation, with no movement of residue 
side chains permitted. To more closely mimic in vivo conditions and improve the accuracy 
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of the docking protocol a degree of flexibility can be conferred on these side chains using 
FlexDock in Discovery Studio.160     
The flexible docking begins by selection of the side chains which will be allowed to move. 
This is usually defined as all residues within either 4 Å or 8 Å of the ligand that was co-
crystallized in the protein binding site. A selection of rotameric states are generated for the 
residue side chains using ChiFlex, and the energy of these rotamers is calculated using 
CHARMm.161  The ligand database is then docked into the active site and the side chains are 
further refined to generate the most favourable ligand-receptor interactions. The resulting 
compound list is ranked based on how well the ligands interacted with the flexible binding 
site following side chain refinement.160  
 
2.4 Homology modelling results 
 
2.4.1 Sequence alignment 
 
As a human nNOS crystal structure was not initially available, a human nNOS homology 
model (HM) was developed for the screening of commercial ligand databases. Rat nNOS, 
with a 93.84% sequence identity to human nNOS, was chosen as the template for 
homology model construction. Full sequence alignments are provided in Appendix 8.1, all 
alignments were performed with Clustal Omega.66 The key binding site residues of the 
arginine binding site, shown in Table 2.1, are largely conserved between the rat and the 
human sequences, with a single residue difference occurring where Leu337 in rat nNOS is 
replaced with His342 in the human isoform. These key residues were within 8 Å of the 
arginine binding site in the rat nNOS crystal structure. The residues have been widely 
reported to form interactions with nNOS inhibitory compounds, see chapter one, section 
1.4.4.  
The hydrophobic pocket containing the Leu337 residue (Met336, Leu337, Tyr706) has been 
noted to play a crucial role in rat nNOS inhibitor binding.53 In human nNOS, Leu337 is 
replaced with a His342. Leucine has a t-butyl side chain, while histidine has an imidazole 
ring containing side chain. The histidine side chain is more amenable to HB formation due 
to the nitrogen in the imidazole ring. It may also form π stacking aromatic interactions, and 
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charge-charge interactions. Leucine may repel potential inhibitors from the pocket due to 
its steric bulk.  Due to the differences in interaction types between these two residues, the 
leucine to histidine change could greatly impact inhibitor binding in the human isoform. It 
has also been observed that a variety of nNOS inhibitors have different IC50 values for rat 
nNOS versus human nNOS. This suggests that the inhibitors interact differently with rat and 
human binding pockets.45,53 Construction of a human nNOS homology model may therefore 
be useful in the identification of a novel class of selective human nNOS inhibitors.   
Table 2.1. Alignment of key binding site residues of human nNOS and rat nNOS. 
Human nNOS Rat nNOS 
M341 M336 
H342 L337 
S482 S477 
Q483 Q478 
R486 R481 
V572 V567 
F589 F584 
S590 S585 
G591 G586 
W592 W587 
Y593 Y588 
E597 E592 
D602 D597 
Y711 Y706 
 
2.4.2 Structural validation 
 
Two human nNOS homology models were developed based on the holo rat nNOS template 
structures. The protein databank (PDB) codes of these template structures were 3PNF (1.94 
Å) and 3RQJ (1.84 Å).65,67 The models based on these templates were constructed as per 
chapter five, section 5.5.1.1. The human nNOS homology models will be referred to as 
3PNF-HM and 3RQJ-HM. Crystal structure waters were explicitly included in the models. 
There were 398 water molecules in the 3PNF template and 388 waters in the 3RQJ 
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template. There were 16 waters within 8 Å of the 3PNF binding site and 10 waters within 8 
Å of the 3RQJ binding site. The position of the remaining water molecules were largely 
conserved between the templates. In both the 3PNF and 3RQJ templates, a water mediated 
HB formed between the ligands and Asp597.65,67  
The generated homology models were first analysed with Procheck.68 This was carried out 
with and without water molecules from the template present, and with and without 
minimizations applied to the models. The minimization method employed was steepest 
descent followed by conjugate gradient using the Chemistry at HARvard Macromolecular 
mechanics (CHARMm) force field.69 The original templates were also analysed via Procheck 
and the results are summarized in Table 2.2 and Table 2.3.  
Table 2.2. 3RQJ homology model variations Procheck scores. 
 3RQJ 3RQJ-HM 
3RQJ-HM 
with water 
3RQJ-HM 
minimized 
3RQJ-HM 
minimized 
with water 
Number of 
residues 
814 836 836 836 836 
Most favoured 92.4% 70.2% 70.2% 82.9% 83.2% 
Allowed 7.3% 26.7% 25.2% 16.3% 16.0% 
Generously 
Allowed 
0.3% 2.6% 4.1% 0.8% 0.5% 
Disallowed 0% 0.5% 0.5% 0% 0.3% 
 
Table 2.3. 3PNF homology model variations Procheck scores. 
 3PNF 3PNF-HM 
3PNF-HM 
with water 
3PNF-HM 
minimized 
3PNF-HM 
minimized 
with water 
Number of 
residues 
819 836 836 836 836 
Most favoured 92.3% 94.4% 93.6% 87.5% 87% 
Allowed 7.7% 5.2% 5.8% 11.8% 12.5% 
Generously 
Allowed 
0% 0.3% 0.5% 0.5% 0.4% 
Disallowed 0% 0.1% 0% 0.1% 0.1% 
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The most favoured, allowed, generously allowed and disallowed classifiers were originally 
determined by examination of the dihedral angles in a set of 463 protein crystal 
structures.70  The most favoured region is defined as areas of the Ramachandran plot which 
contained over 100 residues per pixel when the backbone angles of this test set were 
analysed. The allowed region is defined as areas of the Ramachandran plot which 
contained over eight residues per pixel following test set examination. The generously 
allowed region is the area of the graph which extends out by two pixels around the allowed 
region. All space outside these regions is defined as disallowed.70  
A protein model is deemed stereochemically satisfactory when a high percentage of 
residues (over 90%) are in the most favoured regions.68 This was observed for the non-
minimized 3PNF-HM structures. The minimized 3PNF-HM structures had a greater 
percentage of their residues in the allowed region when compared to the non-minimized 
structures. This indicated that the protein minimization procedure may have resulted in the 
adoption of less favourable backbone bond angles. Also of note was the fact that the 3PNF-
HM models performed slightly better without the water molecules present, although the 
difference between the solvated and non-solvated models was small. It may be beneficial 
to include the water molecules in spite of their detrimental effect on the backbone bond 
angles, as they may mediate HB interactions between the binding site and potential 
inhibitors during docking studies.    
The 3RQJ-HM performed more poorly in this test than the 3PNF-HM. None of the various 
3RQJ-HM structures scored greater than 90% of residues in the most favoured regions. 
Interestingly, the minimized versions of 3RQJ-HM scored better than the non-minimized 
versions. This was the opposite than what was observed for the 3PNF-HM. Similar to 3PNF-
HM, the inclusion or exclusion of waters in the 3RQJ-HM had very little impact on the 
model quality from a structural perspective in the Procheck test. 
The quality of the overall 3-D structure of the models was probed using Verify-3D, a tool 
which compares the 3-D structure of a protein with the expected 3-D structure based on 
the protein’s sequence.71 The non-bonded interaction energies between the heavy atoms 
of the protein backbone were also analysed using Errat (Table 2.4 and Table 2.5).72  
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Table 2.4. Verify 3-D and Errat scores of 3RQJ models. 
Structure Verify 3-D Score Errat Score 
3RQJ 88.89% 93.199% 
3RQJ-HM 88.20% 74.211% 
3RQJ-HM with water 88.20% 74.211% 
3RQJ-HM minimized 90.02% 88.417% 
3RQJ-HM minimized with 
water 
91.66% 83.835% 
 
Table 2.5. Verify 3-D and Errat scores of 3PNF models. 
Structure Verify 3-D Score Errat Score 
3PNF 90.5% 94.598% 
3PNF-HM 88.41% 72.588% 
3PNF-HM with water 89.13% 73.083% 
3PNF-HM minimized 90.44% 90.509% 
3PNF-HM minimized with 
water 
91.64% 86.910% 
 
All versions of both models scored greater than 80% in the Verify 3-D test, which indicates 
that the 3-D structures of the models were robust.71 “Good” protein models should ideally 
score greater than 80% in the Errat test. This examines non-covalent interactions between 
N, C and O atoms.72 All of the non-minimized versions of the models failed this test, 
indicating that in the non-minimized versions, the distances between the heavy chain 
atoms were incorrect. Application of the minimization procedure rectified these errors, 
resulting in a much higher Errat percentage score. This suggests that the interatomic 
distances are more correct in the minimized protein models. Detailed examination of the 
Errat plots of the non-minimized models identified that some of the binding site residues 
displayed high energies, suggesting that these model may be unsuitable for docking 
applications. Based on these results, the non-minimized versions of the homology models 
were omitted from further testing.  
From the structural validation tests it appeared that the 3PNF-HM (minimized) performed 
slightly better than the 3RQJ-HM (minimized), in both the solvated and non-solvated forms. 
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This was particularly evident in the Procheck test. However, as the differences in scores 
between the models were not large for the other structural validation tests, both 3PNF-HM 
and 3RQJ-HM minimized models were taken forward for further testing.  
 
2.4.3  Docking protocol validation 
 
The first test of the docking protocol was re-docking of the template co-crystallized ligand 
into the homology model binding site, and comparison of the re-docked pose with the 
original binding pose using root mean square deviations (RMSD) of the heavy chain atoms. 
The 3RQJ and 3PNF template ligands, 20 and 21, are shown in Figure 2.8.65,73 
 
 
Figure 2.8. Co-crystallised ligands of 3PNF and 3RQJ, 20 and 21.
65,73
 
  
All docking functions for Fast Rigid Exhaustive Docking (FRED) 2.2.5 (Chemgauss 2, 
Chemgauss 3, Chemscore, Consensus, Plp_docked, Screenscore and Shapegauss) were 
analysed and the best scoring function for each model was noted (Table 2.6).74  
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Table 2.6. Comparison of re-docked versus crystalized binding poses using RMSD. 
Model RMSD Score Best FRED docking function 
3PNF HM with water 
minimized 
1.356 Å All equal 
3PNF HM no water 
minimized 
0.678 Å All equal 
3RQJ HM with water 
minimized 
1.79 Å PLP_docked 
3RQJ HM no water 
minimized 
0.82 Å All equal 
 
An RMSD of less than 2 Å indicates that the protocol is capable of accurately docking 
ligands into the protein binding site.75 As can be seen in Table 2.6, the docking protocol 
reproduced the binding pose of the co-crystallized ligand satisfactorily in all models. All 
scoring functions performed equally well in all models, except for the 3RQJ-HM with water 
model. PLP_docked performed best here. PLP_docked places particular emphasis on the 
steric interactions of heavy atoms of the ligand with the protein binding site.76  The better 
performance of this function may suggest that steric interactions play a larger role in the 
binding of the 3RQJ ligand when compared to the 3PNF ligand.  
The docking protocol was further tested through the use of a test set (see chapter five 
section 5.5.3). Only one experimentally validated human nNOS inhibitor was available at 
the time of model construction, therefore the test set was made up of rat nNOS 
inhibitors.45 The accuracy of the docking protocol with the test set was analysed using 
receiver operator characteristic (ROC) curves. The scores are presented in Table 2.7.  
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Table 2.7. Performance of the docking protocol with the models using a test set. 
Model ROC Scores Best FRED docking function 
3PNF HM with water 
minimized 
0.79 Chemscore 
3PNF HM no water 
minimized 
0.69 Chemscore 
3RQJ HM with water 
minimized 
0.76 All equal 
3RQJ HM no water 
minimized 
0.71 All equal 
 
Discovery Studio, which was used to generate the ROC scores in this project, groups the 
scores based on their performance. A score of 0.5-0.6 is a failure, 0.6-0.7 is poor, 0.7-0.8 is 
fair, 0.8-0.9 is good and above 0.9 is excellent.  Although the ROC scores are similar for the 
3PNF-HM and 3RQJ-HM, it was observed that 3PNF-HM performed slightly better than 
3RQJ-HM. The models with explicit waters present also performed better. This, coupled 
with the previous structural validation results and the re-docking of the co-crystallized 
ligand results, led to the conclusion that the minimized version of 3PNF-HM with waters 
was the most structurally and functionally robust model. The inclusion of waters in the 
models may also allow for identification of compounds which form solvent mediated HBs 
with the nNOS binding site. The 3PNF-HM with water model was therefore used for all 
commercial database screening.  
2.4.4 nNOS homology model binding pocket analysis 
 
An overlay of the template 3PNF and the 3PNF-HM is shown in Figure 2.9.  
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Figure 2.9. 3PNF rat template (yellow backbone) overlaid with 3PNF-HM (cyan backbone). BH4shown 
in blue, heme shown in green. Numbering of residues is template/homology model. Waters omitted 
for clarity. 
 
As predicted by the sequence alignment the binding site of the rat and human isoforms was 
similar, with the only residue difference being Leu337 in the rat isoform becoming Hid342 
in the human model. There was also a difference in rotameric states of the Asp597/602 
(rat/HM). In the homology model the side chain of Asp602 is not orientated towards the 
substrate binding site. This may weaken the interactions of potential inhibitors by 
preventing the formation of HBing interactions with the Asp602 residue. 
 
2.4.5 Rotamers of Glu597 and Asp602 in human nNOS homology model 
 
The effect of the differing rotameric states of GLU597/602 (template/HM) was investigated 
by enumerating the three rotamers of this residue in the 3PNF-HM minimized with water 
and re-docking the test set. The ROC scores generated are shown in Table 2.8. 
Chapter Two                                                                                                     Computational Studies                                                                                                                     
 
 
55 
 
Table 2.8. Rotamers of D597. 
Rotamer number ROC score, 3PNF minimised with water 
1 (original) 0.79 
2 0.76 
3 0.73 
  
No improvement in the ROC scores were observed, therefore the original rotameric state 
of Asp602 was retained in the homology model.  
In a further attempt to improve the ROCS score of the 3PNF-HM key binding site 
interactions of nNOS inhibitors, as reported in the literature, were examined in detail. It 
was found that Glu592 in the rat nNOS structure (Glu597 in the 3PNF-HM) mediates crucial 
HB interactions with both the natural substrate (L-arginine) and with a large range of 
inhibitors.48,64,77,78 It has also been noted that this residue can adopt a variety of rotameric 
states depending on the binding mode of nNOS inhibitors.52 Glu597 in the 3PNF-HM has 
seven possible rotameric states. These states were enumerated in turn and the nNOS test 
set was docked into the binding site to see if the ROC scores could be improved. The results 
are summarised in Table 2.9. 
Table 2.9. Analysis of rotamers of Glu597. 
Rotamer Number ROC score, 3PNF minimized with water 
1 (original) 0.79 
2 0.55 
3 0.54 
4 0.54 
5 0.73 
6 0.77 
7 0.63 
 
Again, no improvement was observed on testing of alternate rotameric states for the 
Glu597 residue. Indeed, many of the rotamers resulted in significantly worse ROC scores. 
The original rotamer of E597 was therefore retained for docking applications.   
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2.5 eNOS and iNOS crystal structures 
 
Crystal structures of human eNOS and iNOS were used to assess how isoform specific the 
docking protocol and resulting hit lists were. Two holo structures were studied for eNOS 
and iNOS. The iNOS structures had PDB codes of 3E7G (2.2 Å resolution) and 4NOS (2.25 Å 
resolution).79,80 The eNOS structures used were 1M9M (1.96 Å resolution) and 3NOS (2.40 Å 
resolution).80,81 As the energy minimized 3PNF-HM with co-crystallised waters was to be 
used for nNOS docking, all validations of iNOS and eNOS crystal structures were carried out 
on the minimized versions of the proteins with explicit waters present.  
 
2.5.1 Structural validation 
 
The robustness of the eNOS and iNOS crystal structures were assessed in the same manner 
as the nNOS homology models (Procheck in Table 2.10 and Verify 3-D, Errat Table 2.11). 
 
Table 2.10. Procheck results of eNOS and iNOS crystal structures. 
 1M9M 3NOS 3E7G 4NOS 
Number of 
residues 
830 854 848 854 
Most favoured 91.6% 88.9% 91.0% 89.4% 
Allowed 8.4% 10.8% 9% 10.6% 
Generously 
Allowed 
0% 0.3% 0% 0% 
Disallowed 0% 0% 0% 0% 
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Table 2.11. Verify 3-D and Errat scores of eNOS and iNOS structures. 
Structure Verify 3-D Score Errat Score 
1M9M 91.50% 89.770 
3NOS 90% 90.051 
3E7G 88.12% 94.011 
4NOS 92.87% 90.073 
 
The eNOS 1M9M structure passed the Procheck stereochemistry test, with 91.6% of 
residues in the most favoured regions. The 3NOS structure fell below the 90% limit for 
residues in the most favoured regions, although it was a marginal failure with 88.9% in the 
most favoured region. 1M9M performed better in the Verify 3-D test than the 3NOS 
structure, with scores of 91.5% and 90% respectively. This trend was reversed in the Errat 
test, with 3NOS outperforming 1M9M. However, as previously observed in the Procheck 
tests, the differences between the two eNOS crystal structures in the validation tests was 
minimal, indicating that both 1M9M and 3NOS would be suitable for docking applications.  
For iNOS, 3E7G passed the Procheck test (91% in the most favoured region), while 4NOS 
scored 89.4%, slightly below the desired 90% for residues in the most favoured regions. 
3E7G also scored better in the Errat test, while 4NOS did better in the Verify 3-D test. 
Similar to the eNOS structures, these validation tests revealed that there was very little 
difference between the two iNOS structures. As such, no one crystal structure was chosen 
for docking studies at this stage and further validation tests were required.  
 
2.5.2 Docking protocol validation with eNOS and iNOS crystal structures 
 
The initial test of the docking protocol with the iNOS and eNOS structures involved 
reproducing the binding poses of the co-crystallised ligands for each structure using FRED 
docking. The structures of the co-crystallised ligands, 22-25, are shown in Figure 2.10. The 
re-docked binding poses were compared with the original binding poses using RMSD scores 
(Table 2.12).  
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Figure 2.10. eNOS and iNOS co-crystallised ligands, 22-25.
79–81
 
 
Table 2.12. RMSD scores on reproduction of original binding pose for eNOS and iNOS crystal 
structures. 
Structure RMSD Best FRED docking function 
1M9M 4.66 Å All equal 
3NOS 0.80 Å All equal 
3E7G 1.17 Å All equal 
4NOS 1.16 Å All equal 
The docking pose was successfully reproduced in all models, except for 1M9M. The RMSD 
score for the re-docked ligand in this case was outside of the acceptable 2 Å limit.  Closer 
inspection of the re-docked binding pose revealed that the 1M9M ligand had been flipped 
in the binding site relative to its original position. The ligand was a small heterocycle (Figure 
2.10) which could be orientated into the binding site in a variety of poses. The docking 
protocol was not effective at identifying which of these orientations was correct for binding 
in the 1M9M structure. Although the failure with the 1M9M structure was most likely due 
to the nature of the ligand rather than the crystal structure, it was decided to omit 1M9M 
from further testing.  
Similar to the nNOS procedure, the FRED docking protocol was tested with eNOS and iNOS 
test sets, developed as per chapter five, section 5.5.8. These were docked into the crystal 
structures and ROC scores generated (Table 2.13). Explicit waters were included for all 
structures. 
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Table 2.13. eNOS and iNOS test set ROC scores. 
PDB Code Isoform ROCS best function Function score 
3NOS eNOS ChemGauss3 0.75 
4NOS iNOS Chemscore 0.56 
3E7G iNOS Chemscore 0.70 
 
The 3NOS structure performed relatively well in the test, achieving a ROC score of 0.75 
using the ChemGauss3 docking function. This structure was therefore used for eNOS 
docking applications. For iNOS, 3E7G was seen to score better in the test set screen, scoring 
0.70, compared to 4NOS with a score of 0.56. As a result, 3E7G was deemed to be the iNOS 
structure of choice for docking.  
 
2.5.3 Selectivity human nNOS homology model 
 
One of the aims of this work was to develop a selective human nNOS inhibitor. Attempts to 
build this selectivity into the screening process were made from an early stage. The test 
sets for eNOS and iNOS were docked into the 3PNF-HM to assess whether or not the 
human nNOS homology model and FRED docking protocol were selective for nNOS 
inhibitors over eNOS and iNOS inhibitors. This would also identify which, if any, of the FRED 
scoring functions were more effective at identifying nNOS inhibitors. The ROC score of the 
3PNF-HM with the nNOS haystack is also provided for reference (Table 2.14). 
Table 2.14. 3PNF-HM docked with the iNOS and eNOS test set. 
Scoring function 
3PNF-HM with iNOS 
test set 
3PNF-HM with eNOS 
test set 
3PNF-HM with nNOS 
test set 
Chemgaus2 0.54 0.79 0.68 
Chemgaus3 0.55 0.55 0.57 
Chemscore 0.53 0.51 0.79 
Consensus 0.77 0.70 0.52 
PLP 0.65 0.64 0.59 
Screenscore 0.56 0.69 0.54 
Shapegauss 0.89 0.82 0.73 
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The best performing scoring function for 3PNF-HM with the nNOS test set was Chemscore, 
which achieved a ROC score of 0.79. This function also performed poorly with the iNOS and 
eNOS test sets, scoring 0.53 and 0.51 respectively. This indicated the Chemscore was 
capable of identifying nNOS inhibitors, while being ineffective at identifying iNOS and eNOS 
inhibitors. As a result, the screening of commercial datasets using Chemscore and the 
3PNF-HM should select nNOS inhibitors and discard eNOS and iNOS inhibitors. 
 
2.6 Structure based drug design virtual screening 
 
2.6.1 Docking results using human nNOS homology model 
 
With the homology model and docking protocol verified, the screening of Maybridge 
(screening library, 53,000 compounds, http://www.maybridge.com/) and Zinc (drug-like 
available now subset, 10.6 million compounds, http://zinc.docking.org/) commercial 
databases was conducted as per chapter five, section 5.5. The commercial datasets were 
pre-filtered with a Pipeline Pilot BBB filter. This was carried out in an effort to ensure BBB 
permeability for the hit compounds generated by the screening trials. Following FRED 
docking of the pre-filtered Maybridge and Zinc databases, flexible docking of the top 100 
compounds from each database was carried out as per chapter 5, section 5.5.4. The 
resulting hit lists were analysed and a number of compounds were selected for biological 
evaluation. The selection process was mainly based on the rank of the compound in the 
docking list. The ADMET properties (calculated by Biovia’s Discovery Studio) and the 
potential of the compounds to be structurally modified in subsequent SAR studies were 
also taken into consideration.  
The compounds chosen were also as diverse as possible to ensure maximum possible 
coverage of chemical space. The structures and rank numbers of the hit compounds chosen 
for biological evaluation are presented in Table 2.15 and Table 2.16. The blood brain 
barrier (BBB) levels of the chosen structures from the Maybridge screen (Table 2.15) were 
seen to be very favourable, with all structures apart from one having a BBB level of two or 
less. A BBB level of zero indicates that the compound is extremely BBB permeable, one is a 
compound with high BBB permeability and two is a medium level of BBB permeability, (see 
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chapter five, section 5.4.2). The bloodstream absorption levels were also promising, with all 
compounds apart from one scoring either zero or one. A score of zero indicates that the 
compound would be well absorbed into the bloodstream, while a score of one indicates 
moderate levels of absorption, (See chapter five, section 5.4.2). Finally, the predicted 
aqueous solubility of the chosen compounds varied quite widely. The lower the aqueous 
solubility value, the less aqueous soluble the compound. An ideal value for this attribute is 
four. At this level of aqueous solubility the compound is predicted to be sufficiently soluble 
for drug administration and distribution. A higher value may result in rapid elimination of 
the drug candidate from the body before the active ingredient has an opportunity to pass 
into the bloodstream from the intestine and interact with the desired physiological target.  
Table 2.15. Biologically evaluated compounds derived from 3PNF-HM flexibly docked with 
Maybridge dataset. 
Compound Structure Rank 
Compound 
No. 
BBB 
level 
Bloodstream 
absorption 
level 
Aqueous 
Solubility 
level 
 
1 26 1 0 2 
 
4 27 2 0 3 
 
5 28 2 0 3 
 
7 29 4 2 1 
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9 30 1 0 2 
 
10 31 0 1 1 
 
12 32 0 0 1 
 
16 33 
 
0 
 
1 1 
 
17 34 1 0 2 
 
19 35 1 0 1 
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29 36 2 0 2 
 
An image of 26, which ranked highest in the Maybridge screen, bound into the 3PNF-HM is 
shown in Figure 2.11. Interactions between the ligand and the binding site include HBing to 
Glu597, hydrophobic interactions with Met341, His342, Pro570, Tyr683 and Tyr711. There 
is also a predicted π stacking interaction with the heme moiety. The two main inhibitor 
classes for rat nNOS inhibition have been reported to form interactions with several of 
these residues including Glu592 (Glu597 in human nNOS), Met336 (Met341 in human 
nNOS), Leu337 (His342 in human nNOS), Pro565 (Pro570 in human nNOS),  Tyr711 (Tyr706 
in human nNOS).49 Of particular interest was the predicted interaction with the His342 
residue in the human nNOS binding site. In rat nNOS the His342 becomes a leucine residue. 
Interaction with the His342 residue could therefore help to facilitate the design of a new 
scaffold for human nNOS inhibition. 
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Figure 2.11. 3PNF homology model with 26 bound. Structure of 26 is also shown separately. 
Residues in yellow, heme in green, BH4 in blue, ligand in orange. Waters omitted for clarity. 
 
One of the high ranking compounds of interest from the Maybridge screen with 3PNF-HM 
(Table 2.15) was not available for purchase, 34,. A number of versions of this structure 
were therefore synthesised. The synthesised compounds were chosen based on similarity 
to 34 and are shown in Figure 2.12. 
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Figure 2.12. Compounds synthesised based on 34. (37-40) 
 
The core was modified to a six membered piperazine ring, rather than the more unusual 
seven membered dinitrogen ring seen in 34. This piperazine ring was more synthetically 
accessible than the seven membered ring. A secondary amine was added adjacent to the 
carbonyl group. It was envisaged that this could act as a potential HB donor and interact 
with the acidic residues in the nNOS pocket (Glu597, Asp602). The inclusion of the amine 
also allowed for bond formation via well synthetic methodologies. The chlorine moiety 
from the screening hit was retained, and a version of the compound without the chlorine 
was synthesised to explore the effects of the substituent on activity. Finally, two derivatives 
were synthesised where the carbonyl oxygen was substituted for the less electronegative 
sulphur to examine the electronic effects at this position. It was thought that replacement 
of the oxygen for the sulphur would increase the pKa of the hydrogen on the neighbouring 
nitrogen, strengthening any potential H-bond interactions between it and the binding site. 
The proposed structures were flexibly docked into the nNOS homology model binding site, 
and scored 14.9356, 14.7354, 14.0519 and 13.8756 respectively with cDOCKER, (37-40). 
While these scores were lower than the score of the parent compound (34, 17.3910), they 
were still relatively high and indicated that 37-40 may form interactions with the human 
nNOS binding site.   
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Table 2.16. Biologically evaluated compounds derived from 3PNF-HM flexibly docked with Zinc 
dataset. 
Compound Structure Rank 
Compound 
No. 
BBB 
level 
Bloodstream 
Absorption 
level 
Aqueous 
Solubility 
level 
 
1 41 0 0 2 
 
3 42 1 0 2 
 
9 43 0 0 2 
 
13 44 1 0 3 
 
14 45 1 0 2 
 
18 46 1 0 2 
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19 47 1 0 2 
 
21 48 1 0 2 
 
Similar to the Maybridge screen, the BBB and bloodstream absorption levels for the Zinc 
compounds were again seen to be favourable, while the aqueous solubility levels were all 
either two or three. This was as expected as the Zinc dataset had been pre-selected to 
screen only drug like candidates and the BBB like filter had also been applied. Many of the 
high ranking compounds had broadly similar features, with an aromatic ring at each end of 
the molecules, joined by a linker which contained a HB donor. This would allow interaction 
with the heme propionate and the Tyr711 residue, while the HB donor could potentially 
interact with one or more of the HB acceptors in the 3PNF-HM binding site, such as Glu597 
and Asp602. 
The top ranked compound from the Zinc screen (41) bound to the 3PNF-HM is shown in 
Figure 2.13. Interactions between the ligand and the binding site include π stacking 
interaction with the heme porphoryin, hydrophobic interactions with Val687 and Pro685 
(not shown), and two solvent mediated HBs to Asp717 and Arg723. These interaction types 
have not been previously observed for nNOS inhibition. Interestingly, the disubstituted 
aromatic ring of the hit compound did not form a π stacking interaction with Tyr711. 
Literature precedent suggests that aromatic rings which are situated close to Tyr706 (rat 
nNOS) can form π stacking interactions with the side chain of this residue. The expected HB 
with Glu597 or Asp602 was also not predicted. Compounds from the Zinc screen were 
purchased and 41 was synthesised for biological evaluation.  
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Figure 2.13. 3PNF-HM binding site with 41 bound. 41 is also shown separately. Binding site residues 
in yellow, heme in green, BH4 in blue and ligand in orange. Waters omitted for clarity. 
 
 
2.6.2 Comparison of top docking hits in eNOS, iNOS and nNOS 
 
Zinc and Maybridge were also docked into the human iNOS and human eNOS crystal 
structures as validated in section 2.5.2. The top ten hits from the nNOS screens of Zinc and 
Maybridge are shown in Table 2.17 and Table 2.18, along with the rankings of each hit 
compound in the eNOS and iNOS docking screens (see chapter five, section 5.5.7 for iNOS 
and eNOS docking procedure). An alignment of the key binding site residues in the three 
human isoforms is provided in Table 2.19.  
 
Chapter Two                                                                                                     Computational Studies                                                                                                                     
 
 
69 
 
Table 2.17. Top ten Maybridge hits from nNOS HM, and their ranks when docked with human 
eNOS and human iNOS. 
Structure nNOS HM rank Human eNOS rank Human iNOS rank 
 
1 2 1 
 
2 1 Outside top 100 
 
3 3 Outside top 100 
 
4 4 Outside top 100 
 
5 5 5 
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6 7 4 
 
7 6 Outside top 100 
 
8 9 15 
 
9 19 7 
 
10 8 Outside top 100 
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Table 2.18. Top ten Zinc hits from nNOS HM, and their ranks when docked with human eNOS and 
human iNOS. 
Structure nNOS HM rank Human eNOS rank Human iNOS rank 
 
1 4 2 
 
2 3 10 
 
3 6 Outside top 100 
 
4 1 35 
 
5 10 7 
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6 12 78 
 
7 11 Outside top 100 
 
8 5 3 
 
9 18 Outside top 100 
 
10 15 14 
 
 
 
 
Chapter Two                                                                                                     Computational Studies                                                                                                                     
 
 
73 
 
Table 2.19. Comparison of key binding site residues in human iNOS, eNOS and nNOS.  
iNOS eNOS nNOS 
M120 V104 M341 
T121 F105 H342 
A262 S246 S482 
Q263 Q247 Q483 
R266 R250 R486 
V352 V336 V572 
F369 F353 F589 
N370 S354 S590 
G371 G355 G591 
W372 W356 W592 
Y373 Y357 Y593 
E377 E361 E597 
D382 N366 D602 
Y491 Y475 Y711 
 
iNOS, eNOS and nNOS had many of same compounds in their respective top ten hit lists. 
This was despite the fact that the validation steps with Chemscore suggested that the 
scoring function was capable of identifying selective human nNOS inhibitors. It was not 
surprising that many of the potential hit compounds were the same for the three isoforms. 
As can be seen in Table 2.19 many of the key residues are identical between the NOS 
human isoforms, making selectivity for one isoform difficult to predict and achieve. A 
protein sequence alignment of the three isoforms, conducted with Clustal Omega, revealed 
a 52.6% identity and a 70.9% similarity between the isoforms. It was also observed that the 
docking protocol was more selective for nNOS over iNOS, than nNOS over eNOS. This 
suggests that preventing off target effects in eNOS may be more difficult than preventing 
off target effects in iNOS.   
This has been borne out in the literature, as all reported nNOS inhibitors exhibit some 
degree of inhibitory activity towards the other two isoforms, (chapter one, section 1.4). It 
was decided to continue with biological evaluation of the chosen nNOS hits. If a successful 
hit compound was identified, selectivity for nNOS could then be explored via SAR 
modification. This would potentially be targeted towards the Asp602 residue in nNOS, 
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which is replaced by an Asn366 in eNOS. The pKa of the aspartic acid side chain is 3.9, while 
the asparagine side chain is not deprotonated at physiologically relevant pH levels.82 
Therefore, selective targeting of human nNOS over human nNOS may be achieved by 
targeting a HB donor towards the Asp602 residue. The deprotonated carboxylic acid group 
of aspartic acid will be capable of forming HB interactions with the HB donor, while the 
protonated asparagine side chain in eNOS will not be capable of forming these types of 
interactions.   
Selectivity for nNOS over iNOS could potentially be achieved by targeting of the His342 
residue in nNOS, which is replaced by Thr121 in iNOS. The pKa of the imidazole ring in the 
histidine side chain is ~ 6.0, while threonine’s side chain remains protonated at 
physiologically relevant pH levels.82 The deprontonated imidazole ring of histidine could 
therefore act as a HB acceptor with a potential inhibitor, while the protonated threonine of 
eNOS would not act in this way.  
   
2.6.3 Structure based design conclusion 
 
The structure based design approach described above represented a worthwhile study as 
such a high throughput screening approach with a human nNOS homology model has not 
yet been reported. Also, it was expected that the model that was developed should be 
accurate owing to the sequence similarity between target and template. It was therefore 
hoped that the compounds identified would act as novel human nNOS inhibitors. The 
compounds identified also had favourable PK properties and were predicted to form a 
variety of interactions with the human nNOS binding site. The compounds, as outlined in 
Table 2.15 and Table 2.16, were purchased or synthesised for biological evaluation. This 
structure based design approach was complimented by a ligand based design approach. 
The use of two separate computational methods sought to maximize the chances of 
identifying efficacious and selective human nNOS inhibitors. The ligand based design 
experiments that were conducted will be outlined in the next section.   
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2.7 Ligand based drug design overview 
 
While comparative modelling focuses on the predicted binding site of the protein target of 
interest, ligand based drug design (LBDD) examines known inhibitors of the target. These 
known inhibitors can be used to predict the types of features that may result in enzyme 
inhibition. A pharmacophore is developed where the important features of the active 
ligands are orientated relative to each other. The pharmacophore is then used to screen 
commercial databases to find compounds whose features match the features of the 
pharmacophore. The general approach used in this project is outlined in Figure 2.14. Notice 
that many of the procedural steps for model validation are the same as those used for the 
structure based drug design. The preparation of the commercial database is also identical 
to the methods already described for the structure based drug design.  
 
Figure 2.14. Ligand based drug design overview. 
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2.7.1 Pharmacophore: Construction and validation 
 
A pharmacophore is defined as a set of features that is common to a series of active 
molecules.133 These features are also referred to as pharmacophoric groups and include 
structures such as HB donors and acceptors, positively and negatively charged groups and 
hydrophobic groups. 
All pharmacophores were constructed using CATALYST software.163 This generates and 
validates pharmacophoric models and screens databases in one convenient protocol. 2-D 
pharmacophores are generated using HipHop.163 A 2-D pharmacophore is used when the 
bioactive conformation of the ligands is unknown. 
The input file for pharmacophore generation using HipHop contains a set of active 
compounds which have a high affinity for the target, and a set of inactive compounds 
which have a low affinity for the target. The cut offs for high and low affinity are target 
dependent. The most active compound is assigned a principle number of two, the rest of 
the actives are assigned a principle number of one and the inactives are assigned as zero. A 
range of options can then be altered for the pharmacophore generation, including how 
many features of the active compounds may be omitted from the pharmacophore (max 
omit), whether or not the feature placement is flexible and the number of excluded 
volumes to include. The excluded volumes are regions of space into which placement of a 
pharmacophoric feature would be unfavourable. These are generated using the inactive 
compounds.164,165 Often a combination of these options can be trialled to generate a 
number of pharmacophores that are then validated to determine the best performing 
conditions. 
Validation of pharmacophoric models is conducted in a similar fashion to validation of 
docking protocols, i.e. through the use of a validation set and scoring with ROCS curves. It is 
important to omit the compounds used for pharmacophore generation from this validation 
set.  
2.7.2 Pharmacophore screening 
 
With a pharmacophore model generated and validated it can then be used to screen large 
molecule databases. This involves “matching” of the pharmacophoric features to the 
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ligands in the database. As the bioactive conformation of the ligands is unknown, a 
conformer ensemble of the ligand database is used. The ligands are then ranked using 
FitValue, with larger values indicating a better fitting ligand.166  
 
2.8 Ligand based drug design results 
 
2.8.1 Pharmacophore one construction and validation 
 
Initial attempts to develop a nNOS pharmacophore used large numbers of active and 
inactive compounds from the Chembl database (https://www.ebi.ac.uk/chembl/). All 
compounds with an IC50 of 10 µM or less for nNOS were designated as nNOS actives (550 
compounds), while all compound with an IC50 of 30 µM or more for nNOS were designated 
as inactives (300 compounds). These were clustered as per the chapter five, section 5.5.10 
and the pharmacophore generated. It should be noted that a search of the Chembl 
database using human nNOS as the target returns over 800 compounds. However, 
examination of the publications from which these compounds are derived reveals that no 
testing on human nNOS was conducted in the vast majority of cases.  
Generation of a pharmacophore from this set failed. This was attributed to the fact that 
many of the most active nNOS inhibitors in the Chembl database are small nitrogen 
heterocycles, which do not have enough features to generate a useable pharmacophoric 
model. A pharmacophore usually has 3-6 features, depending on the structures of the 
compounds used to construct the model.  
This lead to the use of individually chosen active and inactive compounds for development 
of the next pharmacophoric model. The active compounds were chosen based on 
structural diversity, and avoidance of the potentially overly simple small nitrogen 
heterocycles. Compounds developed from the structure based design which had proven 
inactive in nNOS inhibition assays were also included in the inactive compound list for the 
training set. The exact compounds used for pharmacophore generation are outlined in 
chapter 5, section 5.5.10. 
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A variety of conditions were trialled for the development of this model, with ten models 
generated for each set of conditions. The pharmacophores were tested using the nNOS test 
set developed during the homology model construction. The test set was carefully checked 
to ensure it did not contain any compounds that had been used in the training set as this 
would potentially skew the validation results. The best scoring pharmacophores from each 
set of conditions is show in Table 2.20 (conditions outlined in chapter five, section 2.7.1).  
 
Table 2.20. Pharmacophore generation conditions and ROC scores of the best model from each. 
Pharmacophore 
Excluded 
Volumes 
Rigid or Flexible 
Max Omit 
Feature 
ROCS score 
A 0 Rigid 0 0.731 
B 0 Rigid 1 0.774 
C 50 Rigid 0 0.765 
D 50 Flexible 1 0.780 
E 0 Flexible 0 0.787 
F 50 Flexible 0 0.805 
 
The six parameter sets all resulted in good to very good ROC scores, ranging from 0.731 to 
0.805. The best performing pharmacophore, pharmacophore F, gave a strong ROC score of 
0.805. The generation parameters for this model allowed for excluded volumes, flexible 
ligand mapping and had a max omit value of zero. The presence of excluded volumes in the 
model was welcome, as the generation set contained several experimentally validated 
inactive human nNOS inhibitors from the structure based design studies. As very few 
compounds have been tested with isolated human nNOS, the inclusion of known inactive 
compounds in the pharmacophore model represented an important step forward in the 
field. Pharmacophore F is shown in Figure 2.15. 
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Figure 2.15. Image of pharmacophore F. HB donor in pink, hydrophobic aromatic in blue, 
hydrophobic non-aromatic in cyan, excluded volumes in grey.  
 
The pharmacophore had three feature types, a HB donor (pink) a hydrophobic aromatic 
(blue) and a hydrophobic non aromatic (cyan). The excluded volumes are shown in grey 
and are derived from the inactive compounds in the training set. These suggested features 
mirrored the features of the human nNOS binding site quite closely.83 The HB donor is 
pointing towards the bottom of the pocket, where the key glutamic acid residue (Glu597) is 
available to form H-bond interactions. The hydrophobic aromatic feature sat above the 
space which is occupied by the heme moiety in the binding site. The residues surrounding 
the heme in the binding site of human nNOS are Ser588, Tyr585 and the three hydrophobic 
residues Gly587, Trp586, Phe589. The excluded volumes around the hydrophobic aromatic 
feature represented these five residues. Finally, the hydrophobic non-aromatic feature sits 
close to where the His342, Met341 and Tyr711 hydrophobic pocket is located in the human 
nNOS binding site. To illustrate this comparison, an image of the most active compound 
used for pharmacophore generation (Chembl1944717, 49, IC50 of 12 µM for human nNOS 
in whole cell assay) is shown aligned to the pharmacophore and docked into the homology 
model binding site in Figure 2.16.84 
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Figure 2.16. Pharmacophore F and 3PNF-HM with compound 49 orientated in similar poses. For 
pharmacophore HB donor in pink, hydrophobic aromatic in blue, hydrophobic non-aromatic in cyan, 
excluded volumes in grey. For 3PNF-HM residues in yellow, heme in green, BH4 in blue and ligand in 
orange. Waters omitted for clarity. 
 
2.8.2 Pharmacophore one screen 
 
The list of compounds chosen for biological evaluation from a screen of commercial 
datasets (Zinc and Maybridge) using pharmacophore F is shown in Table 2.21. The overall 
rank of the compounds in the screening list is also shown. 
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Table 2.21. Pharmacophore round one screening. 
Compound Structure Rank 
Compound 
No. 
BBB 
level 
Bloodstream 
Absorption 
level 
Aqueous 
Solubility 
level 
 
1 50 4 2 1 
 
2 51 1 0 1 
 
4 52 0 0 1 
 
5 53 1 0 2 
 
6 54 1 0 2 
 
7 55 1 0 2 
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8 56 1 0 2 
 
9 57 2 0 2 
 
10 58 2 0 3 
 
11 59 1 0 1 
 
12 60 1 0 1 
 
13 61 1 0 2 
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14 62 0 0 1 
 
15 63 3 0 3 
 
16 64 1 0 2 
 
17 65 3 0 4 
 
18 66 1 0 2 
 
19 67 0 0 2 
 
20 68 2 0 3 
 
21 69 1 0 2 
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42 70 3 0 3 
 
The PK properties of the hits were again largely favourable, although there a larger number 
of non BBB permeable compounds ranked highly in the hit list. Despite their less favourable 
BBB properties, the compounds shown in Table 2.21 were advanced for biological 
evaluation. If one of the compounds proved to have nNOS inhibitory activity, it could be 
chemically modified to improve its PK profile. 
The highest ranked compound (50) from this screen aligned to pharmacophore F, is shown 
in Figure 2.17. 
 
 
Figure 2.17. Pharmacophore F with 50 aligned. 50 is also shown separately.  HB donor in pink, 
hydrophobic aromatic in blue, hydrophobic non-aromatic in cyan, excluded volumes in grey. 
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The secondary amine of 50 sits in the HB donor site, while the disubstituted pyridine ring 
occupies the hydrophobic aromatic feature. The chlorine from the disubstituted benzene 
extends into the non-aromatic hydrophobic region.  The molecule also avoids all excluded 
volumes. The thiazole ring containing portion of the molecule extends below the HB donor 
pocket. This may potentially clash with residues in this region which were not modelled by 
the pharmacophore. This could impact the compound’s binding ability and effectiveness. 
Surprisingly, compounds with a similar core to 23, which matched the pharmacophoric 
elements but lacked the apparently superfluous thiazole “tail”, did not rank in the top 500 
compounds of this screen.  
 
2.8.3 Pharmacophore two construction and validation 
 
Following biological evaluation of the compounds shown in Table 2.21 (Section 4.16) a 
second iteration of the pharmacophore was developed to refine the model. The 
performance of the compounds from the previous pharmacophore in an nNOS inhibition 
assay (chapter four section 4.16) was taken into account for generation of the second 
pharmacophore. The generation of the second pharmacophore also included the best 
reported human nNOS inhibitor, Figure 2.18.45 This inhibitor was omitted form the 
generation of the first pharmacophore as it was not indexed in the Chembl database. 
Failure of the first pharmacophore to identify a novel human nNOS inhibitor prompted a 
more thorough search of the literature for active human nNOS inhibitors, which resulted in 
the identification of the compound shown Figure 2.18. Ten pharmacophores were 
generated in this second iteration, using the previously identified optimum parameters (50 
excluded volumes, flexible fitting, max omit zero). The ROC scores for the ten 
pharmacophores are shown Table 2.22. These ROC scores were generated using the same 
test set as was used in the first pharmacophore iteration (section 2.8.1). 
 
Chapter Two                                                                                                     Computational Studies                                                                                                                     
 
 
86 
 
 
Figure 2.18. Human nNOS inhibitor used as active for generation set.
45
 
 
Table 2.22. ROC scores of the second generation of pharmacophores (50 Excluded volumes, 
flexible fitting, max omit zero). 
Pharmacophore ROC score 
G 0.672 
H 0.607 
I 0.506 
J 0.712 
K 0.546 
L 0.651 
M 0.540 
N 0.557 
O 0.632 
P 0.515 
 
The best scoring pharmacophore was pharmacophore J, Figure 2.19. The ROC scores were 
less impressive for this round of pharmacophore generation, suggesting that the second 
pharmacophore was less accurate at identifying nNOS inhibitors. The inclusion of the extra 
excluded volumes in pharmacophore J compared to pharmacophore F may have made it 
more difficult of the compounds of the test set to align with the pharmacophoric features 
of pharmacophore J, thus resulting is lower ROC scores for this iteration. 
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Figure 2.19. Image of pharmacophore J. HB donor in pink, hydrophobic non-aromatic in cyan, 
excluded volumes in grey. 
 
The HB donor feature and its direction were retained in pharmacophore J. This would allow 
compounds that matched pharmacophore J to form HB interactions with the key Glu597 
residue in the human nNOS binding pocket. A hydrophobic non-aromatic feature sat close 
to the HB donor feature. Similar to pharmacophore F, this suggested that the residues 
surrounding the heme moiety in the binding site were hydrophobic in nature. However, the 
change of the feature from an aromatic hydrophobic (pharmacophore F) to a non-aromatic 
hydrophobic (pharmacophore J) was unexpected. It was initially thought that this feature 
represented the aromatic heme moiety in the nNOS binding site, and compounds which 
formed aromatic π stacking interactions with this moiety would fit pharmacophore F well. 
This π stacking interaction was deemed less important in pharmacophore J.    
The final non-aromatic hydrophobic feature in pharmacophore J matched the remaining 
non-aromatic hydrophobic feature in pharmacophore F. There were a larger number of 
excluded volumes in pharmacophore J due to the increased number of inactives in the 
training set. This provided a more complete view of the binding pocket. 
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2.8.4 Pharmacophore two screen 
 
Screening of Maybridge and Zinc was conducted with pharmacophore two, and the 
compounds chosen for biological evaluation are shown in Table 2.23.  
 
Table 2.23. Pharmacophore 2 screened list. 
Compound Structure Rank 
Compound 
No. 
BBB 
level 
Bloodstream 
Absorption 
level 
Aqueous 
Solubility 
level 
 
1 71 1 0 1 
 
2 72 4 1 1 
 
4 73 1 2 2 
 
5 74 1 0 2 
 
6 75 2 0 1 
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9 76 4 2 2 
 
11 77 4 0 2 
 
13 78 1 0 1 
 
18 79 4 2 1 
 
22 80 1 0 1 
 
40 81 1 0 1 
 
The features of pharmacophore J suggested that non aromatic moieties would be favoured 
close to a HB donor. Taking 71 as an example, the disubstituted phenol ring is non aromatic 
as represented in Table 2.23. However, it is unlikely that 71 exists solely as this tautomer. 
The most likely structure would reform the aromaticity of the ring, while breaking the 
carbonyl double bond. This would then potentially form a second HB donor feature on the 
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ring with the protonation of the oxygen. As the ligand databases are screened through the 
pharmacophore as localised structures, this potential delocalisation and reformation of the 
aromatic character of the ring was not taken into account by the algorithm.  
The napthyl ring at the other end of 71 is obviously aromatic, and therefore does not match 
with the other non-aromatic hydrophobic feature of pharmacophore J. It is questionable, 
therefore, if there is a large difference between aromatic and non-aromatic hydrophobic 
features in the pharmacophore generation and screening procedure. The other molecules 
in the hit list all follow this type of trend, with large degrees of aromatic character being 
retained across the list.  
The BBB values of the hit compounds from this screen were markedly increased relative to 
previous screens. Several compounds with a BBB of three or four ranked highly in the list. 
While this did present a potential PK issue, it was decided to continue with testing of these 
compounds as the initial goal of the project was to identify a human nNOS inhibitor. The 
BBB permeability issues could then potentially be addressed through structural 
modifications. These may include removal of ionisable groups and decreasing the 
molecular weight of the compound to below 300 Da. The absorption levels were seen to be 
favourable for the top ranked compounds, while the aqueous solubility levels were less 
favourable.  
The highest ranking compound from this screen, 71, is shown overlaid with pharmacophore 
J in Figure 2.20. The alcohol group occupies the HB donor feature, while the ring it is 
attached to occupies the non-aromatic hydrophobic pocket nearby. The di substituted 
napthyl group occupies the remaining non aromatic hydrophobic feature.   
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Figure 2.20. Pharmacophore J with 71 aligned, along with 71 shown separately. 
 
 
2.9 Human nNOS Crystal Structure 
 
2.9.1 Comparing homology model and crystal structure binding sites 
 
The first crystal structure of human nNOS only became available in 2015, PDB code 4DN1.83 
This was expedient as it allowed for screening of commercial databases using the actual 
structure of the human protein. It also allowed for comparison of the homology model with 
the crystal structure to assess the accuracy of the modelling experiments. An image of the 
human nNOS binding site taken from the crystal structure is provided in Figure 2.21. An 
overlay of the 3PNF-HM with the 4DN1 crystal structure is shown in Figure 2.22. 
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Figure 2.21. 4DN1 human nNOS crystal structure binding site. The residues are shown in yellow, 
heme in green and BH4 in blue.  Waters omitted for clarity.
83
   
 
 
Figure 2.22. Overlay of 3PNF Homology model (cyan) with 4DN1  crystal structure (yellow). The 
heme moiety is in green and BH4 is in blue. Waters omitted for clarity.
83
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It was observed that the crystal structure and homology model binding site residues were 
identical, and their side chains adopt similar orientations. Two of the residues exhibited 
alternate rotamer states in the crystal structure than was predicted by the homology 
model. Asp602 has been reported to form HB interactions with nNOS inhibitors in the rat 
binding site.48,49,63 Due to the similarity of the rat and human pockets it is reasonable to 
assume that Asp602 is capable of forming HBs with inhibitors in the human isoform also. In 
the homology model the side chain of this residue was pointed away from the pocket 
cavity, which is centred over the heme moiety, while in the crystal structure the side chain 
was pointed into the cavity, available to form HB interactions. The difference between the 
heavy chain atoms of Asp602 in the crystal structure, and the heavy chain atoms of D602 in 
the homology model was measured using RMSD (Å). An RMSD value of 2 Å or lower 
indicates that the two structures being compared are largely similar.75 The difference 
between Asp602 in the homology model an D602 in the crystal structure was found to be 
2.06  Å, very slightly above the 2 Å cut off point which indicates similarity. This difference in 
rotameric states of the side chains may impact on the types of inhibitors which dock 
successfully into the human nNOS crystal structure binding site.   
The second rotameric difference between the crystal structure and the homology model 
was at Tyr711. In the homology model the aromatic ring of the residue was seen to adopt a 
conformation that would facilitate π stacking with an inhibitor in the binding site. 
Examination of the 3PNF rat nNOS template structure revealed that its ligand (Figure 2.8) 
adopted a “flipped” binding pose, placing its aminopyridine moiety close to Tyr706. This 
induced rotation of Tyr706 and this rotameric state was conserved in the homology 
model.65 In the crystal structure the ring is pushed behind Ser482, perhaps eliminating this 
potential interaction. The difference in the position the heavy chain atoms for Tyr711 in the 
crystal structure and the homology model were again assessed using RMSD. A value of 4.28 
Å was obtained, indicating that the position of the Tyr711 side chain was considerably 
different in the homology model when compared to the crystal structure. This may cause 
different compounds to interact with the crystal structure binding site than those that were 
previously seen to interact with the homology model binding site.  
Overall, the homology model and the crystal structure were in good agreement, with the 
only real differences being the rotameric states of the residues as outlined above. This was 
encouraging as it suggests that the nNOS homology modelling procedure had been 
accurate, and had produced a reliable representation of the human nNOS binding site.  
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2.9.2 Screening results 
 
The FRED docking protocol had been updated to 3.0.0 during the course of this work. This 
used only one docking scoring function, Chemgauss4, as opposed to the seven functions 
used by FRED 2.2.5, (for a more in depth discussion of FRED 3.0.0 and FRED 2.2.5 see 
chapter five, section 2.3.1). The nNOS test set was docked though the nNOS crystal 
structure using the new Chemgauss4 architecture. This achieved a ROC score of 0.76. As a 
comparison, the test set was re-docked through the 3PNF-HM using Chemgauss4 and 
achieved a ROC score of 0.81. This was interesting as the homology model performed 
better than the crystal structure with the test set, perhaps due to the differences in 
rotameric states as described above. The homology model also performed better with the 
Chemgauss4 scoring function than with the previous FRED scoring function, suggesting that 
Chemgauss4 may be more accurate at docking molecules into the human nNOS binding 
site.  
The commercial databases (Zinc and Maybridge) were screened with the human nNOS 
crystal structure, 4DN1, using this new Chemgauss4 scoring functions in the hopes of 
identifying a potential hit compound. The crystal structure was screened as an energy 
minimized structure with co-crystallized waters included.   
The compounds chosen for biological evaluation from this screen, and their rank in the 
docking list, are shown in Table 2.24.  
Table 2.24. Top hits from human nNOS crystal structure screening. 
Compound Structure Rank 
Compound 
No. 
BBB 
level 
Bloodstream 
Absorption 
level 
Aqueous 
Solubility 
level 
 
1 82 4 3 5 
 
5 83 2 0 3 
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7 84 4 0 3 
 
11 85 2 0 2 
 
12 86 3 0 4 
 
26 87 3 0 3 
 
34 88 3 0 3 
 
36 89 2 0 3 
 
54 90 3 0 2 
 
82 91 4 1 2 
 
91 92 2 0 3 
 
106 93 2 0 2 
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Interestingly, the compounds which scored best for the crystal structure docking generally 
had a higher BBB level than was observed for the high ranking compounds from the 
homology model docking. The lowest BBB score for these compounds was two, which 
indicates a medium level of BBB permeability. Three compounds scored three (which is low 
level of BBB permeability), while three more, including the highest ranking compound, 
scored four. The compounds which scored four were seen to have multiple ionisable 
groups such as amines and alchohols which are not ideal for BBB permeability. The top 
ranking compound also had a poor aqueous soulbilty score and an unfavorable absorption 
profile. Nevertheless, biological evaluation was conducted with these compounds. If a 
postive hit was identified from this screen, structural modifications could be performed at a 
latter date to improve the pharmacokinetic profile of the compounds.  
 An image of the top ranking hit from this screen, 82, in the 4DN1 binding site is shown in 
Figure 2.23. 
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Figure 2.23. 4DN1 crystal structure binding site with 82. 82 is also shown separately. Residues in 
yellow, heme in green, BH4 in blue, ligand in orange. Waters omitted for clarity. 
 
It was predicted that 82 would form two HBs with Arg486, two with Arg608, Tyr567, (not 
shown) Tyr593, Glu597 and with the heme propionate. There is also a predicted 
electrostatic interaction with Glu597 and Asp602, a π stacking interaction with the heme 
ring and hydrophobic interactions with Pro570 (not shown) and Val572. This appears 
promising as the compound forms an array of interactions with the binding site which have 
been previously observed in the literature, including interacting with the key Glu597 
residue (See chapter one, section 1.4.4).   
Similar to the homology model docking, not all of the compounds of interest were 
commercially available. Therefore, a number of compounds based on compound 85 were 
synthesised for biological evaluation. The compounds were chosen based on synthetic 
accessibility and availability of starting materials and are shown in Figure 2.24. 
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Figure 2.24. Synthetic targets based on compound 85, compounds 94-97. 
 
For ease of synthesis, the chiral centre was removed from the molecules. It was envisaged 
that if nNOS inhibitory activity was observed with this family of compounds, the chiral 
centre would be re-introduced to determine its effect on activity. It was hoped that the 
inclusion of HB donors close to both aromatic rings would allow the compounds to bind 
into the active site in a variety of poses. The HB donor beside either ring could form 
interactions with Glu597 or Asp602, while the adjacent aromatic ring would pi stack with 
the nNOS heme moiety. The other aromatic ring could then stretch to interact with Tyr711, 
facilitating the formation of a HB between the donor and the heme propionate groups, as is 
often observed for the aminopyridine class of inhibitors (See chapter one, section 1.4). 
These proposed structures were re docked into the 4DN1 binding site, and received 
Chemgauss4 scores of 15.6342, 15.0324, 14.8652 and 14.6398 respectively (94-97). These 
were lower scores than was observed for the parent compound (85, 15.705), however they 
were still sufficiently high to make their synthesis and testing a worthwhile exercise.  
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2.10 Mixed arginine/diaminopyridine compounds 
 
As outlined in chapter one, section 1.4.4, the two main classes of inhibitors for nNOS at this 
time are modified arginines and substituted aminopyridines. It was hypothesised that 
combining of both arginines and aminopyridine motifs into a single structure may generate 
a novel human nNOS inhibitor. Modified arginines, such as L-NNA, attempt to mimic the 
interactions of the natural substrate, L-arginine with the nNOS binding site. These include 
HB interactions with Trp592 and Glu597 and as well as water mediated HB interactions 
with the heme propionate.83 The guanidinium group of L-arginine is also capable of forming 
π stacking interactions with aromatic systems such as the heme porphoryin ring.  
The substituted diaminopyridine group is capable of interacting with the nNOS binding site 
in two ways. The first being through π stacking with the heme ring, and formation of HBs 
with the Glu597 and Asp602 residues located below the ring. The second interaction that 
these motifs can form is with the Tyr711 residue via π stacking and with the heme 
propionate via HBing.55 Compounds with two substituted aminopyridine moieties can form 
both of these interaction types at once.54  
As of yet, no “mixed” modified arginine and diaminopyridine structures have been 
attempted for synthesis or biological evaluation. It was envisaged that a mixed compound 
could be capable of forming the arginine type interactions, as well as the aminopyridine 
type interactions with the human nNOS binding site, perhaps resulting in a potent nNOS 
inhibitor. The synthesis of one such structure, 98, was attempted and is shown in Figure 
2.25. The compound was docked into the 4DN1 binding site to verify the predicted binding 
pose. This is shown in Figure 2.26. 
 
 
Figure 2.25. Mixed arginine/diaminopyridine, 98.  
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Figure 2.26. Predicted binding mode of 98 in the human nNOS crystal structure. Binding site residues 
in yellow, heme in green, BH4 in blue and ligand in orange. 
 
The guanidinium group of 98 was positioned close to the heme moiety, mimicking the 
binding of the L-arginine substrate. HB interactions were observed between the 
guanidinium nitrogens and the Glu597, Trp592 and Ser482. The aminopyridine moved 
towards the Tyr711 and formed HB interactions with the heme propionate as expected. 
Although, in this prediction, the Tyr711 is not orientated to form a π stacking interaction 
with the aminopyridine, it is possible that this residue would rotate to facilitate this type of 
interaction. This has been previously observed in aminopyridine based inhibitors, (see 
chapter, one section 1.4).52  It was hoped, therefore, that 94 would be capable of binding to 
the human nNOS binding site, and would elicit an inhibitory response.  
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2.11 Conclusion 
 
Following the general theme of this work, these computational studies have focused on the 
human isoforms of the NOS enzymes by development of a human nNOS homology model 
based on a rat nNOS template. A key residue difference of Leu337 (rat) versus His342 
(human) was incorporated into the model. Also noted was a difference in rotameric state 
of Asp602 in the homology model. The model performed well with structural validation 
testing, and achieved an acceptable ROC score of 0.79 when analysed with a test set 
containing nNOS inhibitors and decoy compounds. The binding pose of the template’s co-
crystallized ligand was also successfully reproduced with the model. The data suggests that 
a robust human nNOS homology model was developed. Docking was conducted with the 
Maybridge and Zinc commercial databases, which generated a list of compounds for 
biological evaluation in the nNOS inhibition assay. 
A pharmacophore was also developed for nNOS. This was generated utilising compounds 
from the Chembl database, as well as from experimentally tested compounds from the 
homology model screen. The first pharmacophore scored well when tested with a 
validation set, achieving a ROC score of 0.805. Commercial datasets were screened against 
this model and a hit list generated. Some of the best ranking compounds were biologically 
evaluated. 
The pharmacophoric model was then refined, using experimental data from biological 
evaluations, to generate a second model. This was again validated and commercial datasets 
screened to yield a third hit list for biological screening. 
The first human nNOS crystal structure was reported in 2015.83 The arginine binding site of 
the homology model was compared to the crystallized binding site and the two were found 
to be in close agreement. However, different rotameric states were observed in the Tyr711 
and Asp602 residues, which may have affected the interactions of potential inhibitors. The 
crystal structure was validated and screened to give a 4th list of compounds for biological 
testing.   
A de novo scaffold was also designed based on the literature precedent of modified 
arginines and aminopyridines as nNOS inhibitors. This was seen to dock well into the crystal 
structure binding pocket, forming the expected interactions such as a HB with E597.   
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A number of potential nNOS inhibitors had been identified using an array of computational 
methods. This approach to nNOS inhibitor design is not utilised in the literature, with the 
current trends for nNOS inhibition favouring modification of two major known scaffolds 
(modified arginines and modified aminopyridines). With these potential nNOS inhibitors 
identified, the next step in the process was to synthesize the promising inhibitor 
candidates. The results of this work are presented in the following chapter.  
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3.1 Introduction 
 
Several of the potential human nNOS inhibitors identified through the computational 
studies needed to be synthesised, while others could be purchased directly. The synthetic 
approaches employed will be discussed in this chapter.  
 
3.2 Classes of inhibitory compounds and their synthesis 
 
3.2.1 Piperazine containing compounds 
 
3.2.1.1 Synthesis of 41 
 
 
Figure 3.1. Structure of 41. 
 
The compound (Figure 3.1) was identified from initial screens of the nNOS homology model 
with the Zinc database, (chapter two, section 2.6.1). Both enantiomers were ranked top of 
the hit list in this screen, but neither were commercially available. The synthesis of the 
racemic product was conducted based on the retrosynthetic plan illustrated in Scheme 3.1. 
It was envisaged that the target compound could be synthesised in a single step from the 
commercially available epoxide and aryl piperazine Scheme 3.2. This strategy would exploit 
nucleophilic attack by the aryl piperazine and epoxide ring opening to give 41. 
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Scheme 3.1. Retrosynthetic plan for 41. 
 
The procedure for the forward reaction was based on a previous literature report, which 
utilised a similar epoxide and piperazine system.85 The two reagents were reacted neat in a 
1:1 ratio with no base added. A mechanism for the forward reaction is shown in Scheme 
3.2. 
 
 
Scheme 3.2. Forward reaction for 41. 
 
The protonated piperazine attacks the epoxide at the less sterically hindered site, opening 
the ring to generate the intermediate. Subsequent protonation of the anionic oxygen, and 
deprotonation of the cationic piperazine nitrogen generated the product as shown. The 
product, purified by column chromatography, was obtained in 56% yield. Using NMR, mass 
spectrometry and IR spectroscopy 41 was characterised.  
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3.2.1.2 Structural characterisation of 41 
 
The structure of 41 with numbered protons and carbons is provided in Figure 3.2. 
 
 
Figure 3.2. 41 with numbered protons and carbons. 
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The full 1H NMR spectrum of AC001 is shown in Figure 3.3 and an expansion of the 
aromatic region signals is shown in Figure 3.4. There are four clear aromatic signals, a 
triplet at 7.18 ppm (1H), an unsymmetrical doublet at 7.09 ppm (1H), a multiplet from 6.99-
6.95 ppm (2H) and another multiplet from 6.80-6.74 ppm (3H).  
 
Figure 3.3. Full 
1
H spectrum of AC001. 
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Figure 3.4. Aromatic proton signals of AC001. 
 
The four aromatic signals can be considered as two separate spin systems, as evidenced by 
the COSY spectrum (Figure 3.5). One spin system is made up of H3, H5, H6 and H7 while the 
other is comprised of H16, H18 and H19.  
 
Chapter Three                                                              Synthesis of Computational Hit Compounds 
 
109 
 
 
Figure 3.5. COSY spectrum of AC001, expansion of aromatic region 
 
The first spin system involves the signal at 7.18 ppm (1H) and the broader signal at 6.80-
6.74 ppm (3H). The second system involves the signal at 7.09 ppm (1H) and the signal at 
6.99-6.95 ppm (2H). To assign the peak at 7.18 ppm the resonance contributors of each 
aromatic ring were examined to predict which protons were the most deshielded, (Figure 
3.6).  
 
 
Figure 3.6. Resonance contributors of the ether substituted aromatic ring. 
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None of the resonance contributors carry a negative charge on C6, where as a negative 
charge can be found on C3, C5 and C7. Therefore H6 is the most deshielded as it has the 
lowest electron density, and will appear the most downfield of H3, H5, H6 and H7. Based 
on the first order approximation of signal splitting H6 could be expected to appear as a 
doublet of doublets, as it is split by the inequivalent protons H5 and H7. However, the 
difference in the coupling constants of H5 and H7 is small. Therefore, while the signal for 
H6 is expected to be a double of doublets (see splitting tree Figure 3.7), it may instead 
appear as an apparent triplet. The signal at 7.18 ppm appears as an apparent triplet 
supporting its assignment as H6. 
 
 
Figure 3.7. First order approximation splitting tree for H6. 
 
From the COSY spectrum (Figure 3.5), it is clear that the H6 signal is in the same spin 
system as the signal integrating for three at 6.80-6.74 ppm. These three protons are 
therefore assigned as H3, H5 and H7, all appearing as one overlapping signal. All are 
shielded by the electron donating effect of the ether group and adopt similar chemical 
shifts. It is not possible to distinguish between these protons.  
For the second aromatic ring several possible resonance contributors can be drawn due to 
electron delocalisation from the piperazine or the chlorine atom. These structures are 
shown in Figure 3.8 and Figure 3.9. 
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Figure 3.8. Resonance contributors, delocalisation of the piperazine ring nitrogen lone pair.  
 
 
Figure 3.9. Resonance contributors from the delocalisation of the chlorine lone pair. 
 
None of the resonance contributors place a negative charge on C19 and hence the most 
deshielded proton in this spin system is H19. H19 is expected to appear as a doublet, split 
by the neighbouring H18. Of the remaining aromatic proton signals, the one appearing at 
7.09 ppm appears as a doublet and integrates for one proton. This signal is therefore 
assigned to H19. 
Two aromatic protons remain to be assigned, H16 and H18. In the COSY spectrum it can be 
seen that the H19 signal (7.09 ppm) couples to the multiplet signal integrating for two at 
6.99-6.95 ppm. This signal is therefore assigned to H16 and H18, appearing as one 
overlapping signal.  
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The next two proton signals appear at 4.16-4.14 ppm (1H) and 4.02-4.00 ppm (2H) (1H NMR 
spectrum expansion in Figure 3.10 and COSY spectrum expansion in Figure 3.11). 
 
 
Figure 3.10. Expanded image of 4.35-3.90 ppm region of AC001 
1
H NMR spectrum. 
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Figure 3.11. Expanded image of 4.18-2.50 ppm region in AC001 COSY spectrum. 
 
The multiplet centred at 4.15 ppm integrates for a single proton and is heavily split. The 
proton on the chiral centre, H9, is a likely candidate for this signal. Due to the chiral centre, 
the protons at C8 and C10 are diastereotopic and will all split H9 independently. H9 may 
also be split by the alcohol proton. The small differences in the diastereotopic protons 
results in a difference in coupling constants with H9, hence the observed heavy splitting 
pattern. 
H9 is coupled to the multiplet at 4.02-4.00 ppm and to the multiplet at 2.66-2.62 ppm. The 
multiplet at 4.02-4.00 ppm is assigned as the two H8s, which are deshielded by the 
adjacent ether oxygen. The splitting for this signal is again complex as the diastereotopic 
protons split each other via geminal coupling, and both are split separately by H9. Two 
separate doublet of doublets would be expected (Figure 3.12), however an overlapping 
multiplet is observed.   
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Figure 3.12. Splitting tree for one of the diastereotopic H8 protons. 
 
The next three signals appear between 3.00 ppm and 2.60 ppm (Figure 3.13). These 
account for the piperazine (H11-H14) and H10 adjacent to the piperazine ring. Based on the 
integrations, the simplest assignment would appear to be that H11 and H12 account for 
one of the signals integrating for four, H13 and H14 account for the other signal integrating 
for four, and H10 accounts for the signal integrating for two. However, examination of the 
COSY spectrum shows this is not the case (Figure 3.14), as all three signals are coupled 
together. The piperazine protons H13 and H14 are too far removed from H10 to couple to 
it (5 bonds), so the simple assignment is incorrect.    
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Figure 3.13. Expanded view of the 3.15 ppm to 2.50 ppm region of the 
1
H NMR spectrum. 
 
 
Figure 3.14. COSY spectrum of the 3.05 ppm to 2.55 ppm region. 
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In order to assign the 1H NMR signals in this region of the spectrum the piperazine ring was 
considered to be in a locked chair confirmation as shown in Figure 3.15.  
 
 
Figure 3.15. Piperazine ring with axial and equatorial protons shown. The R substituent represents 
the alcohol substituted carbon chain, and R’ is the disubstituted aromatic ring. a = axial, e = 
equatorial.  
 
The signals for H13a/H13e and H14a/H14e are overlapping at 2.95 ppm, integrating to 4H. 
These protons are more deshielded than H11a/H11e and H12a/H12e as the nitrogen 
adjacent to H13a/H13e and H14a/H14e can donate electron density into the neighbouring 
aromatic ring, resulting in a partial positive charge on the nitrogen atom. Electron density is 
therefore withdrawn from the H13 and H14, resulting in a higher chemical shift for these 
protons.  
It is proposed that the 1H signal for H11e and H12e occurs at 2.84 ppm, integrating for 2H. 
This signal couples to the signal for H13a/H13e and H14a/H14e (2.95 ppm) in the COSY as 
expected (Figure 3.14). We suggest that H11a and H12a are more shielded than H11e and 
H12e, perhaps due to a partial anomeric type effect from the nitrogen lone pair. We 
therefore assign H11a and H12a to the signal at 2.64 ppm. This signal couples to the signal 
for H11e/H12e at 2.84 ppm as expected. The signal at 2.64 ppm integrates for four protons. 
We therefore consider this signal to consist of the two H10 protons, as well as H11a and 
H12a protons. The signal at 2.64 ppm also couples to H9 (4.15 ppm) in the COSY spectrum 
(Figure 3.11), as would be expected for H10.  
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This assignment is strengthened by the fact that in the HSQC, the signals at 2.84 ppm 
(H11e/H12e) and 2.64 ppm (H11a/H12a) couple to the same equivalent 13C signal (53.7 
ppm), indicating that the protons are bonded to the same carbon, C11/C12 (Figure 3.16). 
The HSQC also shows the signal at 2.64 ppm (H10) couples to the 13C signal at 60.7 ppm 
(C10).  
 
Figure 3.16. HSQC showing the protons in the signal at 2.64 ppm and 2.84 ppm couple to the same 
carbon signal at 53.7 ppm. 
 
The two remaining proton signals in the 1H NMR account for the two methyl groups, H1 
and H21 (Figure 3.17). Using the HMBC it can be seen that the two methyl proton signals 
couple to separate aromatic spin systems. This is expected as C1 is part of one aromatic 
spin system, while C21 is part of the other.  
 
Chapter Three                                                              Synthesis of Computational Hit Compounds 
 
118 
 
 
Figure 3.17. Methyl proton signals of AC001 
1
H NMR spectrum. 
 
Figure 3.18. HMBC expansion of the alkyl region. 
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As H6 (7.17 ppm) had been well characterised and identified in the proton spectrum 
analysis it was used as a reference to assign the methyl proton signals. The HSQC identifies 
C6 as the signal at 139.8 ppm, coupling to H6 (7.18 ppm). In the HMBC a clear coupling can 
be seen between the carbon signal at 139.8 ppm (C6) and the more deshielded of the two 
methyl signals (2.34 ppm). It is suggested that H6 and the methyl protons at 2.34 ppm are 
bonded to the same aromatic ring. Therefore the signal at 2.34 ppm was assigned as the H1 
methyl protons, leaving the signal at 2.26 ppm to account for the H21 protons. 
 
 
Figure 3.19. AC001 with numbered protons and carbons. 
 
A full carbon spectrum for AC001 is shown in Figure 3.20. The quaternary carbon signals 
were first to be assigned. Using an overlaid 13C and DEPT135 spectra (Figure 3.21) the 
quaternary carbons were identified as the signals at 158.9 ppm, 152.5 ppm, 139.7 ppm, 
131.9 ppm and 130.9 ppm.   
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Figure 3.20. Full 
13
C NMR spectrum of AC001. 
 
 
Figure 3.21. Overlaid DEPT135 spectrum and 
13
C NMR spectrum  
Chapter Three                                                              Synthesis of Computational Hit Compounds 
 
121 
 
The most deshielded quaternary carbon is C4. It is adjacent to an electronegative oxygen 
that withdraws electron density from C4 via induction. This oxygen also donates electron 
density into the aromatic ring via resonance. This results in a partial positive charge on the 
oxygen which will further withdraw electron density from C4. The signal at 158.9 ppm is 
assigned to C4. 
The next most deshielded carbon is C15. This is the aromatic carbon adjacent to the 
piperazine ring. Delocalisation of the piperazine nitrogen lone pair into the aromatic ring, 
results in a partial positive charge on the nitrogen and a deshielding of C15. The signal at 
152.5 ppm is assigned to C15.  
Using the HMBC, it is suggested that the carbon signal at 139.6 ppm is part of the 
disubstituted aromatic spin system. This signal is therefore assigned to C2, as it was the 
only remaining quaternary carbon in this spin system.  
This leaves the assignment of C20 and C17 to the two quaternary signals at 131.9 ppm and 
130.9 ppm. C20 has a partial negative charge due resonance contributions from the 
piperazine ring and the chloro group (Figure 3.8 and Figure 3.9), where C17 does not 
experience this effect. C20 therefore is more shielded than C17 and is expected to appear 
at 130.9 ppm. The signal at 131.9 ppm is therefore assigned to C20.   
C6, C8, C9 and C19 are identified by HSQC as the signals at 129.3 ppm, 70.3 ppm, 65.8 ppm 
and 132.1 ppm respectively. Individual identification of the aryl signals for C3, C5 and C7 is 
not possible. However, in the HSQC spectrum the overlapping H3, H5 and H7 1H signals 
couple to the 13C signals at 122.0 ppm, 115.6 ppm and 111.6 ppm. C18 and C16 were 
assigned to 123.2 ppm and 119.7 ppm. In the resonance hybrid representing this aromatic 
ring a partial negative charge is found on C18, shielding it. The C18 signal is therefore at 
119.7 ppm, while C16 is at 123.2 ppm.  
The methyl carbon signals were then assigned using the HSQC. The signal for H1 at 2.34 
ppm is coupled to the carbon signal at 21.7 ppm. This is assigned to C1. Similarly, the signal 
for H21 is coupled to a carbon signal at 17.6 ppm. This represents C21 (Figure 3.22). 
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Figure 3.22. HSQC to identify methyl carbons. 
 
The three remaining unassigned 13C signals appear at 51.7ppm, 53.8 ppm and 60.8 ppm. 
H13 and H14 appear at 2.95 ppm, these couple to the carbon signal at 51.7 ppm in the 
HSQC. This is the C13/C14 signal. The proton signal at 2.86 ppm and 2.64 ppm are both 
caused by piperazine protons on carbons 11 and 12. Both of these proton signals couple to 
the carbon signal at 53.7 ppm in the HSQC, which we assign to C11/C12. The final carbon 
signal at 60.8 ppm is assigned to C10 which appears as a CH2 in the DEPT135. This couples  
to the H10 1H NMR signal (2.64 ppm) in the HSQC. 
 
3.2.1.3 Synthesis of 37-40 
 
A set of piperazine containing compounds were synthesised based on a compound 
identified from the flexible docking of the Maybridge database into the human nNOS 
homology model (chapter two, section 2.6.1), (Figure 3.23).  
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Figure 3.23. 34, identified from the flexible dock of Maybridge with the nNOS homology model. 
 
The compound appeared promising as it contained a napthyl moiety and an aromatic 
chloro substituted ring. These could potentially form π stacking interactions with the heme 
moiety and the Tyr711 residue in the human nNOS binding site. The structure was also 
synthetically accessible and was not commercially available. Given the high rank of 34 
(ranked 17) in the docked list, it was decided to synthesis several derivatives of this 
compound (Figure 3.24) 
 
 
Figure 3.24. Derivatives of 34 which were chosen for synthesis, 37-40. 
 
The core was modified to a six membered piperazine ring, rather than the seven 
membered ring found in 34. This piperazine ring was more synthetically accessible than the 
seven membered ring. A secondary amine was added adjacent to the carbonyl group. It 
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was envisaged that this could act as a potential HB donor and interact with the acidic 
residues in the nNOS pocket (Glu597, Asp602). The inclusion of the amide also allowed for 
bond formation via well reported synthetic methodologies. The chlorine moiety from the 
screening hit was retained, and a version of the compound without the chlorine was 
synthesised to explore the importance of the substituent for activity. Finally, two 
derivatives were synthesised where the carbonyl oxygen was substituted with sulphur to 
examine the effect NH acidity may have on inhibitory activity. Thiourea groups are stronger 
acids than urea groups.86 It is therefore expected that that the sulphur containing 
derivatives would form stronger HB interactions with anionic species such as the Glu597 
and Asp602 in the arginine binding site. The synthetic targets were docked into the arginine 
nNOS binding site, and received robust cDOCKER scores, thus validation this synthetic 
approach (discussed in chapter two, section 2.6.1). The retrosynthetic analysis for these 
compounds, 37-40, is shown in Scheme 3.3. 
 
 
Scheme 3.3. Retrosynthetic analysis of piperazine compounds, X = O, S ; R = p-Cl, H. 
 
The isocyanate, isothiocyanate and the napthyl substituted piperazine were commercially 
available. The forward reaction involved stirring the two reactants together in a 1:1 ratio in 
dry DCM under a flow of nitrogen, followed by purification via column chromatography. A 
proposed mechanism using 39 as an example is shown in Scheme 3.4. 
 
Chapter Three                                                              Synthesis of Computational Hit Compounds 
 
125 
 
 
Scheme 3.4. Proposed mechanism for the formation of 39.  
 
The formation of the thiourea moiety was facilitated by nucleophilic attack of the 
secondary piperazine nitrogen at the carbonyl carbon of the isothiocyanate. The resulting 
intermediate was deprotonated by a second piperazine species, followed by formation of 
the thiourea product. A similar mechanism is proposed when using the isocyanate in place 
of the isothiocyanate.  
41 and the four synthetic derivatives of 34 were successfully synthesised in moderate to 
good yields. Interestingly, the chloro substituted derivatives of 34 were isolated in higher 
yields than the respective non-chloro substituted derivatives. This may be due to the 
inductive electron withdrawing ability of the chloro group, which may increase the 
electrophilic character of the isocyanate or isothiocyanate reaction centres. The yields 
obtained for 37, 38, 39 and 40 were 81%, 66%, 58% and 76% respectively.   
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3.2.1.4 Structural characterisation of 39 
 
The structure of AC007 with numbered carbons and protons is shown in Figure 3.25. 
 
 
Figure 3.25. AC007 with numbered protons and carbons. 
 
The full 1H spectrum of AC007 is shown in Figure 3.26. An expanded view of the aromatic 
region of AC007 is shown in Figure 3.27, where the relative integrations in this region add 
up to 13 protons. AC007 has only 12 aromatic protons. The signal at 7.16 ppm (1H) does 
not couple to a carbon signal in the HSQC. This signal is also distinctively broad, and is 
therefore assigned as the NH proton, H17. All of the remaining signals shown in Figure 3.27 
are caused by protons on either the napthyl group or on the phenyl ring.  
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Figure 3.26. Full 
1
H NMR spectrum of AC007. 
 
 
Figure 3.27. Expanded aromatic region of 
1
H NMR spectrum of AC007. 
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Examination of the COSY spectrum (Figure 3.28) reveals two distinctive spin systems in the 
aromatic region, as expected due to the separation of the napthyl and phenyl moieties.  
 
Figure 3.28. COSY spectrum of AC007, expansion of the aromatic region. 
 
The signals at 7.08 ppm (2H), 7.12 ppm (1H) and 7.31 ppm (2H) couple to form one spin 
system, while the remaining signals form another, larger system. The larger system is 
expected to represent the napthyl group, with the signals of the smaller system at 7.08 
ppm, 7.12 ppm and 7.31 ppm attributed to H19-H23 of the phenyl ring.   
Due to the monosubstitution pattern of the phenyl ring, it is expected that H19 and H23 
are equivalent, and that H18 and H22 are equivalent. This leads to an assignment of H21 as 
the signal at 7.12 ppm, integrating for 1H. To distinguish between the signals for H19/H23 
an H18/H22 the resonance contributors from the electron donating nitrogen were 
considered (Figure 3.29).  
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Figure 3.29. Resonance contributors of phenyl ring on AC007. 
 
A negative charge can be found on C19 and C23, while none of the contributors show a 
negative charge on C20 or C22. H19 and H23 are therefore more shielded than H20 and 
H22 and are responsible for the signal at 7.08 ppm (2H). The remaining aromatic signal in 
this spin system at 7.31 ppm (2H) is accounted for by H20 and H22. Due to the conjugated 
nature of the aromatic system, the splitting of the three proton signals in the phenyl ring 
does not occur according to first order approximation rules. H21 appears as an 
unsymmetrical doublet, with H22/H20 and H19/H23 appearing as unsymmetrical triplets 
with some peak shouldering in evidence.  
The second and larger aromatic spin system is caused by the napthyl moiety. This ring 
system contains seven protons, which matches the integration of the remaining signals in 
the aromatic region (Figure 3.27). Due to the highly conjugated nature of this group it is 
difficult to assign individual protons to each signal.  
The signals for the non-aromatic protons, H11-H15, are shown in Figure 3.30. H11 is easily 
identified as it is expected to appear as a singlet integrating for two, while the two sets of 
piperazine protons (H12/H13 and H14/H15) are expected to appear as triplets integrating 
for four. H11 is assigned to the peak at 3.93 ppm. Due to the proximity of the electron 
withdrawing thiourea group, it is expected that H14/H15 are more deshielded than 
H12/H13. The signal at 3.80 ppm (4H) is therefore assigned to H14/H15, leaving the signal 
at 2.57 ppm to account for H12/H13.  
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Figure 3.30. Non-aromatic signals for AC007, 
1
H NMR spectrum. 
 
The full 13C spectrum of AC007 is shown in Figure 3.31. Using DEPT135 spectroscopy the 
five quaternary carbons (C1, C6, C10, C16 and C18) were identified as the signals at 183.3 
ppm, 140.1 ppm, 133.9 ppm, 133.2 ppm and 132.4 ppm. The only non-aromatic carbon in 
this group is C16. This is assigned to the signal at 183.3 ppm. C18, on the phenyl ring, was 
identified via HMBC interactions with H23/H19 (7.08 ppm) and H22/H20 (7.31 ppm), Figure 
3.32. 
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Figure 3.31. 
13
C NMR spectrum of AC007. 
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Figure 3.32. HMBC for AC007 showing coupling between the proton signals at 7.31 ppm and 7.08 
ppm and the carbon signal at 140.0 ppm. 
 
The signals for H22/H20 and H23/H19 both couple to the quaternary carbon signal at 140.1 
ppm in the HMBC, this signal was therefore assigned to C18. Interestingly, the HMBC 
correlation between H20/H22 and C18 is stronger than the correlation between H19/H23 
and C18, despite H19/H23 being closer to C18. This is due to the fact that HMBC 
correlations follow a Karplus type relationship, with angle of the coupling species relative 
to each other playing a key role in the strength of the correlation.87,88 The remaining 
quaternary carbon signals, at 133.9 ppm, 133.2 ppm and 132.4 ppm are attributed to the 
three napthyl quaternary carbons, C1, C6 and C10. These are difficult to assign individually 
due to the conjugated nature of the system. 
The aromatic carbons C19/C23, C20/C22 and C21 were identified via HSQC coupling with 
their protons. These signals occur at 122.6 ppm, 129.2 ppm and 125.1 ppm respectively. 
The remaining seven aromatic 13C signals correspond to C2, C3, C4, C5, C7, C8 and C9. 
These seven signals appear at 128.5 ppm, 128.3 ppm, 127.5 ppm, 125.9 ppm, 125.7 ppm,  
125.1 ppm and 124.7 ppm.  
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The final remaining carbon signals for AC007 are the non-aromatic carbons, C11-C15. These 
were again identified using HSQC, with C11 assigned to the peak at 60.9 ppm, C12/C13 
assigned to 52.5 ppm and C14/C15 to 49.8 ppm.  
All targets 37-40, were successfully synthesised and characterised via NMR, mass 
spectrometry and IR spectrum.  Compounds 37, 38, 40 were assigned in a similar fashion to 
39, with many of the same signals and splitting patterns being retained across the four 
compounds. The Cl substituted derivatives, 37 and 40, had one less 1H NMR signal due to 
the replacement of H21 by the chlorine. Both 37 and 40 also had one additional quaternary 
13C NMR signal each, identified at 130.5 ppm and 129.9 ppm respectively via DEPT135 
spectroscopy.  Replacement of the sulphur with oxygen, as in 37 and 38, caused a change in 
the chemical shifts of the H19/H23 signals. The H19/23 signal for the sulphur containing 39 
appears at 7.08 ppm, while in the oxygen derivative, 38, the H19/H23 signal appears at 
7.30-7.27 ppm. The more deshielded signal in 38 is attributed to the more electronegative 
oxygen of this compound withdrawing electron density from the nitrogen, thus reducing 
the effect of the donation of its lone pair into the aromatic ring. 
 
3.2.2 Urea containing compounds 
 
A class of urea containing compounds were synthesised based on the structures shown 
Figure 3.33. The compounds in Figure 3.33 ranked highly in the screening of the published 
human nNOS crystal structure with the commercial databases, chapter two, section 2.9.2. 
The ranks of each of the compounds in the docking list are also shown.  
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Figure 3.33. Urea containing compounds which ranked highly in the crystal structure screen of the 
Maybridge and Zinc databases.  
 
A class of compounds that were similar in structure to those in Figure 3.33 were designed 
and selected as synthetic targets. These synthetic targets are shown in Figure 3.34. 
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Figure 3.34. Class of urea containing synthetic targets, 94-97. 
 
For ease of synthesis, the chiral centre from some of the docking hits was removed from 
the target molecules. It was envisaged that if nNOS inhibitory activity was observed with 
this family of compounds, the chiral centre would be re-introduced to determine its effect 
on activity. One of the docking hits (ranked 48th, Figure 3.33) did not have this chiral centre 
and so it was felt that its removal for synthetic feasibility was justified and may still result in 
an nNOS inhibitory compound. Furthermore, docking of the target compounds (Figure 
3.34) into the human nNOS crystal structures resulted in favourable Chemgauss4 scores, as 
previously described in chapter two, section 2.9. 
It was hoped that the inclusion of HB donors close to both aromatic rings would allow the 
compounds to bind into the active site in a variety of poses. The HB donor beside either 
ring could form interactions with Glu597 or Asp602, while the adjacent aromatic ring would 
pi stack with the nNOS heme moiety. The other aromatic ring could potentially interact 
with Tyr711, facilitating the formation of a HB between the donor and the heme 
propionate groups, as is often observed for the aminopyridine class of inhibitors (See 
chapter one, section 1.4). 
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3.2.2.1 Synthesis of 96 and 97  
  
The retrosynthetic analysis for 96 and 97 is shown below (Scheme 3.5). Breaking the urea 
functional group resulted in two accessible synthetic equivalents. The benzamide could be 
generated from ethylenediamine and the commercially available acyl chloride.  
 
 
Scheme 3.5. Retrosynthetic analysis for 96 and 97, R = p-F (w). R = H (x) 
 
The synthetic scheme for 96 and 97 is detailed in Figure 3.35. The ethylenediamine was 
monoprotected with the BOC protecting group. This reaction was carried out at 0 0C to 
minimize the formation of the diprotected species. Following purification, the 
monoprotected amine was reacted with the aryl acyl chloride. Subsequent deprotection 
using TFA in DCM generated the free amine. Reaction of this amine with the isocyanate 
resulted in the formation of the urea linkage. Following purification, via column 
chromatography, 96 was isolated as a white solid in a 39% yield, while 97 was isolated as a 
white solid in a 36% yield. These were characterised via NMR, IR, mass spectrometry and 
melting point analysis. 
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Figure 3.35. Synthetic scheme used for the synthesis of 96 (R = F) and 97 (R = H)..  
 
 
3.2.2.2 Structural characterisation of 97 
 
The structure of 97 with numbered hydrogens and carbons is shown in Figure 3.36. 
 
 
Figure 3.36. Numbered protons and carbons of 97. 
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The full 1H spectrum of 97 is shown in Figure 3.37, and an expansion of the 9.0 ppm-6.30 
ppm region shown in Figure 3.38. Using HSQC, the three NH 1H NMR signals were identified 
as appearing at 8.96 ppm (1H), 8.54 ppm (1H) and 6.40 ppm (1H). None of these proton 
signals show a one bond correlation to a carbon signal in the HSQC. In the HMBC, the two 
NH proton signals at 8.96 ppm and 6.40 ppm couple to the same quaternary carbon signal 
(155.4 ppm). This is assigned to C12. This therefore leaves H8 as  the 1H NMR signal at 8.54 
ppm. H13 is expected to be more deshielded than H11 due to electron donation by N13 
into the aromatic ring. H13 is assigned to the signal at 8.96 ppm, leaving H11 to be assigned 
to 6.40 ppm. All remaining signals in the 9.0 ppm to 6.30 ppm region (Figure 3.38) are 
caused by hydrogens on the two aromatic rings of 97.  
 
 
Figure 3.37. 
1
H NMR spectrum of 97. 
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Figure 3.38. Expansion of the 9.0 ppm to 6.3 ppm region of the 97 
1
H NMR spectrum. 
 
With C12 assigned to 155.4 ppm, C7 was assigned to the carbon signal at 166.7 ppm. 
Analysis of the HMBC (Figure 3.39) revealed that C7 coupled to the proton signal at 8.54 
ppm (H8) and to the multiplet at 7.86-7.83 ppm (2H). This multiplet was assigned as H4 and 
H5, appearing as one signal.   
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Figure 3.39. HMBC of 97 showing the signals at 166.7 ppm correlating to the 
1
H signals at 8.54 ppm 
and 7.86-7.83 ppm. 
 
H20 is the only aromatic proton which could be expected to appear as a singlet and hence 
is assigned to the singlet peak at 7.96 ppm (1H). Examination of the COSY spectrum (Figure 
3.40) reveals that the signal for H20 is coupled to the signal at 7.51 ppm (2H) and at 7.21 
ppm (1H). 
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Figure 3.40. Aromatic region of 97 COSY NMR spectrum. 
 
The resonance contributor which places a negative charge on C17 is the most stable 
contributor for this system due to the separation of the positive and negative charges 
(Figure 3.41). H17 is therefore more shielded than H15 and H16 and is assigned to the 
signal at 7.21 ppm (1H).  
 
 
Figure 3.41. Resonance structures of CF3 substituted aromatic ring of 97. 
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A clear 1H-1H correlation can be seen between the signals at 7.96 ppm (H20) and the signal 
at 7.21 ppm (H17) in the COSY spectrum. A 1H-1H correlation is therefore expected 
between the signal for H20 and the signal for H15. It is expected that no correlation, or at 
best a very weak correlation, will be observed between H16 and H20 due to the 5 bond 
distance between them. H15 is therefore assigned to the signal at 7.51 ppm (2H).  
The signal at 7.51 ppm (2H) is coupled to several 1H NMR signals in the COSY spectrum. 
These include the signals at 7.96 ppm (H20), 7.85 ppm (H4, H5) and the multiplet at 7.48-
7.41 ppm. This extensive coupling suggests that the signal at 7.51 ppm is an overlapping 
signal, caused by one proton on the CF3 substituted ring, and by one proton on the other, 
monosubstituted, phenyl ring.  It is expected that the 1H NMR signal for H2 and H3 will 
appear as an equivalent signal. Therefore, if H2 and H3 were responsible for the single at 
7.51 ppm, along with H15, the signal at 7.51 ppm would integrate for 3H. This is not the 
case as the 7.51 ppm signal only integrates for 2H. Therefore, H1 is assigned as the second 
proton responsible for the signal at 7.51 ppm (2H). 
The remaining aromatic proton signal at 7.48-7.41 ppm (3H) is assigned to the three 
remaining aromatic protons, H16, H2 and H3. This signal is coupled to the 1H signals at 7.21 
ppm (H17), 7.51 ppm (H15 and H1) and to the multiplet 7.86-7.83 ppm (H4 and H5) in the 
COSY spectrum. 
The final two groups of protons to be assigned are H9 and H10. One of these signals can be 
clearly seen in the 1H spectrum at 3.30ppm (2H) as an apparent quartet (Figure 3.37). Both 
H9 and H10 would be expected to appear as a doublet of triplets. As can be seen in the 
HMBC spectrum (Figure 3.42), the proton signal at 3.30 ppm couples to the carbon signal at 
155.4 ppm. This carbon signal is attributed to C12, the more shielded of the two carbonyl 
carbons. The proton signal at 3.30 ppm is therefore assigned to the hydrogen adjacent to 
C7, i.e. H10.  
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Figure 3.42. HMBC spectrum of 97 showing coupling of H9 and H10 to their neighbouring carbonyl 
carbons. 
 
The expected signal for H9 is masked by the water present in the deuterated DMSO. A 
correlation, similar to the one described between H10 and C12 described above, can be 
seen between the 13C NMR signal for C12 and a shoulder which appears under the H2O 
peak in the HMBC (Figure 3.42). H9 is assigned to this shoulder at 3.37 ppm. The presence 
of two CH2 groups in 97 is confirmed by analysis of the DEPT135 spectrum, which clearly 
shows two CH2 signals close to the DMSO solvent signal at 39.5 ppm and 38.7 ppm (Figure 
3.43). 
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Figure 3.43. DEPT135 spectrum of 97, proving the presence of two CH2 groups in 97. 
 
A full 13C NMR spectrum for 97 is shown in Figure 3.44. Using DEPT135 spectroscopy the 
quaternary carbons signals are identified at 166.5 ppm, 155.4 ppm, 141.4 ppm, 134.4 ppm, 
124.3 ppm and 129.5 ppm.  
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Figure 3.44. 
13
C NMR spectrum of 97. 
 
The carbonyl carbons are assigned based on their relative shieldings, with C12 being more 
shielded than C7. C12 is assigned to the peak at 155.4 ppm and C7 to 166.7 ppm. C14 is 
attributed to the signal at 141.4 ppm, with HMBC correlations observed with H13 (8.98 
ppm) and H20 (7.96 ppm). The quaternary signal at 134.4 ppm is coupled to the 1H signals 
at 7.48-7.41 ppm (H16,H2,H3) and  7.50 ppm (H1 and H15). C6 is therefore assigned to the 
signal at 134.4 ppm.  
The two remaining quaternary carbons, C18 and C19, are adjacent to a fluorine atom that 
causes the signals for both carbons to be split into quartets with large coupling constants. 
C19 appears as a quartet with a J value of 272.2 Hz at 124.3 ppm. C18 also appears as a 
quartet at 129.5 ppm, with a J value of 31.2 Hz.  
Using HSQC (Figure 3.45), the 13C signals for C20 and C17 are assigned to the peaks at 113.7 
ppm and 117.3 ppm respectively (H20 at 7.96 ppm, H17 at 7.21 ppm). These 13C signals are 
split into quartets by the fluorine atoms, with the C20 signal having a J value of 3.9 Hz and 
the C17 signal having a J value of 4.1 Hz. H4 and H5, 7.86-7.81 ppm, are coupled to the 13C 
signal at 127.2 ppm in the HSQC, and this signal is thus assigned to C4 and C5.  
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The HSQC also reveals that the signal at 7.50 ppm (2H), which is attributed to H1 and H15, 
couples to two carbon signals at 131.2 ppm and 121.2 ppm. C15 is expected to be more 
shielded than C1 due to the electron donating group ortho to C15. C15 is assigned to the 
signal at 121.2 ppm, while C1 is assigned to the signal at 131.2 ppm.  
Similarly, the 1H signal at 7.48-7.41 ppm (H2, H3 and H16) is coupled to two 13C signals at 
128.3 ppm and 129.8 ppm. These signals are caused by C2/C3 and C16. To differentiate 
between the carbon signals the HMBC was used to observe a correlation between the 1H 
signal for H4 and H6 (7.86-7.83 ppm, 2H) and the 13C signal at 128.3 ppm. C2 and C3 are 
therefore assigned to the signal at 128.3 ppm, with C16 assigned to the remaining aromatic 
13C signal at 129.8 ppm.  
 
Figure 3.45. Expanded view of the aromatic region of the HSQC for 97. 
 
The signals for C9 and C10 are expected to appear near 40 ppm in the 13C spectrum. Both of 
these signals are obscured by the solvent peak. However, the HSQC of the region shows 
two clear CH2 correlations (Figure 3.46). The presence of the two CH2 groups is proven by 
the DEPT135 spectrum as previously discussed (Figure 3.43). The signal at 38.7 ppm is 
assigned to C10, leaving the signal at 39.5 ppm to be assigned to C9.  
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Figure 3.46. HSQC showing two clear and separate CH2 correlations, proving the presence of C9 and 
C10 in 97. 
 
The NMR data of 96 was assigned using a similar approach to the one described above for 
97. The key differences in the spectra of 96 compared to 97 are caused by the addition of a 
fluorine atom onto the aromatic ring at C1. The 1H NMR spectrum of compound 96 has one 
less signal proton signal than the 1H spectrum of 96 due to this substitution.  
In the 13C NMR of 96, the signal for C1 (seen as a singlet at 131.2 ppm in 97) becomes 
quaternary and is shifted to 164.3 ppm. This signal becomes a doublet ( J = 248.3 Hz), split 
by the fluorine. Similarly, the 13C signals for C2/C3 and C4/C5 of 96 both appear as doublets 
and are shifted to 115.6 ( J = 21.7 Hz ) and 130.3 ppm ( J = 8.0 Hz) respectively. In the 13C 
spectrum of 97 C2/C3 appears as a singlet at 128.3 ppm and C4/C5 also appears as a singlet 
at 127.2 ppm.   
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3.2.2.3 Synthesis of compounds 94 and 95  
 
Compound 94 and 95 were synthesised in a different manner than 96 and 97. The 
retrosynthetic analysis for 94 and 95 is shown in Scheme 3.6. 
 
 
Scheme 3.6. Retrosynthetic analysis for 94 and 95, R = p-F (w), R = H (x) 
 
Reaction of the aryl acyl chloride and ethylenediamine followed the same retrosynthetic 
methodology as has been previously discussed for 96 and 97, section 3.2.2.1. However, 
while the appropriate isocyanate starting material was commercially available for the 
synthesis of 96 and 97, the required isocyanate for 94 and 95 was not available. The 
synthesis of this isocyanate was achieved by subjecting the carboxylic acid derivative of the 
starting material to a Curtius rearrangement (Scheme 3.7). 
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Scheme 3.7. Conversion of carboxylic acid to require isocyanate, 99, via Curtis rearrangement. 
 
This conversion is a two-step process, where the carboxylic acid group is converted to an 
azide using diphenyl phosphoryl azide (DPPA). DPPA represents a more stable and less toxic 
azide source than the “classic” sodium azide.89 Once the azide is formed, the reaction is 
heated to cause a Curtius rearrangement. This results in elimination of nitrogen gas and 
formation of the isocyanate group. A proposed mechanism is provided in Scheme 3.8.  
The azide formation step involves the reaction of the carboxylic acid with diphenyl 
phosphoryl azide in the presence of a base, such as triethylamine, at room temperature. 
This results in the formation of a phosphate intermediate which is attacked by the azide 
ion. The phosphate group is eliminated, leaving the desired acetyl azide product. The 
phosphate anion deprotonates the conjugate acid of the triethyl amine to form diphenyl 
hydrogen phosphate, which can be removed via column chromatography or by tritiration 
with hexane once the reaction is complete. Once azide formation is complete, the reaction 
is heated to 80 0C to eliminate nitrogen gas and leave the isocyanate product.  
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Scheme 3.8. Isocyanate, 99, formation from carboxylic acid and DPPA via an azide intermediate. 
 
The isocyanates products are water sensitive and can react with moisture to form carbamic 
acid, which can then undergo spontaneous decarboxylation. Due to this instability the 
isocyanate products are not routinely isolated. Formation of the isocyanates product can 
be confirmed by 1H NMR analysis of the crude reaction mixture, and identification of the 
proton signals alpha to the isocyanate group. An example of such a spectrum is shown in 
Figure 3.47. 
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Figure 3.47. 
1
H NMR spectrum demonstrating formation of 99. 
 
The singlet at 3.58 ppm in Figure 3.47 represents the protons alpha to the carboxylic acid in 
the starting material. The appearance of a new singlet at 4.55 ppm represents the 
formation of the isocyanate. The protons alpha to the isocyanate are more deshielded than 
the equivalent protons in the carboxylic acid species. Using the relative integrations of the 
two peaks, an estimate of the amount of isocyanate that has formed can be calculated.  
With the necessary isocyanate on hand, the synthesis of 94 and 95 was conducted 
according to the synthetic scheme outlined in Scheme 3.9. The steps are similar to the 
forward reaction scheme detailed for 96 and 97, but the synthesised isocyanate, 99, was 
used for 94 and 95 while the commercially available isocyanate was utilised for the 
synthesis of 96 and 97.  
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Scheme 3.9. Synthetic scheme used for the synthesis of 94 (R = F) and 95 (R = H).  
 
3.2.2.4 Structural characterisation of compound 94 and compound 95 
 
Much of the 1H and 13C NMR assignment for 94 and 95 was similar to the assignments for 
96 and 97, with the relative integrations and positions of the protons appearing as 
expected. The splitting of the 13C signals of the carbons adjacent to the fluorine groups was 
similar to the splitting patterns of 96 and 97. The most obvious change in the NMR spectra 
of compounds 94 and 95 was the inclusion of an extra CH2 group. The 
1H NMR signal for this 
group appears at 4.33 ppm and 4.35 ppm, and the 13C NMR signal appears at 42.7 ppm and 
43.0 ppm for compound 94 and compound 95 respectively.   
Using the synthetic methodologies described above, the urea containing synthetic targets 
as outlined in Figure 3.34 were successfully synthesised in a range of yields. They were 
purified and characterised via a range of analytical techniques, most notably NMR 
spectroscopy. The intricacies of these NMR assignments have been discussed in detail for 
97 with notable NMR signal shifts described for the other three target compounds in this 
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class.  These four compounds, elucidated from computational screening of the nNOS crystal 
structure, were now on hand for biological evaluation.  
 
3.2.3 Modified arginine and thioether compounds 
 
The third class of compounds which were synthesised comprised of the 
arginine/diaminopyridine which was discussed in chapter 2, section 1.4.4.3, and a triazole 
compound which ranked 34th in the crystal structure screen, but was not available for 
purchase. Both of these compounds are shown in Figure 3.48. 
 
 
Figure 3.48. Third class of synthetic targets, 98 and 88. 
 
3.2.3.1 Attempted synthesis and characterisation of arginine/aminopyridine, 
compound 98 
 
The retrosynthesis of arginine/aminopyridine compound is outlined in Scheme 3.10. 
 
 
Scheme 3.10. Retrosynthetic analysis for 98. 
 
The forward reaction using the two synthetic equivalents shown in Scheme 3.10 was 
complicated by the presence of multiple primary amino groups, and the moderately 
nucleophilic guanidinium moiety on the arginine. A protecting group strategy was used to 
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address these issues. One of the primary amines on the 2,6 diaminopyridine was protected 
with BOC. The primary amine on the arginine was protected with the same group. The 
guanidinium side chain was protected with the less common 2,2,4,5,7-
pentmethyldihydrobezofuran-5-sulfonyl (Pbf) protecting group (Figure 3.49).90 
 
 
Figure 3.49. A Pbf protected amine. 
 
The Pbf group is used in peptide bond forming reactions involving arginine as the 
guanidinium side chain has some nucleophilic character. This can result in self-cyclization 
with the arginine carbonyl group, and potential intermolecular nucleophilic attack with 
other species in the reaction mixture.91 The use of Pbf with the BOC protecting groups was 
advantageous, as the two groups are acid labile and so could be removed in one cleavage 
step, once peptide bond formation was achieved.91 The synthetic scheme for formation of 
98 is shown in Scheme 3.11. 
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Scheme 3.11. Forward reaction scheme for 98. 
 
The diprotected arginine species, compound 100, was commercially available, while the 
aminopyridine was mono protected as described in the chapter 5, section 5.6.3. The 
peptide coupling was trialled with a variety of coupling reagents before the conditions in 
Scheme 3.11 were identified. The conditions trialled included 4-(4,6-dimethoxy-1,3,5-
trianzin-2-yl)-4-methyl-morphorlyin chloride (DMTMM) and 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronuim tetraflurorborate/hydroxybenzotriazole (TBTU/HOBT) in DCM 
and DMF. The various conditions trialled and the results of these experiments are outlined 
in Table 3.1. 
 
Table 3.1. Coupling conditions trialled for the synthesis of 98. 
Coupling reagent Solvent Temperature Result 
DMTMM DCM R.T Complex mixture 
DMTMM DMF R.T Complex mixture 
TBTU/HOBt DCM R.T Complex mixture 
TBTU/HOBt DMF R.T Complex mixture 
TBTU/HOBt DCM 50 0C Complex mixture 
TBTU/HOBt DMF 50 0C 90% yield 
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DMTMM is a triazine based peptide coupling reagent and was freshly synthesised from 2-
chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) and N-methyl-morpholine (NMM) in a 1:1 ratio 
as outlined in Scheme 3.12. This coupling reagent is not as popular as others due to its 
relatively short shelf life and instability in organic solvents, particularly DCM, which is a 
popular solvent for peptide bond formation.92 DMTMM can decompose through loss of the 
methyl group on the quaternary nitrogen, rendering it inactive as a peptide coupling 
reagent.92 
 
 
Scheme 3.12. DMTMM, 101, synthesis. 
 
It was anticipated that DMTMM would form an activated ester species when reacted with 
the carboxylic acid of the diprotected arginine. This should then react with the protected 
2,6 diaminopyridine to form the product as shown in Scheme 3.13. 
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Scheme 3.13. Activated ester formation and peptide bond formation using DMTMM. 
 
This coupling approach with DMTMM did not yield the expected product, it instead 
resulted in a complex mixture. It is not uncommon in peptide coupling reactions to trial a 
variety of coupling conditions. Prediction of which set of conditions will be successful is 
difficult, and often a wide screen of reagents is necessary to form the desired product.93  
HOBt/TBTU in DMF proved to be successful for this reaction. HOBt prevents racemisation, 
and has been reported to form the OBt activated ester. It is possible that OBt activated 
esters have increased reactivity due to their ability to stabilize the approach of the amine 
through HBing.94 The formation of the activated ester from TBTU and subsequent amine 
coupling is shown in Scheme 3.14. 
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Scheme 3.14. Formation of activated ester from TBTU and subsequent coupling of the amine. 
 
Coupling of the diprotected arginine and the mono protected diaminopyridine gave the 
triprotected species (Figure 3.50) in a 90% yield. The coupling of the two partners was 
confirmed via NMR and mass spectrometry. Three distinctive protecting group signals for 
the two BOC groups and the Pbf group were observed at 1.43 ppm (9H), 1.44 ppm (6H) and 
1.48 ppm (9 H). The alkyl chain signals were also in evidence, with complex splitting due to 
the diastereotopic nature of the protons. The total combined integration for the alkyl 
signals observed was seven. The aromatic signals for the pyridine ring were clearly visible at 
7.36 ppm (t, 1H), 7.19 ppm (d, 1H) and 6.13 ppm (d, 1H). 
 
 
Figure 3.50. Triprotected product, 102, obtained from TBTU coupling. 
 
Once the coupling had been completed, the deprotection of 102 was attempted using TFA. 
While the coupling of the protected species was successful and the triprotected product 
was obtained in high yields, the subsequent deprotection using TFA did not yield the 
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expected product. The protecting group signals for both BOC groups and the Pbf group 
were not present in the 1H NMR, demonstrating that they had been removed. However, 
the expected CH2 signals for the arginine chain were absent, and the aromatic region did 
not contain the expected 1:1:1 ratio of aromatic proton peaks for the aminopyridine ring 
protons. It is possible that the use of high concentrations of TFA, which are required for Pbf 
removal, resulted in degradation of the product. Also, the deprotection of the nucleophilic 
guanidinium group on the arginine side chain may have contributed to unpredictable side 
reactions. The deprotected species, compound 98, was therefore not successfully 
synthesised.  
3.2.3.2 Attempted synthesis and characterisation of thioether, compound 88 
 
The synthesis of a triazole containing sulphur ether, shown in Figure 3.48 was also 
attempted. The retrosynthetic analysis of this compound is shown in Scheme 3.15. 
 
 
Scheme 3.15. Retrosynthetic analysis of 88. 
 
 
Breaking of the peptide bond gives the commercially available triazole carboxylic acid, and 
the thioether compound with a free primary amine. The thioether could be generated from 
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thiophenol and 2-chloroethanamine. While this amine was available, it was thought that 
treatment of this compound with base could result in self-reaction via nucleophilic attack 
of the deprotonated amino group at the carbon alpha to the chloro leaving group. To 
prevent this possible complication, the free amine was protected using a phthalimide 
group. Once the thiophenol and the phthalimide protected amine had reacted, the 
protecting group could be removed via treatment with hydrazine in the presence of 
methanol and acetic acid. This amine could then be coupled with the triazole species. A 
proposed synthetic scheme is outlined in Scheme 3.16. 
 
 
Scheme 3.16. Synthetic scheme for 88. 
 
The attack of the thiophenol on the carbon alpha to the chlorine yields the desired product 
in an 86% yield. Clear 1H NMR signals were observed for the two CH2 groups at 3.72 ppm (t, 
2H) and at 3.05 ppm (t, 2H). The 13C NMR signals for the two carbonyl carbons appears as 
one equivalent signal at 167.7 ppm. A HMBC correlation is observed between the CH2 
signal at 3.72 ppm and this carbon signal. This correlation, along with the presence of the 
expected number of aromatic signals, indicated formation of the desired product. 
The deprotection using hydrazine generated the primary amine in a 77% yield. The two CH2 
signals were again visible in the 1H NMR at 2.90 ppm and 2.80 ppm. A characteristically 
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broad amine 1H NMR signal was observed at 1.49 ppm, along with the expected aromatic 
1H NMR signals in a 2:2:1 ratio.  
A proposed mechanism for the hydrazine deprotection, which is similar to the phthalimide 
removal in the Gabriel synthesis, is outlined in Scheme 3.17.95,96 The dione side product is 
insoluble in methanol and so can be removed via filtration.  
 
 
Scheme 3.17. Phthalimide removal in the presence of hydrazine and acetic acid.
96
 
  
Coupling of this amine with the triazole carboxylic acid was then attempted using a variety 
of conditions (Table 3.2). The coupling reaction could not be completed successfully, and 
88 was not isolated for biological testing. 
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Table 3.2. Coupling conditions trialled for the synthesis of 88. 
Coupling reagent Solvent Temperature  Result 
DMTMM DCM R.T Complex mixture 
DMTMM DMF R.T Complex mixture 
TBTU/HOBt DCM R.T Complex mixture 
TBTU/HOBt DMF R.T Complex mixture 
TBTU/HOBt DCM 50 0C Complex mixture 
TBTU/HOBt DMF 50 0C Complex mixture 
DCC DMF R.T Complex mixture 
DCC DCM R.T Complex mixture 
 
It is possible that the triazole has some nucleophilic properties, and may attack the 
activated ester upon its formation. Triazole has been observed to act as a nucleophile in 
the presence of organcatalysts.97 Protection of the triazole NH may address this issue; 
however it is possible that the all nitrogens of the triazole possess some nucleophilic 
properties. Protection of one nitrogen may therefore not eliminate potential side reactions 
when attempting to couple the triazole carboxylic acid with the desired amine. 
 
3.3 Synthesis conclusion 
 
A variety of non-commercially available potential human nNOS inhibitors had been 
identified by the computational screening studies that were conducted in chapter two. Two 
classes of compounds were synthesised based on some of the high ranking structures from 
these screens. The first class, with five members, had a piperazine core and was 
synthesised using a range of methodologies, including epoxide ring opening and 
nucleophilic attack on isocyanates and isothiocyanate. The five synthetic targets, all of 
which were novel compounds, were successfully synthesised in a range of yields.  
The second class of compounds contained a urea linkage that was synthesised via amine 
attack on isocyanates. Two of the required isocyanates were first synthesised via azide 
formation and Curtius rearrangement. The four members of this second class of 
compounds were isolated as white solids, and their structural characterisation has been 
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discussed in detail. The core structure of this class of compounds was well represented in 
the hit list which was generated from docking with the human nNOS crystal structure. It is 
hoped that this strong computational performance would translate to inhibitory activity in 
a human nNOS assay. 
Synthesis of a third class of compounds, containing a de novo designed mixed arginine-
aminopyridine and a computationally identified triazole thioether, was also attempted. Key 
intermediates of these two synthetic targets were successfully isolated, but the production 
of the final target compounds was not achieved. 
The successfully synthesised compounds from class one and class two were now available 
for testing in a human nNOS inhibition assay. These compounds were novel and had been 
identified via a variety of computational screening methods. In order to test their inhibitory 
activity, a human nNOS assay was now required.  
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4 NOS Expression, Assay 
Development and 
Compound Evaluation 
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4.1 Introduction 
 
The vast majority of nNOS inhibitor evaluation is currently performed using the rat isoform 
of the enzyme, with inhibitor selectivity routinely being determined by testing with bovine 
eNOS and murine iNOS.32,49,52,57,98,99 This use of different isoforms is not an accurate system 
for determining the effectiveness of compounds against human nNOS. This work aimed to 
address these issues by expressing all three human isoforms of NOS in E. coli cells, and to 
use the recombinant proteins in a robust and reproducible NOS assay system. Additionally, 
the NOS proteins will be co-expressed with human calmodulin (CaM), a protein which is 
vital to NOS function.10,100 It was expected that this co-expression approach, not reported 
thus far in the literature, would improve NOS activity in subsequent assay systems. The 
avoidance of human NOS enzymes by the scientific community suggests that the 
expression and purification of these enzymes is non-trivial. As such, it was anticipated that 
the development of a reliable human NOS recombinant expression system would be 
challenging and would present a range of difficulties that would have to be overcome.  
To address the challenges that would be associated with human NOS production, the 
approach outlined in Figure 4.1 was used. Each stage of this process required careful 
optimisation and consideration of the experimental approach. The overall experimental 
design first involved the amplification of the NOS DNA, followed by transformation of a 
suitable expression host with the amplified DNA. The growth and lysis conditions at this 
stage were scrutinised closely, as were the optimum affinity purification conditions. If the 
NOS/CaM protein complex could be isolated from these experiments, it would then be 
used in a Griess assay system. Each stage of this process and the difficulties faced will be 
described in this chapter.  
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Figure 4.1. Flowchart describing the general steps for NOS/CaM expression. 
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4.2 DNA sequencing and verification of insert 
 
The first stage of the expression protocol was to transform TOP10 E. coli cells with the 
plasmid containing the human NOS (either eNOS, iNOS or nNOS) and calmodulin genes. 
This was done to amplify the DNA and ensure sufficient DNA stocks were available for 
analysis and future experimental work. TOP10 E. coli cells were used for this step because 
they have high transformation efficiency (1*109 colony form units (cfu) /µg of plasmid DNA) 
and have been genetically modified to knock out a number of E. coli genes that code for 
restriction enzymes. If present, these restriction enzymes could degrade the plasmid 
DNA.101 
The TOP10 cells were transformed with the DNA as per chapter five, section 5.2.2.1. 
Following transformation, the clones were analysed via agarose gel electrophoresis to 
ensure that the transformation process was successful, and to ensure that the NOS and 
calmodulin gene sequences were the correct length. Five clones were grown for each gene 
and the plasmid DNA removed from them. The NOS and CaM genes were excised using 
restriction digestion and ran on agarose gels. The resulting gels for the five colonies of 
iNOS, eNOS, nNOS and calmodulin are shown in Figure 4.2 to Figure 4.5. The expected 
band sizes for each digested plasmid are in Table 4.1. (See chapter five, section 5.2.1 for 
plasmid maps). 
 
Table 4.1. Expected DNA band sizes (bp). 
 iNOS eNOS nNOS CaM 
Band Size 1 
(plasmid)* 
4041 kb 3803 kb 4386 kb 4274 kb 
Band Size 2 
(insert) 
2840 kb 3221 kb 3381 kb 540 kb 
  *Plasmid vector with NOS or CaM gene excised 
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Figure 4.2. Agarose gel analysis of five DNA samples containing the iNOS plasmid. The upper band 
represents the plasmid vector with the iNOS gene excised, while the lower band represents the iNOS 
gene. Digested product was observed in four clones, while the clone in lane two was not successfully 
transformed. 
 
 
Figure 4.3. Agarose gel analysis of five DNA samples containing the eNOS plasmid. The upper band 
represents the plasmid vector with the eNOS gene excised, while the lower band represents the 
eNOS gene. The eNOS gene was observed in all five samples.  
 
 
Figure 4.4. Agarose gel analysis of five DNA samples containing the nNOS plasmid. The upper band 
represents the plasmid vector with the nNOS gene excised, while the lower band represents the 
nNOS gene. The nNOS gene was observed in all five samples. 
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Figure 4.5. Agarose gel analysis of five DNA samples containing the CaM plasmid. The upper band 
represents the plasmid vector with the CaM gene excised, while the lower band represents the CaM 
gene. The CaM gene was observed in all five samples. 
 
All band sizes were as expected, with one band for the insert and one for the cleaved 
vector observed in each construct. The only exception was for the iNOS clone in lane two of 
Figure 4.2. This clone was not successfully transformed with the iNOS DNA. This type of 
random failure of transformation can occur in these experiments. This was why five 
transformed clones, and not just one, were analysed for each construct. As the other four 
clones of iNOS were successfully transformed, this single failure was not a concern. The 
results presented in the agarose gel analysis demonstrate that DNA of target genes was 
successfully amplified, and that genes of the correct size were present in each construct. To 
ensure that the bands represented the NOS and CaM genes, sequencing analysis was 
carried out.  
The suspected NOS and CaM genes were sequenced as per chapter five, section 5.2.2.6. All 
genes matched their reported sequences with 100% accuracy, with the exception of a 
single mutation in the human nNOS gene. However, this mutation (R1297S) did not occur 
close to the arginine binding site and was unlikely to affect inhibitor binding to human 
nNOS.102 Full alignments of the four sequenced genes with their published sequences 
(taken from Uniprot http://www.uniprot.org/) are available in appendix, chapter 8. 
The human NOS and CaM genes had been successfully verified via sequencing, and the 
DNA constructs had been amplified using the TOP10 E. coli cells. With this DNA in hand 
attention was turned to expression of the target proteins in a bacterial system.  
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4.3 nNOS expression and purification 
 
As human nNOS was the key target for this project, efforts were initially focused on the 
development of an effective expression and purification strategy for this isoform. Initial 
expression trials were based on the published rat nNOS expression protocol, and personal 
communication with the leading groups in the field.103 It was anticipated that these initial 
expression conditions would need to be significantly modified to improve the expression, 
solubility and purification of the target protein. It was of key importance to optimize this 
procedure so that the maximum amount of human nNOS could be captured from each 
experiment. This would improve the likelihood of developing a successful assay protocol. It 
was hypothesised that if a successful human nNOS expression and purification protocol 
could be developed; then the same conditions could be applied to human eNOS and iNOS.  
 
4.3.1 Establishing a jackpot clone 
 
The two most popular strains for E. coli recombinant expression are the BL21 strain, and 
the M15 strain. The M15 strain contains an extra plasmid, prep4. This plasmid codes for 
kanamycin resistance. If M15 cells were used for expression, the media would have to be 
treated with three types of antibiotic when the cells were transformed with the NOS and 
CaM plasmids. Namely, kanamycin for the prep4 plasmid, ampicillin for the NOS plasmid 
and chloramphenicol for the CaM plasmid. This may decrease overall NOS expression levels 
as the cells would need to expend a large amount of resources in expressing the proteins 
which confer antibiotic resistance. BL21(DE3) cells were therefore chosen for the 
expression work. Use of this strain would mean that the media would only need two 
antibiotics, ampicillin and chloramphenicol. Kanamycin would not be required as BL21(DE3) 
cells do not contain a prep4 plasmid. BL21 cells were also used in the published rat nNOS 
expression protocol.103 
BL21(DE3) cells  were initially transformed with human nNOS DNA and four clones were 
assessed to determine their ability to express the protein. The four clones were grown in 3 
mL of LB media to an OD600 of 0.600 at 37 
0C. These were then induced with 1 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown overnight at 37 0C. The cells were 
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then pelleted and solubilised in 400 µL of sample buffer (chapter five, section 5.2.3). The 
levels of human nNOS present in each sample were then analysed via Western blot using 
equal volume loadings (40 µL) for each sample (Figure 4.6). A specific anti-human nNOS 
antibody was used to probe the samples at a concentration of 1:1000 in PBST. The clone 
which expressed the largest amount of the target protein was termed the “jackpot” clone. 
Human nNOS (MW ~160 kDa) was successfully expressed in three out of four clones. 
Similar to the DNA amplification experiments, failure of individual clones to express the 
target protein is not an issue if other clones are expressing the protein.  Relatively high 
levels of human nNOS were detected in the samples from clones two and three. No 
expression was observed in clone one and a trace amount of nNOS was detected in clone 
four (Figure 4.6). BL21(DE3) cells had now been successfully transformed with the human 
nNOS gene and the protein was expressing successfully. The expression experiments could 
now be scaled up to in the hope of generating sufficient quantities of protein for the assay 
work. A glycerol stock was made from clone three for storage of the jackpot clone.  
 
 
Figure 4.6. Jackpot clone trials for human nNOS. Clone one in lane one shows no detectable level of 
nNOS expression. Clones two and three show good levels of expression, while clone four shows very 
little expression. (1:1000 anti-human nNOS). Expected band size of human nNOS 160 kDa. All lanes 
loaded with equal volumes of whole cells lysed in sample buffer.  
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4.3.2 Initial large scale expression conditions 
 
With a strongly expressing clone identified, large scale expression trials were attempted. 
The scale of expression needed to be relatively large ( ~ 2 L cultures) to generate enough 
functional protein for use in the Griess assay. The development of an optimised, large scale 
expression procedure was to prove challenging, and required a large degree of refinement. 
The glycerol stock for clone three (Figure 4.6) was grown on agar plates and individual 
colonies were transferred to LB media containing appropriate antibiotic (50 µg/µL 
ampicillin). After overnight growth, the LB culture was used to inoculate fresh TB media 
containing 50 µg/µL ampicillin and supplemented with 2 µM riboflavin and 1 mM 
aminolevulinic acid. These additives acted as FAD/FMN and heme precursors 
respectively.104,105 The cells were grown to an OD600 of 0.600, induced with 1 mM IPTG and 
grown overnight for 42 hours at room temperature. These are the growth times and 
temperatures that are reported for rat nNOS expression post induction.103 Once the cells 
were grown, they needed to be lysed so that any expressed human nNOS could be purified. 
Lysis of the cells was conducted using a lysis buffer.  
All buffers for human nNOS lysis and purification were adjusted to pH 8. This is within one 
unit of biological pH, which should aid in protein folding. A pH closer to 7 was not used as 
while it could aid in protein folding, the isoelectric point (pI) of human nNOS is 7.1. Use of a 
buffer with a pH too close to this pI value may result in severe protein aggregation due to 
loss of secondary structure folding interactions. pH 8 was used for buffers instead of pH 6 
as the pKa of the histidine side chain is roughly 6.
106 If a pH of 6 had been selected, this 
could have resulted in the protonation of the His-tag histidine imidazole rings. This would 
render the nNOS protein unable to bind to the Ni-NTA resin, making it unsuitable for 
purification by column chromatography. Calcium chloride was also added to all buffers as 
this expression strategy involved the co-expression of nNOS and calmodulin. The CaCl2 
would allow the calmodulin to bind to the nNOS protein during these co-expression 
experiments. 
In the initial lysis buffer, the ionic strength was provided by NaCl, while the Na2HPO4 was 
used to buffer the pH. β-Mercaptoethanol was used to disrupt potential disulphide bonds, 
while the Trition X-100 was a detergent used to solubilize cell membranes. Proteases were 
inhibited using the Sigma inhibitor cocktail and phenylmethylsulfonyl fluoride (PMSF). 
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Lysozyme was included to help break open the cells, while the glycerol was present to help 
stabilize human nNOS. The inclusion of glycerol for target protein stabilisation is routine in 
these types of experiments. BH4 is a key co-factor of nNOS that is not provided by E. coli 
and the inclusion of CaCl2 has been explained above. The components and their final 
concentrations are outlined in Table 4.2. 
Table 4.2. Initial nNOS lysis buffer (pH 8).  
Component Concentration 
Na2HPO4 50 mM 
NaCl 300 mM 
Β-Mercaptoethanol a 10 mM (140µL/100mL) 
Triton X-100 1% 
Sigma inhibitor cocktail a 1 tablet/100ml 
PMSF a 1 mM (0.0435g in 2.5ml IPA, 1mL/litre) 
Lysozyme 2 mg/ml 
Glycerol 20% 
Tetrahydrobiopterin 10 µM 
CaCl2 2 mM 
aAdded just before use 
The lysis process was conducted as per chapter five, section 5.2.3.2. For purification, the Ni-
NTA resin was pre-equilibrated with 10 mM imidazole in stock purification buffer (50 mM 
Na2HPO4, 300 mM NaCl, 20% glycerol and 2 mM CaCl2) to reduce the interactions of non-
specific proteins with the resin. The resin was loaded into a polypropylene column and the 
flowthrough was collected. The resin was then washed with the stock purification buffer 
containing 20, 40 and 60 mM imidazole and the proteins eluted from the column with 250 
mM imidazole. The fractions were analysed for human nNOS content via Western blot 
analysis, shown in Figure 4.7. 
Chapter Four                           NOS, Expression, Assay Development and Compound Evaluation 
 
174 
 
 
Figure 4.7. Western blot demonstrating initial human nNOS expression and purification conditions. 
Lane one contains the pellet sample, lane two the cleared lysate and lane three the column 
flowthrough. Lane four, five and six contain samples from 20, 40 and 60 mM imidazole washing and 
finally lane seven contains the elution sample. (1:1000 anti-human nNOS). The lower panel is actin 
loading control, expected M.W of actin was 42 kDa.  
 
Expression was successful as clear bands at the correct molecular weight for human nNOS 
(160 kDa) could be seen in lanes one, two, six and seven. The higher molecular weight 
species in lanes one and two was possibly an aggregate or a dimer of human nNOS. This 
blot demonstrated that significant portions of the expressed protein had become trapped 
in the insoluble fraction (lane one). This was not desirable as any NOS protein which was in 
the insoluble fraction could not be purified and had to be discarded. The soluble fraction 
(lane two) was taken forward for Ni-NTA purification. The nNOS in the soluble fraction 
bound strongly to the Ni-NTA resin as no band is observed in the flowthrough lane (lane 
three). This confirmed that affinity purification is a suitable purification technique for this 
protein. The 20 mM and 40 mM imidazole washes (lanes four and five) did not remove any 
of the nNOS protein, while a small amount was washed off the column with 60 mM 
imidazole (lane six). Finally, the elution fraction in lane seven shows a clear nNOS band, 
indicating that the protein was indeed removed from the resin using a 250 mM imidazole 
elution. To ensure that these results were robust an actin loading control blot was also 
produced, proving that the total protein concentration was the same in each lane.  
The results generated by the above experiment were encouraging. They demonstrated that 
the jackpot clone, as established in section 4.3.1, could be used for a larger scale 
expression. Human nNOS was successfully expressed and was purified using affinity 
chromatography. However, several issues needed to be addressed from this initial 
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expression, lysis and purification procedure. The solubility of the target protein was an 
issue, with a significant portion of human nNOS remaining in the insoluble fraction 
following cell lysis. The amounts of aggregated species were also of concern. To try and 
improve this situation, and to increase the amount of protein captured from the resin in 
the elution step, a variety of expression, lysis and purification experiments were 
conducted. The results of these experiments are outlined in the following sections.  
     
4.4 nNOS expression and cell growth conditions 
 
Solubility of a recombinantly produced protein can vary greatly depending on the growth 
and induction conditions used. A number of these conditions were examined for this 
system to assess their impact on human nNOS solubility. These conditions included; 
1. Induction conditions  
2. The effect of growth medium  
3. The effect of temperature  
4. Expression and solubility levels at various time points post induction 
These conditions were chosen for experimentation as they are well reported as having a 
major impact on recombinant protein production and solubilisation.107 It was hoped that 
varying these conditions would address the issues surrounding human nNOS production as 
described above.  
Equal volume loading was used for the Western blot analysis of the optimisation trials. 
When two conditions were to be compared, e.g. IPTG versus no IPTG, the cultures were 
grown in identical conditions with identical volumes of media. Following the growth and 
expression procedures the same volume of lysis buffer was used to resuspend the pelleted 
cells in both conditions. These cells were then lysed and centrifuged, resulting in an 
insoluble and a soluble fraction for both conditions. The insoluble material was 
resuspended in PBS. An equal volume of all material, both soluble and insoluble, was then 
loaded onto the gels.108 This allows for comparison of nNOS protein levels across lanes of 
the Western blots that will be presented in the following sections.  
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4.4.1 IPTG induction 
 
Recombinant protein production makes use of the host cell’s transcription and translation 
machinery to produce the target protein. This process can strain the host cell, as resources 
are rapidly consumed in the production of the recombinant protein, to the detriment of 
native protein production. If the recombinant production begins too early in the cell 
culture’s growth cycle, the cells may die from the strain. Also, if the recombinant protein of 
interest is toxic to E. coli cells, production of large volumes of the target early in the cell 
growth cycle may lead to total cell death.107  
To prevent this from occurring, the expression from the genes for the recombinant protein 
can be controlled via inducible expression.109 A promotor is located upstream from the 
gene of interest, in this case human nNOS. This promotor is “turned off” in its native state 
due to the binding of an inhibitory protein to the promoter sequence. This inhibitor 
prevents mRNA polymerase from transcribing the human nNOS gene. Gene expression can 
be “turned on”, or induced, by addition of IPTG. This binds to the promoter sequence and 
causes the inhibitor protein to be cleaved from the promoter sequence. The mRNA 
polymerase can then bind to the promoter, and the human nNOS gene can be 
transcribed.110,111 
In theory, production of the human nNOS protein should therefore not occur before 
addition of IPTG. However, many gene constructs under the control of the lac operator 
exhibit “leaky” expression of the target protein, i.e. expression of the protein in the 
absence of an inducing agent.112 If significant leaky expression occurs then addition of IPTG 
may make little difference to the level of soluble protein produced. If leaky expression 
occurs, at a very low level, omission of IPTG may result in extremely poor soluble protein 
yields. The effect of IPTG addition therefore needed to be investigated for the nNOS 
expression system.  
Two cultures of human nNOS were grown to an OD600 of 0.600 as described in section 
4.3.2. Protein expression was induced in one of these cultures with 1 mM IPTG, while the 
other was not induced. These were grown for 42 hours at room temperature. The cultures 
were lysed and the soluble and insoluble fractions for each were analysed (Figure 4.8). No 
purification steps were carried out as the goal of this experiment was to examine the effect 
of IPTG on protein solubilisation. Purification was therefore not required.   
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Figure 4.8. Human nNOS induction trials. Lanes one and two contain uninduced (without IPTG) pellet 
and cleared lysate, respectively. Lanes three and four contain induced (with IPTG) pellet and cleared 
lysate, respectively (1:1000 anti-human nNOS antibody). All lanes loaded with equal volumes. 
 
For the induced samples (lane three and four), it appeared that more of the protein moved 
into the soluble fraction when compared to the uninduced samples. This suggested that 
induction with IPTG was preferable for human nNOS expression. A degree of “leaky” 
expression (expression of the target protein without IPTG addition) was observed in this 
system. This is commonly found with pQE-30 plasmid as the T5 promotor is recognised by 
E. coli mRNA polymerase.110 This leaky expression could be controlled or eliminated by 
switching to a T7 promotor which is not recognized by E. coli mRNA polymerase, or by the 
use of M15[prep4] cells for expression.111,113 The prep4 plasmid held by these cells 
produces excess lac repressor to help silence the T5 promotor prior to induction. As nNOS 
was already expressing successfully even with the leaky expression, none of these solutions 
were required.113 
An IPTG concentration screen can be conducted to determine the optimum concentration 
for protein expression. However, as 1 mM is the recommended concentration for induction 
of expression from a pQE-30 vector (Qiagen manual) and because 1 mM IPTG worked well 
in the nNOS system, this trial was deemed unnecessary. The existing system was observed 
to function correctly, and induction with 1 mM IPTG resulted in a better solubilised target 
protein when compared to the uninduced samples. 
 
4.4.2 Growth Media 
 
The effect of the growth media on target protein expression and solubility was then 
examined. TB media is richer in nutrients than LB media, allowing cultures to reach a higher 
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density than is possible in LB media. However, solubilisation of the target protein is equally 
important. The solubility of a target protein can be affected by the media in which the host 
is grown and so the relative levels of soluble protein resulting from each media must also 
be examined.114  
To determine the most suitable media for human nNOS production a culture was grown in 
each media to an OD600 of 0.600, induced with 1 mM IPTG, grown for 42 hours at room 
temperature and lysed as before. Both media cultures were supplemented with 2 µM 
riboflavin and 1 mM aminolevulinic acid. No purification was carried out. The resulting blot 
is shown in Figure 4.9. 
 
 
Figure 4.9. LB vs TB growth media trial for human nNOS expression. Lanes one and two contain 
pellet and cleared lysate samples of cultures grown in LB media. Lanes three and four contain pellet 
and cleared lysate samples of cultures grown in TB media (1:1000 anti-human nNOS antibody). 
Expected weight of human nNOS 160 kDa. All lanes loaded with equal volumes. 
 
When expression was induced in LB media almost all of the protein was retained in the 
insoluble fraction (lane one), and a large portion of it aggregated, rendering it useless for 
functional assays. For the TB media, large portions of the protein do remain insoluble (lane 
three). However, a significant portion of the protein is observed in the TB soluble fraction 
(lane four) and is notably better than the LB soluble fraction (lane two). TB media has been 
specifically engineered to improve recombinant protein stability and yield, so its superior 
performance was as expected.107 It was important to compare its performance to the 
performance of LB, as LB was the media of choice for rat nNOS expression, and is also one 
of the most popular media for recombinant protein expression.115 Due to the increased 
solubility observed with TB, it was chosen as the media for human nNOS protein 
expression.  
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4.4.3 Growth temperature 
 
With media and induction conditions optimised, growth temperature post induction was 
examined. Growing E. coli cells at 37 0C post induction may cause the cells to produce the 
target very quickly, resulting in the formation of insoluble aggregates of misfolded protein 
called inclusion bodies. Lower growth temperatures post induction may prevent the 
formation of these aggregates and aid in recombinant protein solubilisation.114 
Two separate cultures were grown to an OD600 of 0.600 in TB media supplemented with 2 
µM riboflavin and 1 mM aminolevulinic acid, and induced with 1 mM IPTG. One culture was 
grown at 37 0C for 42 hours and one was grown at room temperature for 42 hours. The 
resulting cells were lysed and analysed via Western blot (Figure 4.10).  
 
 
Figure 4.10. Temperature trial for human nNOS expression. Lanes one and two contain pellet and 
cleared lysate samples from TB cultures grown at room temperature. Lanes three and four contain 
pellet and cleared lysate samples from TB cultures grown at 37 
0
C (1:1000 anti-human nNOS 
antibody). Expected weight of human nNOS 160 kDa. All lanes loaded with equal volumes. 
Growth at 37 0C resulted in severe aggregation of human nNOS, evidenced by the “streaky” 
bands in lane three. The vast majority of the protein was also rendered insoluble under 
these conditions as no band was observed at the correct molecular weight in lane four. At 
37 0C there was considerable degradation of the NOS protein as a large number of bands 
were seen below the 160 kDa marker.  
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Cultures grown at room temperature were noted to have some degree of aggregation. 
However, a much greater portion of the human nNOS was found in the room temperature 
soluble fraction (lane two) in comparison to the 37 0C soluble fraction (lane four). Room 
temperature was chosen as the better option for human nNOS production. 
 
4.4.4 Cell growth time course 
 
The final optimisation experiment for the expression and growth conditions focused on 
optimising the time taken to grow the cell cultures post induction. So far, all cultures had 
been grown for 42 hours, as this was the growth time used for rat nNOS.103 Long time 
courses for culture growth may result in greater cell densities and thus higher protein 
yields. This must be balanced against the possible formation of inclusion bodies, as the 
cellular concentration of recombinant protein increases.  
A TB culture was induced at an OD600 of 0.600 and grown at room temperature. Samples 
were taken at 8, 12, 24 and 42 hours (h) post induction. Pellet and cleared lysate of each 
sample were analysed as before (Figure 4.11). Time points as far as 42 hours were taken in 
order to compare with the reported expression time for rat nNOS expression.103 Longer 
time points were not analysed as one of the goals of the experiment was to decrease the 
overall growth time, if possible, and to improve processing times for human nNOS 
recombinant production. Also, after 42 hours at room temperature, TB cultures were 
observed to have reached maximum confluency as measured by OD600 measurements. 
Further growth time was therefore not required.  
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Figure 4.11. Time course for human nNOS expression. Lanes one and two contain pellet and cleared 
lysate sample from culture which was grown for 8 h post induction. Lanes three and four are from 
12 h post induction, five and six from 24 h post induction and seven and eight are pellet and cleared 
lysate samples taken 42 h post induction (1:1000 anti-human nNOS antibody). Expected weight of 
human nNOS 160 kDa.  All lanes loaded with equal volumes. 
 
At any time point past 24 hours it was seen that nearly all of the nNOS protein had 
migrated to the insoluble fraction. Although previous experiments had shown some level of 
protein solubilisation after 40 hours, this experiment suggested that 12 hours was the 
optimal growth time for the cultures. Any shorter resulted in lower levels of nNOS 
expression, while longer time points showed severe aggregation and insolubility. This was 
considerably shorter than the growth time suggested in the rat nNOS expression 
procedure.103 The 12 hour growth period resulted in better solubilised protein, and also 
increased the speed at which large quantities of the protein could be produced for 
functional assay testing. 
 
4.4.5 nNOS expression and cell growth conditions conclusion 
 
The experiments described above were designed to probe the cell growth and protein 
expression conditions, in the hope of improving the solubility and overall yields of human 
nNOS. The initial conditions used were based on those previously published rat nNOS 
recombinant expression conditions.103 This used LB media, grown at room temperature for 
42 hours, with expression being induced with 1 mM IPTG. Following examination of these 
conditions, and trials of alternatives, the optimum conditions for human nNOS expression 
were found to be growth in TB media, at room temperature for 12 hours, using 1 mM IPTG 
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for induction. These resulted in a significant improvement in protein solubility, and in 
efficiency of protein production. The new conditions were carried forward for the next set 
of experiments, which involved optimising the lysis and purification conditions for human 
nNOS recombinant expression.  
 
4.5 nNOS lysis and purification conditions 
 
As alluded to in section 4.3.2, optimal lysis and purification buffer conditions are difficult to 
predict for recombinant protein experiments. These buffers play a key role in the solubility 
and overall yield of target proteins, and therefore merit careful examination. Four separate 
buffers were analysed for human nNOS expression. The results with each buffer are 
presented in the following section.   
 
4.5.1 Lysis buffer screen 
 
Four separate, yet identical one litre nNOS cultures were grown according to the new 
optimal growth conditions, section 4.4.5. Upon cell harvesting the pellets were 
resuspended in equal volumes of one of four possible lysis buffers (Table 4.3). All four 
buffers contained protease inhibitor tablet, 1% Triton X-100, 10 mM β-mercaptoethanol, 1 
mM PMSF, 2 mg/mL lysozyme, 10 µM BH4 and 20% glycerol, 2 mM CaCl2 but varied in their 
ionic strength and buffer components as outlined in Table 4.3. Each culture was lysed with 
rolling and sonication as before, and purified via affinity chromatography. The purification 
buffers were made up of the stocks as shown in Table 4.3, with the appropriate amount of 
imidazole added. The ability of each of the four lysis buffers to solubilise human nNOS was 
assessed via Western blot, Figure 4.12-Figure 4.15. 
Table 4.3. Buffer conditions screened for nNOS solubilisation. All buffers at pH 8. 
Buffer A Buffer B Buffer C Buffer D 
300 mM NaCl 500 mM NaCl 500 mM NaCl 500 mM NaCl 
50 mM Na2HPO4 50 mM Na2HPO4 50 mM Tris.HCl 50 mM HEPES 
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Figure 4.12.  Lysis and purification buffer A. Lane one contains the pellet sample, lane two the 
cleared lysate, lane three the column flowthrough. Lanes four, five and six contain samples of the 
20, 40 and 60 mM imidazole column washes, respectively. Lane seven contains a sample of the 
elution fraction, eluted with 250 mM imidazole. (1:1000 anti-human nNOS antibody). All lanes 
loaded with equal volumes. 
 
 
Figure 4.13. Lysis and purification buffer B. Lane one contains the pellet sample, lane two the 
cleared lysate, lane three the column flowthrough. Lanes four, five and six contain samples of the 
20, 40 and 60 mM imidazole column washes, respectively. Lane seven contains a sample of the 
elution fraction, eluted with 250 mM imidazole. (1:1000 anti-human nNOS antibody). All lanes 
loaded with equal volumes. 
 
Chapter Four                           NOS, Expression, Assay Development and Compound Evaluation 
 
184 
 
 
Figure 4.14. Lysis and purification buffer C. Lane one contains the pellet sample, lane two the 
cleared lysate, lane three the column flowthrough. Lanes four, five and six contain samples of the 
20, 40 and 60 mM imidazole column washes, respectively. Lane seven contains a sample of the 
elution fraction, eluted with 250 mM imidazole. (1:1000 anti-human nNOS antibody). All lanes 
loaded with equal volumes. 
 
 
Figure 4.15. Lysis and purification buffer D. Lane one contains the pellet sample, lane two the 
cleared lysate, lane three the column flowthrough. Lanes four, five and six contain samples of the 
20, 40 and 60 mM imidazole column washes, respectively. Lane seven contains a sample of the 
elution fraction, eluted with 250 mM imidazole. (1:1000 anti-human nNOS antibody). All lanes 
loaded with equal volumes. 
 
Buffer A was the lysis buffer which had been used for the initial experiments with human 
nNOS (section 4.3.2). Buffer B was the same buffer but with twice the NaCl concentration. 
This would investigate how increased ionic strength affected human nNOS solubilisation. 
Ionic strength of lysis and purification buffers plays a key role in recombinant protein 
solubilisation and, similar to many aspects of recombinant expression, is difficult to 
predict.116 Buffer C was chosen as this was previously reported for rat nNOS production 
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from E. coli. 103 Buffer D was chosen with an ionic strength between A and B. HEPES was 
also used in Buffer D as the Griess assay system that was to be used for compound testing 
employed a HEPES buffer. It may be advantageous to use a HEPES based buffer for lysis, 
purification and in the functional assay to avoid unpredictable interferences that may be 
caused by mixed buffer systems.  
Buffers A (300 mM NaCl, 50 mM Na2HPO4, 20% glycerol) and D (500 mM NaCl, 50 mM 
HEPES, 20% glycerol) were the most successful, with use of each resulting in a strong nNOS 
band in the elution fraction. Both also showed efficient nNOS solubilisation when 
compared to buffers B (600 mM NaCl, 50 mM Na2HPO4, 20% glycerol) and C (500 mM NaCl, 
50 mM Tris.HCl, 20% glycerol). Buffer B, as reported for rat nNOS production, and buffer C 
were therefore deemed to be ineffective in this system.  
Buffer D was chosen over buffer A for future nNOS expression experiments as the former 
contained sodium phosphate. This resulted in the formation of insoluble calcium phosphate 
when the calcium chloride was added. This white, insoluble material was not removed by 
the purification or dialysis steps. It was feared that the resulting turbidity could interfere 
with the absorption readings during the Griess assay. Also, buffer A showed some degree of 
human nNOS aggregation in the cleared lysate lane, as evidenced by the streaking of the 
band in the Western blot. The Griess assay system which was to be used for compound 
evaluation employed a HEPES buffer. Buffer D was also a HEPES based buffer and so may 
be more compatible with the assay system. For these three reasons buffer D was chosen 
over buffer A as the optimal lysis and purification buffer.  
 
4.5.2 Ni-NTA purification screen 
 
The growth, expression and lysis conditions had now been examined and improved. The 
final aspect of the protocol that required examination was the purification conditions used 
for affinity chromatography. All human NOS constructs used in this work were expressed 
with a histidine affinity tag (His-tag). This sequence of six histidine residues binds strongly 
to Ni-NTA affinity columns. Some non-specific E. coli proteins will also bind to this column 
despite not having a His-tag. These can be removed from the column using low 
concentration imidazole washes. The purified target protein can then be eluted using a 
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high concentration imidazole wash.117 The exact figures for “low” and “high” imidazole 
concentrations differ from protein to protein, with some recombinant proteins binding 
strongly to the Ni-NTA column, while some bind more transiently. Imidazole wash screens 
therefore had to be conducted to determine the optimal conditions for human nNOS 
purification.  
The Western blot shown in Figure 4.15 demonstrates that some of the human nNOS 
protein was removed from the Ni-NTA column even when relatively low imidazole 
concentrations (20 mM) washes were used. Any loss of the target protein was undesirable. 
However, the overall purity of the eluted sample also had to be considered. The use of 
extremely low imidazole concentrations (<20 mM) may result in more of the target protein 
being retained on the column and ultimately captured in the elution fraction. However, the 
use of such low imidazole concentrations may also result in large amounts of non-specific 
protein being retained on the column and co-eluted with the human nNOS in the elution 
fractions. Further purification experiments were conducted to ascertain the imidazole 
concentrations that gave the best balance between protein purity and overall nNOS 
recovery.  
Cultures were grown and purified as described for buffer D in section 4.5.1. To minimize 
binding of nonspecific proteins to the column, the Ni-NTA was equilibrated with the stock 
buffer containing 10 mM imidazole prior to purification. The lysed nNOS containing cells 
were incubated with the Ni-NTA resin as per chapter five, section 5.2.3.3. The resulting Ni-
NTA column was then washed with stock purification buffer containing increasing 
concentrations (20, 40, 50, 60, 70, 80 and 100 mM) of imidazole. All remaining proteins 
were then eluted from the column with a 250 mM imidazole wash. A Western blot and 
Coomassie analysis of these experiments are shown in Figure 4.16.  
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Figure 4.16. Imidazole screen for human nNOS expression. Lane one contains a cleared lysate 
sample pre Ni-NTA incubation and lane two contains the column flowthrough. Lanes three to nine 
contain column washes using increasing imidazole concentrations as follows: 20 mM, 40 mM, 50 
mM, 60 mM, 70 mM, 80 mM, 100 mM and 250 mM. Also shown in the lower gel is the 
corresponding Coomassie stain of the same samples with the same layout (1:1000 anti-human nNOS 
antibody). All lanes loaded with equal volumes. 
 
It can be seen that nNOS protein is removed from the column at 40 mM imidazole 
concentration and higher. It may therefore be desirable to only wash the Ni-NTA with low 
(< 20 mM) imidazole concentrations. However, upon examination of the Coomassie gel, it 
can be seen that the 40 mM wash removes a large amount of non-specific proteins. The 
loss of target protein with the 40 mM wash was therefore deemed acceptable in order to 
achieve greater protein purity.  The final conditions chosen were to wash the column with 
10 column volumes of 40 mM imidazole. This provided a reasonable balance between 
purity and yield of human nNOS protein.  
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4.5.3 nNOS lysis buffer and purification conditions conclusion 
 
The initial lysis buffer conditions, as described in section 4.3.2, did solubilize human nNOS, 
and resulted in the isolation of some the target protein in the elution fraction. However, 
this buffer did not fully solubilize human nNOS and a portion of the protein remained 
trapped in the insoluble fraction. Following experimentation with a variety of lysis buffers, 
a new buffer system was chosen for the human nNOS system. This demonstrated superior 
solubilisation of the recombinantly expressed protein, and also used the same buffer 
components as those to be used in the Griess functional assay. The development of this 
new lysis buffer system was therefore a considerable success. 
With the optimised lysis buffer in hand, the purification wash steps and procedures were 
examined. Optimal column wash conditions were identified, which balanced target protein 
yield with overall purity. This represented the final step in the optimisation of the human 
nNOS expression conditions. These conditions were then applied to the co-expression 
experiments, where human nNOS and human calmodulin were to be expressed in the same 
cell culture.  
 
4.6 nNOS co-expression with calmodulin 
 
Calmodulin is a key co-factor for all NOS enzymes, and is vital for their function.10,100 
Calmodulin may be expressed and purified separately and added to NOS preparations, 
however this is time consuming and wasteful as it requires two separate expression and 
purification experiments to isolate the calmodulin and NOS proteins separately. It has been 
observed for human iNOS that co-expression with calmodulin aids in protein folding and 
helps to ensure maximal NOS activity.118 Human eNOS has also been expressed with and 
without calmodulin. It was reported that expression with calmodulin resulted in an 
increased yield of human eNOS and in a more active protein.119 Based on the trends 
observed for the other two isoforms, it was hypothesised that co-expression of human 
nNOS with calmodulin could increase protein yield and activity. Such an approach has not 
been previously reported and may result in significant improvement in human nNOS 
production.   
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Human nNOS was co-expressed with human calmodulin using the protocol that had been 
developed in section 4.4 and 4.5. The calmodulin construct did not have a His-tag and so 
would not bind to the Ni-NTA resin during the purification process. To avoid losing the 
calmodulin at this stage, 2 mM CaCl2 was included in all growth media, lysis and purification 
buffers. In the presence of calcium calmodulin binds to the eNOS and nNOS proteins 
forming an active complex which produces NO.1 This mechanism is one of the in vivo 
regulatory controls of the NOS proteins, ensuring that they are not constantly active. As 
iNOS is inducibly expressed this regulatory control is not as important, i.e. iNOS binds 
calmodulin even in the absence of calcium.1 In theory, inclusion of CaCl2 should facilitate 
nNOS/calmodulin complex formation and allow the two proteins to be captured together 
from the Ni-NTA resin. This remained to be experimentally verified prior to this study.  
 
4.6.1 Co-expression with optimised conditions 
 
To achieve the co-expression of the two proteins, BL21(DE3) E. coli cells were transformed 
with the DNA for both genes as per chapter five, section 5.2.3.1. The veracity of both the 
nNOS and the calmodulin containing plasmids had been previously established using 
restriction digestion and DNA sequencing (see section 4.2). Small (3 mL) cultures of these 
co-transformed BL21(DE3) cells were grown, the plasmid DNA extracted and analysed via 
agarose gel. No restriction digestion was performed on the isolated DNA as the nNOS and 
calmodulin constructs contained many of the same restriction sites. Digestion would 
therefore have resulted in poorly resolved bands of a range of sizes which would not have 
been helpful. Instead, the isolated DNA was examined for presence of full length plasmids. 
An example of such an analysis is shown in Figure 4.17. The expected length of the full 
length nNOS and calmodulin constructs was 7767 bps and 4936 bps respectively.  
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Figure 4.17. Undigested plasmid DNA isolated from three clones transformed with both nNOS and 
calmodulin plasmids.  
 
The band below the 8,000 bp marker represented the human nNOS construct while the 
band below the 6,000 bp marker represented human calmodulin. The lowest band was 
potentially supercoiled DNA. Streaky bands, such as those as observed in Figure 4.17, are 
characteristic of supercoiled DNA.120 The supercoiled DNA was not an issue as bands of the 
expected size for the two genes were also observed. These would provide sufficient 
sequence information for nNOS and calmodulin transcription. The transformation was 
therefore deemed a success and a glycerol stock was made for storage from the culture 
that provided the DNA sample in lane two of Figure 4.17.  
The glycerol stock was used to grow a large culture and to express the two target proteins 
according to the optimised human nNOS expression methodology which was developed in 
section 4.4 and 4.5. The cells were lysed and purified and the various fractions were 
analysed via Western blot, Coomassie and mass spectrometry. The results of the Western 
blot and Coomassie are shown in Figure 4.18. 
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Figure 4.18. Optimised human nNOS/calmodulin co-expression protocol. Lane one contains the 
pellet sample, lane two contains the cleared lysate sample, lane three the column flowthrough, lane 
four a 40 mM imidazole wash and finally elution with 250 mM imidazole (1:1000 anti-human nNOS 
antibody). Expected size of calmodulin 17 kDa, expected size of human nNOS 160 kDa. 
Representative blot, n=5. 
 
As expected the Western blot confirmed the presence of human nNOS at 160 kDa. The 
optimised nNOS protocol was consistently producing nNOS, with all of the nNOS protein in 
the soluble fraction (lane two) and none remaining insoluble (lane one). The nNOS bound 
well to the affinity column and a loss of protein was observed with the 40 mM imidazole 
wash as expected (lane four). This 40 mM wash did remove impurities from the column, as 
can be seen in the corresponding coomassie lane. The heaviest nNOS band is observed in 
the elution lane (lane five). To ensure that these results were robust an actin loading 
control blot was also produced, proving that the same concentration of protein was 
present in each lane.  
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The co-expression strategy had resulted in improved nNOS expression and solubilisation, as 
well as human nNOS co-expressed with human calmodulin. The presence of calmodulin 
was confirmed by excising a number of bands from lane five of the coomassie gel between 
15 kDa and 20 kDa (M.W of calmodulin 17 kDa). Following in gel digestion, human 
calmodulin was identified using an ion trap mass spectrometer and the Mascot search 
engine.121 Using the Swiss Prot database and Homo sapien as the species, Mascot protein 
scores greater than 37 were deemed to be significant (p < 0.05).  
The Mascot score for the calmodulin band was 86, with sequence coverage of 22% and 
three human calmodulin peptides being identified. Mass spectrometry was also used to 
confirm the presence of human nNOS in lane five of the coomassie in Figure 4.18. After in 
gel digestion, a Mascot score of 67, with sequence coverage of 19% and three human nNOS 
peptides were identified. These mass spectrometry results served to verify the Western 
blot results and demonstrated that human nNOS was indeed being expressed in the 
bacterial system. This final confirmation was important as the expression of human nNOS 
in E. coli cells had not yet been reported in the literature.  
 
4.7 nNOS protocol development conclusion 
 
An optimised human nNOS/human calmodulin co-expression system was developed. 
Briefly, BL21(DE3) cells co-transformed with human nNOS and human calmodulin were 
induced with 1 mM IPTG, grown in TB media (supplemented with 2 µM riboflavin and 1mM 
aminolevulinic acid) at room temperature for 12 hrs and harvested in a 500 mM NaCl, 50 
mM HEPES, 20% glycerol buffer at pH 8 containing the components outlined in Table 4.4. 
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Table 4.4. Components to be added to the buffer for human nNOS lysis and purification buffers. 
Component Concentration 
β mercaptoethanol a 10 mM (140µL/100mL) 
Triton X-100 1% 
Sigma inhibitor cocktail a 1 tablet/100ml 
PMSF a 1 mM (0.0435g in 2.5ml IPA, 1mL/litre) 
Lysozyme 2 mg/ml 
Glycerol 10% 
Tetrahydrobiopterin 10 µM 
CaCl2 2 mM 
a Added immediately before use 
Purification was then conducted with Ni-NTA, washing with 10 column volumes of 40 mM 
imidazole and eluting the recombinantly expressed proteins with one column volume of 
250 mM imidazole. The imidazole washes were made up in the stock buffer of 500 mM 
NaCl, 50 mM HEPES and 20% glycerol, with CaCl2 added.  
Human nNOS has been successfully co-expressed with human calmodulin using a bacterial 
system. When the initial expression conditions were used, a large amount of the human 
nNOS protein remained insoluble and unusable for functional assays (Figure 4.7). A variety 
of experiments were conducted surrounding the cell growth, cell lysis and human nNOS 
purification procedures to solve these issues. Such an optimisation study is not reported in 
the literature for human nNOS, and it resulted in a considerable improvement in the 
solubility, purity and overall yield of the target protein. The new process was also 
considerably faster than the protocol reported for rat nNOS, with the former using a 12 
hour growth time, and the latter a 42 hour growth time.103 The NOS protein was also co-
expressed with human calmodulin for the first time.  
The novel and efficient system which had been developed for human nNOS was next 
applied to the expression of human iNOS and human eNOS. Currently, functional assays in 
the field of NOS inhibition most often use bovine eNOS, rat nNOS and murine iNOS for 
comparison of inhibitor efficacy across isoforms. This approach is sub optimal due the 
mixture of species which are used in the assay systems. In addition, the reported assay 
systems also do not use the human isoforms of the proteins, which is an obvious 
disadvantage when looking to address human diseases. It was hoped that application of the 
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human nNOS procedure to the human iNOS and human eNOS isoforms would result in an 
all human assay system that could accurately assess the efficacy of potential NOS 
inhibitors.   
 
4.8 Human iNOS and human eNOS expression 
 
Human iNOS and human eNOS were the next targets for the expression and assay 
development work. Once an inhibitor of human nNOS was identified, these two isoforms 
were to be used to determine the specificity of the inhibitor for nNOS. Both human iNOS 
and human eNOS were to be co-expressed with human calmodulin. This was to ensure 
uniformity with the nNOS expression procedure, and to reduce variance between the 
isoforms in the assay system. The approach taken for the co-expression procedure involved 
using the previously developed human nNOS protocol for human iNOS and human eNOS. 
This would hopefully result in a rapid and reliable system for the expression an isolation of 
all three isoforms. Use of the same conditions would also allow for production of all three 
isoforms at the same time. This approach could then be used for the rapid expression of 
the NOS proteins for biological applications.   
 
4.8.1 Co-transformation of human eNOS and human iNOS with human 
calmodulin 
 
BL21(DE3) cells were co-transformed with human eNOS and CaM, and with human iNOS 
and CaM as per chapter five, section 5.2.3.1. These transformations were analysed via 
agarose gel electrophoresis for the presence of full length plasmids. The eNOS plasmid 
contained 7024 base pairs, the iNOS plasmid contained 6881 base pairs and the calmodulin 
plasmid contained 4936 base pairs. The analysis of the plasmids is shown in Figure 4.19. 
 
Chapter Four                           NOS, Expression, Assay Development and Compound Evaluation 
 
195 
 
 
Figure 4.19. Left panel: Plasmid DNA extracted from three clones co transformed with human eNOS 
and calmodulin. The band below 6000 bp represents the calmodulin construct, while the band above 
the 6000 bp marker represents human eNOS construct. The upper most band is potentially 
aggregated DNA. Right panel: Plasmid DNA extracted from three clones co transformed with human 
iNOS and calmodulin. The band below 6000 bp represents the calmodulin construct, while the band 
above the 6000 bp marker represents human eNOS construct.  
 
A band representing the respective NOS isoforms can be seen at the correct size in each 
agarose gel. All samples also show a band at the correct length for human calmodulin. Co-
transformation of human iNOS and human eNOS with human calmodulin was therefore 
deemed a success. The clone in lane two of the eNOS gel and the clone in lane one of the 
iNOS gel were used to create glycerol stocks for the co-expression studies.  
Expression and purification was then carried out as per the optimised nNOS protocol, 
section 4.4 and 4.5. The only difference was that the iNOS lysis and purification buffer was 
adjusted to pH 7.5 (rather than pH 8, which was used for eNOS and nNOS). This was 
because the isoelectric point (pI) of human iNOS is pH 8.2. Use of lysis buffers with a pH 
close to the pI of the target protein is not advisable as it can result in loss of secondary 
structure and protein aggregation, ultimately leading to insoluble protein samples. The pI 
of human nNOS and eNOS is 7.1 and 6.94 respectively. Human calmodulin has a pI of 4.09.  
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4.8.2 eNOS expression and purification 
 
The glycerol stocks, derived from clone two in the left panel of Figure 4.19, was used to 
grow a culture in TB media using the nNOS conditions. The cells were lysed with the nNOS 
buffer and the cleared lysate purified by affinity chromatography. A range of imidazole 
concentrations were trialled for the purification process to determine the best wash 
concentrations for eNOS. All column fractions, as well as the soluble and insoluble material 
from the lysis steps, were analysed via Western blot for the presence of human eNOS and 
human calmodulin (Figure 4.20 and Figure 4.21). 
 
 
Figure 4.20. Human eNOS expression. Lane one contains a pellet sample, lane two a cleared lysate 
sample pre Ni-NTA incubation, lane three contains the column flowthrough. Lanes four to eight 
contain column washes using increasing imidazole concentrations as follows: 20 mM, 40 mM, 60 
mM, 80 mM, 250 mM. (Antibody Human eNOS, 1:1000). Lane numbers correspond to lane numbers 
in Figure 4.21 (eNOS M.W 133 kDa). 
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Figure 4.21. Human calmodulin co-expressed with human eNOS. Lane one contains a pellet sample, 
lane two a cleared lysate sample pre Ni-NTA incubation, lane three contains the column 
flowthrough. Lanes four to eight contain column washes using increasing imidazole concentrations 
as follows: 20 mM, 40 mM, 60 mM, 80 mM, 250 mM (Human calmodulin 1:500). Lane numbers 
correspond to lane numbers in Figure 4.20. Expected size of human calmodulin ~ 17 kDa. 
 
Figure 4.20 and Figure 4.21 represent analysis of the same samples. The blot in Figure 4.20 
was probed with the anti-human eNOS antibody, while the blot in Figure 4.21 was probed 
with the anti-human calmodulin antibody. These results were encouraging as the 
expression and solubilisation of human eNOS was successful (Figure 4.20). Clear bands can 
be seen at the correct molecular weight for eNOS in lanes one to four. Some of the protein 
was trapped in the insoluble fraction (lane one), although a heavier band was seen in the 
soluble fraction (lane two). Bands were also seen in the flowthrough lane (lane three) and 
the 20 mM imidazole wash lane (lane four). However, no eNOS protein was detected in the 
elution lane (lane eight). The presence of human eNOS in the soluble fraction (lane two) 
was confirmed via mass spectrometry analysis. Human eNOS was identified with a Mascot 
score of 54, 9% sequence coverage and two peptides identified.  
Human calmodulin was also successfully expressed in this system, with bands observed at 
the correct molecular weight in lanes one to four. Mass spectrometry confirmed the 
presence of the calmodulin protein in these fractions (Score 79, 20% coverage, three 
peptides identified). Both eNOS and calmodulin were observed in the same fractions, 
suggesting that the two proteins were forming a complex.  
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While the expression and solubilisation of both target proteins was successful, their 
purification proved challenging. The blot shown in Figure 4.20 suggests that eNOS binds 
very poorly to the Ni-NTA resin as a strong band is observed in the flowthrough lane (lane 
three). A weaker band is seen in the 20 mM wash lane (lane four), with no detectable eNOS 
in lanes five to eight. This demonstrated that all eNOS was displaced from the resin with 
relatively low imidazole concentrations (<20 mM). This analysis is borne out in the 
literature, with some groups suggesting that 7.5 mM is the maximum imidazole 
concentration that will not cause elution of the protein from the column.122 The weak 
interaction between eNOS and the column may be due to the folding of the eNOS protein 
which may result in the histidine tag being buried or partially buried in an internal cavity. It 
would then be unavailable to interact with the Ni-NTA resin. Ni-NTA affinity 
chromatography was therefore not ideal for human eNOS purification.  
It was postulated that the lack of affinity of human eNOS for the Ni-NTA column may have 
been caused by the position of the histidine tag in the gene sequence. Human nNOS, which 
bound strongly to the Ni-NTA column, had its His-tag on the N terminus of the protein, 
where as human eNOS had the his tag on the C terminus of the protein (see chapter five, 
section 5.2.1 for plasmid maps). The folding of human nNOS may make the N terminus 
histidine tag more available for interaction with the affinity resin, where as in eNOS, the C 
terminus may be partially buried in an internal cavity, thus rendering it inaccessible.  This 
hypothesis would be further explored when human iNOS, with a C terminus histidine tag, 
was expressed and purified.  
Other options for purification were considered at this stage. Size exclusion chromatography 
could be used to purify the eNOS/CaM complex that had clearly been successfully 
produced. While this may have resulted in a purified complex, this was not guaranteed. The 
optimisation and experimental development surrounding size exclusion chromatography 
would also have been quite considerable.  
It was hypothesised that highly pure human eNOS may not be necessary for the Griess 
assay. This hypothesis was supported by the manufacturer of the Griess assay kit.123 It was 
therefore decided to test cellular lysates containing eNOS protein in the Griess assay 
system. Use of these lysates would address the issues surrounding human eNOS 
purification via affinity chromatography. The cleared lysate sample (lane three, Figure 4.20) 
was taken forward for human eNOS assay development.  
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4.8.3 iNOS expression and purification 
 
The human iNOS glycerol stock, derived from clone one in the right panel of Figure 4.19, 
was used to grow a culture in TB media as per the nNOS methodology. The cells were lysed 
and purified using affinity chromatography. Two imidazole washes were used, at 20 mM 
and 40 mM concentrations, before elution with 250 mM imidazole in the purification 
buffer. Lower imidazole concentrations were used in the wash steps for iNOS than were 
used for eNOS as it was suspected that iNOS would be removed from the Ni-NTA column at 
imidazole concentrations above 40 mM. This would be consistent with the trend observed 
for human eNOS and human nNOS. For this reason, only two imidazole concentrations 
were used for column washings. 
The samples that resulted from this expression and purification trial were analysed via 
Western blot for the presence of human iNOS and human calmodulin, (Figure 4.22 and 
Figure 4.23). 
 
 
Figure 4.22. Human iNOS expression. Lane one contains a pellet sample, lane two a cleared lysate 
sample pre Ni-NTA incubation, lane three contains the column flowthrough. Lanes four, five and six 
contain column washes using 20 mM, 40 mM and 250 mM imidazole concentrations respectively. 
(1:5000 anti-Histidine). Lane numberings correspond to lane numbers in Figure 4.23. (iNOS MW 131 
kDa). All samples were loaded with equal volumes.  
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Figure 4.23. Human calmodulin co-expressed with human iNOS. Lane one contains a pellet sample, 
lane two a cleared lysate sample pre Ni-NTA incubation, lane three contains the column 
flowthrough. Lanes four, five and six contain column washes using 20 mM, 40 mM and 250 mM 
imidazole concentrations respectively. (1:500 anti-human calmodulin).Lane numberings correspond 
to lane numbers in Figure 4.22. 
 
Bands of the correct molecular weight were observed in lanes two and three of Figure 4.22. 
This indicated that human iNOS was expressing and was soluble under the conditions used. 
However, the presence of iNOS bands in the flowthrough lane (lane three), and the 
absence of bands in the wash and elution lanes, suggested that human iNOS did not bind 
strongly to the Ni-NTA. This was similar to the results found for human eNOS previously 
described. This suggests that a C terminus histidine tag is not suitable for human NOS 
purification via affinity chromatography. The two C terminus tagged proteins, eNOS and 
iNOS, did not bind strongly to the column, while the N terminus tagged protein, nNOS, did 
bind successfully.  
The presence of human iNOS was confirmed via mass spectrometry of bands around the 
130 kDa M.W marker in lane two and three (score of 59, 11% sequence coverage and three 
peptides identified). However, the bands in Figure 4.22 are much less distinct than those 
previously observed for human eNOS and human nNOS. This was because an anti-histidine 
antibody had to be used for human iNOS detection. Despite multiple attempts, the human 
iNOS specific antibody did not produce bands in Western blot analysis. It was thought that 
this was a problem with the antibody sample itself, as human iNOS was successfully 
identified using mass spectrometry. As an alternative supplier of anti-human iNOS antibody 
was not available, the anti-His antibody was employed. 
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The anti-His antibody recognises the His-tag on recombinantly produced proteins, rather 
than protein specific epitopes. The His-tag on the human iNOS construct was most likely 
partially buried inside a protein cavity as the construct was unable to bind to the Ni-NTA 
resin. This same tag was the epitope that the anti-His antibody recognises. Since the 
antibody could not fully access the partially buried His tag, the bands in the Western blot in 
Figure 4.22 appear quite indistinct. The anti-histidine antibody is also notoriously “dirty” 
and use of it can result in indistinctive and non-specific bands as seen in Figure 4.22.124 The 
low band molecular weight bands in lanes two, three and six of Figure 4.22 are examples of 
these non-specific bands. These low molecular weight bands were analysed via mass 
spectrometry and no human iNOS was identified.   
Human calmodulin was also expressed in this system, and was present in the same lanes as 
human iNOS (Figure 4.23). This is as expected as iNOS binds to calmodulin most strongly 
out of the three NOS isoforms. The band in lanes two and three of Figure 4.23 were 
confirmed to represent human calmodulin via mass spectrometry.  
Although expression and solubilisation of human iNOS with human calmodulin was 
achieved, affinity purification with Ni-NTA was not ideal for this isoform. Size exclusion 
chromatography was a possible alternative to affinity chromatography for iNOS/CaM 
purification. However, a similar approach was taken for human iNOS/CaM as was adopted 
for human eNOS/CaM. A cleared lysate solution, taken from lane two of Figure 4.22, was to 
be trialled in the Griess assay. It was now envisaged that the purified human nNOS/CaM 
complex could be used to test inhibitor efficacy, while the cleared lysate samples of 
eNOS/CaM and iNOS/CaM would be used to evaluate inhibitor specificity.  
 
4.9 Human iNOS and human eNOS expression conclusion 
 
Human iNOS and human eNOS proteins were successfully expressed in the bacterial system 
and both were co-expressed with human calmodulin. This represented an important step 
towards the establishment of an all human isoform NOS assay. Purification of the isoforms 
via affinity chromatography proved challenging, with both iNOS and eNOS binding very 
weakly to the column. While purification of these isoforms may be better achieved via an 
alternate technique, such as size exclusion chromatography, this would be time consuming 
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and had no guarantee of success. The cleared lysate samples containing human iNOS and 
human eNOS were therefore taken forward for testing in a functional biological assay. The 
use of crude protein preparations in such an assay system had been previously reported, 
and the assay manufacturers suggested that the lack of purity of the iNOS and eNOS 
proteins would not be problematic. 123  Samples of all three human NOS isoforms were now 
on hand for functional assay development.  
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4.10 Functional assay development 
 
4.10.1 Assay Components 
 
The assay system which was employed for compound testing made use of the 
recombinantly expressed NOS proteins. When active, the NOS isoforms produce the radical 
nitric oxide, which is quickly degraded into nitrate and nitrite metabolites.125 The Griess 
assay system provides a convenient and quantifiable method of measuring the levels of 
nitrites that are produced by active NOS. To calculate total NOS enzyme activity, it is 
necessary to ensure that all nitrates are first reduced to nitrites.126 The nitrites are then 
reacted with sulphanilamide (103) to produce a diazonium salt (104), which is then further 
reacted with N-1-napthylethylenediamine (105) to produce a bright purple azo compound 
(106) (Scheme 4.1). 
 
 
Scheme 4.1. Griess reaction involving nitrite metabolites to produce azo dye. 
 
The absorbance is then read at 540 nM, the λ max for the azo dye. The more active the 
NOS protein, the more nitrites are produced and the more intense the purple colour 
becomes. The absorbances readings then increase accordingly and can be converted to 
nitrite concentrations using a standard curve. In the presence of a NOS inhibitor, the 
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decreased activity of the NOS proteins results in a decrease in absorbance levels, and a 
lower nitrite concentration. Comparisons can then be made between treated and 
untreated NOS samples to determine the effectiveness of the inhibitor.  
In addition to NOS proteins, the Griess assay used in this work required several co-factors 
and additional components which were supplied with the assay kit (Oxford Biomedical, part 
number NB78). The NOS enzymes were incubated with these, as per chapter five, section 
5.2.5 prior to performing the reaction described in Scheme 4.1. These additives as 
described by the assay kit manufactures are outlined in Table 4.5.127 
Table 4.5. Additional components required for NOS activity using the assay system.
127
 
Component Contents 
Assay buffer 20 mM HEPES; 0.5 mM EDTA 
NADPH Part A NADP+, Glucose 6-phosphate, L-arginine 
NADPH Part B Glucose 6-phosphate dehydrogenase 
Co-factor mix FAD, FMN, calmodulin 
 
The assay buffer was a HEPES based buffer, with added ethylenediaminetetraacetic acid 
(EDTA). The EDTA functioned as a protease inhibitor to prevent degradation of the NOS 
proteins by any residual E. coli proteases that may have been present in the samples. 
NADPH part A provided the NOS substrate, L-arginine, as well as NADP+ and glucose 6-
phosphate. These two species react to form NADPH which is required for NOS activation. 
The formation of NDAPH is catalysed by glucose 6-phosphate dehydrogenase, provided in 
NADPH part B. Finally, the co-factor mix supplies FAD and FMN, which are key components 
of the electron transport chain in NOS enzymes. Calmodulin is also provided by this 
cofactor mix, although this additional calmodulin may not be required for the system used 
in this project, as all NOS enzymes were co-expressed with calmodulin.  
Other assay systems are available for isolated NOS functional assay testing. One of the 
most popular systems involves measuring the conversion of radiolabelled L-arginine to L-
citrulline to determine the level of NOS activity.128 Due to the costs, hazards and regulatory 
constraints associated with using radioactive material, this assay was not employed for this 
project.  Assays which measure the conversion of hemeoglobin to methemeoglobin are 
also reported.129 This is a side reaction of the nitrite formation cycle. This system was 
initially considered for this project; however it would have had to be conducted in a 1 mL 
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cuvette, thus dramatically increasing the quantities of human NOS protein that would have 
been needed for each assay test. The Griess assay was conducted in a 96 well plate which 
minimized enzyme wastage.  
 
4.11 Standard curve construction 
 
Along with the assay components described above, the Griess assay kit also contained 
nitrite standards, which were used to construct a standard curve for conversion of 
absorbance at 540 nM to nitrite concentration. The same standard curve could be used 
when testing all NOS isoforms. The standards supplied with the kit were diluted according 
to manufacturer’s instructions (Table 4.6). The resulting solutions were read at 540 nM and 
a standard curve constructed (Figure 4.24).    
Table 4.6. Dilutions and final nitrate concentrations of the nitrate standards for standard curve. 
Standard 
Final nitrate 
concentration (µM) 
Deionised H2O (µL) Diluted standard (µL) 
B0 0 1000 0 
S1 0.5 995 5 
S2 1 990 10 
S3 5 950 50 
S4 10 900 100 
S5 25 750 250 
S6 50 500 500 
S7 100 0 250 
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Figure 4.24. Standard Curve for Griess assay system. Representative graph, n=3. 
 
The standard curve had a robust R2 value of 0.9961, indicating that the curve would be 
reliable for the conversion of absorbance to nitrite concentration in the NOS assays. With 
the standard curve constructed the attention was turned to the establishment of the 
functional assay using the recombinantly produced NOS proteins. This was divided into two 
separate experiment groups. The assay for nNOS was developed first as it was the key 
target of the project, and it was the NOS enzyme of highest purity. The assay system using 
the crude lysates of eNOS and iNOS was then examined.  
 
4.12 NOS assay development 
 
As with all assay systems, it was important to use the proper controls in the NOS inhibition 
assay. The positive control in all assays was to be an untreated NOS sample. If activity was 
observed in these untreated wells, it would prove that the NOS assay was functional and 
producing NO. The second control was a negative control. This involved treating the 
recombinantly produced NOS samples with a known inhibitor. The inhibitor chosen for this 
task was L-NNA (Figure 4.25). This was chosen as it was relatively inexpensive and available 
in large quantities. It is also a known non-specific inhibitor of the NOS proteins, and so 
could be used as the negative control in all three NOS isoform assays. Wells containing the 
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NOS proteins were treated with 50 µM of this known inhibitor. This concentration was 
chosen as the reported IC50 of L-NNA for rat nNOS was 6.0 µM.
45 To ensure a response was 
seen with human NOS proteins, a final concentration of 50 µM was used in the assay 
systems.   
 
 
Figure 4.25. L-NNA, the NOS inhibitor used as a negative control in the assay system. 
 
The final control which was included in each assay run was a vehicle control. The vehicle 
refers to the solvent used to dissolve the potential inhibitory compounds that were to be 
tested against the human NOS isoforms. The vehicle chosen was DMSO as it was to be used 
to dissolve the small molecules for biological evaluation. Therefore, each assay plate would 
include a set of wells containing the NOS protein treated with DMSO. The enzyme activity 
levels in the wells treated with potential inhibitors would be compared to the activity level 
in the vehicle treated wells. This would ensure that any change in activity caused by the 
DMSO vehicle could be negated prior to statistical analysis. 
  
4.13 Human nNOS Griess assay development 
 
As previously mentioned, human nNOS was the enzyme system first studied for assay 
development. It was envisaged that once the controls had been established for the nNOS 
system, the same principles and experimental methodology could be applied to the iNOS 
and eNOS systems. The human NOS proteins used in all of these assays had been co-
expressed with human calmodulin as described.  
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4.13.1 Positive and negative controls 
 
The positive and negative controls for human nNOS were first established. In a 96 well 
plate, one set of wells contained untreated human nNOS and the necessary assay 
components. A separate set of wells contained human NOS, the assay components and 50 
µM L-NNA dissolved in water. Water was used to dissolve L-NNA as it proved to moderately 
insoluble in DMSO. A set of wells containing no protein, the assay components and 50 µM 
L-NNA was also tested to ensure that nitrates were not being formed in the absence of 
human nNOS. The assay was conducted as per chapter five, section 5.2.5 and the 
absorbances of each sample read at 540 nM. The absorbances were converted to nitrite 
concentration using the standard curve (Figure 4.24). These were then converted to 
percentage activity, using the positive control as the 100% activity standard. The results are 
shown in Figure 4.26. 
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Figure 4.26. Purified human nNOS functional assay with positive control. nNOS was co-expressed 
with calmodulin. A three star significant difference was observed between the purified nNOS and 
the purified nNOS treated with L-NNA (p=0.0008). Representative graph, n=5.  
 
The human nNOS was functional, with the presence of nitrates being immediately obvious 
due to the purple colour that developed in the plate upon addition of the Griess reagents. 
The absorbance readings confirm this activity, with a clear decrease in percentage activity 
observed for the L-NNA treated samples. To the eye, the purple colour in the treated 
protein well was far less intense than in the treated wells. When using a t test (p<0.05) a 
three star significant difference was found between the treated and untreated wells. The 
purified human nNOS was therefore functional and was successfully inhibited by the known 
inhibitor, L-NNA. Small amounts of nitrates are observed in the absence of the nNOS 
protein, indicating that the NOS protein was responsible for the vast majority of the nitrite 
production. These small amounts of nitrites would also be present in the control samples 
and hence do not affect the final result.  
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This was a very encouraging result, and represented the first report of functional human 
nNOS that has been co-expressed with human calmodulin in a bacterial system. The protein 
was also clearly inhibited by L-NNA, indicating that the enzyme was functioning as 
expected. This result also represented the achievement of one of the key goals of this 
project, to establish a functional and reproducible human nNOS assay.  
 
4.13.2 Vehicle control 
 
Vehicle control testing was also conducted. While L-NNA is sparingly water soluble, it was 
probable that may of the in silico derived hits would not be soluble in aqueous solutions. As 
with many biological assays, DMSO was to be the solvent of choice for compound delivery 
due to its ability to solubilize most organic compounds. The assay was conducted as before, 
using untreated human nNOS and nNOS treated with L-NNA. A second sample was also 
tested with 0.5% DMSO to examine the effect of the vehicle on the enzyme function. The 
results of this are shown in Figure 4.27.  
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Funtional human nNOS DMSO vehicle testing
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Figure 4.27. Functional nNOS DMSO vehicle testing. The purified nNOS treated with L-NNA showed a 
two star significant difference from the vehicle treated nNOS (p=0.0071). There was no significant 
difference between purified nNOS and purified nNOS treated with the DMSO vehicle. Representative 
graph, n=3.  
 
Human nNOS was again observed to be functional and was inhibited by L-NNA. On 
examination of the histogram (Figure 4.27) there did appear to be a small decrease in 
nitrite concentration between the untreated and the vehicle treated sample groups, but 
importantly, this was not statistically significant. DMSO was therefore a suitable vehicle for 
this assay.  
This result represented the final control experiment for this system. A human nNOS assay 
system for screening of computationally derived potential human nNOS inhibitors had now 
been established. The screening of compounds against human nNOS always included a 
positive, negative and vehicle control to ensure that the enzyme and assay was functioning 
correctly. 
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4.13.3 Dose response studies with human nNOS 
 
While it was clearly demonstrated that L-NNA had inhibited human nNOS as expected, it 
was decided to further explore the human nNOS/L-NNA interaction. There was one 
previous report of human nNOS being treated with L-NNA.45 This paper reported the IC50 of 
L-NNA for their human nNOS protein as 4.4 µM +- 1.0 µM. The system reported in this 
paper differed significantly from the work of this project. The publication did not optimise 
the nNOS expression/purification procedure, did not co-express with human calmodulin 
and used a methemeoglobin assay for measurement of nNOS activity. As such, it was 
necessary to complete a dose response study for our optimised system.  
To determine the IC50 of L-NNA for the human nNOS isoform co-expressed with calmodulin, 
identical wells containing the protein complex were treated with increasing doses of the 
inhibitor. The concentrations used were 0.5 µM, 5 µM, 10 µM, 50 µM and 100 µM. All 
concentrations were introduced to the appropriate wells in an equal volume. Following 
incubation as per chapter five, section 5.2.5, the absorbances were read at 540 nM and a 
dose response curve was constructed. This is shown in Figure 4.28.  
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Figure 4.28. Normalised graph of L-NNA concentration versus nNOS response (Representative graph, 
n=3). 
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The IC50 of L-NNA for human nNOS in this work was found to be 8.0 µM +/- 2.0 µM. This is 
in the same range as the previously reported IC50 value discussed above. The increase in 
IC50 observed in this system may be due to the fact that the human nNOS was co-expressed 
with calmodulin. Based on reported human iNOS and human eNOS trends, this co-
expression approach is likely to increase the activity of human nNOS, thus requiring a 
higher concentration of L-NNA to achieve a 50% reduction in enzyme activity.  
This result further demonstrated that the human nNOS assay system established in this 
work was functional and would respond to relatively small changes in inhibitor 
concentration. It was also the first dose response curve constructed with human nNOS that 
had been co-expressed with calmodulin in a bacterial system.  
 
4.13.4 nNOS lysate assay 
 
The expressed and purified human nNOS was now known to be functional based on the 
previous experiments. As the assays of human iNOS and human eNOS were to be 
conducted with cleared lysates rather than purified enzyme samples, it was decided to test 
if the assay system was functional using cleared nNOS lysates. As the purified nNOS was 
clearly functional, failure of the assay with the nNOS lysate would indicate that the assay 
system was, in fact, not suitable for use with impure protein samples.   
An nNOS culture was grown, induced and lysed using the optimised human nNOS 
methodology. Half of the cleared lysate was frozen in aliquots before purification, while the 
other half was purified using affinity chromatography. Aliquots of the impure and the 
purified nNOS were then tested simultaneously, with both a positive and negative control 
being analysed for the pure and impure samples. The absorbances were read for all 
samples, and the results are shown in Figure 4.29. 
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Figure 4.29. Testing of nNOS lysates for suitability in human nNOS assay. A three star significant 
difference (p=0.0008)  was seen between the purified nNOS and the partially purified nNOS treated 
with 50 µM L-NNA. Presence of precipitates in assay wells of the lysate samples interferes with 
absorption readings.  Representative graph, n=2. 
 
The purified samples worked as before, and a clear inhibition was seen with L-NNA. There 
was a three star significant difference between the purified untreated and the purified 
treated samples as shown in Figure 4.29. The wells containing the lysate samples did turn 
purple upon addition of the Griess reagents, however, the samples contained a large 
amount of precipitated material (most likely non-specific E. coli protein) which may have 
interfered with the absorbance readings. This resulted in a large increase in absorbance 
readings that were not attributable to human nNOS activity. There was a slight difference 
between treated and untreated samples but this was not statistically significant.  
The inability to use nNOS lysates for the assay system was not overly concerning as the 
purified human nNOS had been previously demonstrated to function as expected. 
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However, the problems encountered with the nNOS lysates suggested that development of 
the eNOS and iNOS assay using cleared lysates would be difficult.  
 
4.14 eNOS and iNOS assay development 
 
As has been previously described, affinity purification of the human eNOS construct was 
not successful as the histidine tag did not bind strongly to the Ni-NTA resin. Cleared cell 
lysates containing human eNOS were therefore trialled in the Griess assay. Similar to the 
nNOS assay, the positive control was an untreated sample of the eNOS containing lysate, 
while the negative control was eNOS containing lysate treated with 50 µM L-NNA. The 
assay was conducted as before, the absorbances measured and the results graphed. (Figure 
4.30). 
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Figure 4.30. Testing of eNOS lysates for suitability in human eNOS assay. Presence of precipitates in 
assay wells interferes with absorption readings.  Representative graph n=2. 
Similar to the nNOS lysate tests, a large amount of precipitate was observed in the assay 
wells of both the treated and untreated sample, which interfered with the absorbance 
readings. No difference was observed between the treated and untreated wells due to this 
interference. A purple colour was observed in the wells when the Griess reagents were 
added, which indicates the presence of nitrites in the lysate. This purple colour was less 
intense in the wells treated with L-NNA. It was thought that the eNOS protein was 
functional and capable of being inhibited, but the large amounts of interferents present in 
the assay wells meant the activity did not translate to reliable absorbance readings. 
A similar outcome was observed when iNOS lysates were tested for activity (Figure 4.31). 
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iNOS lysate Griess assay test
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Figure 4.31. Testing of iNOS lysates for suitability in human iNOS Griess assay. Presence of 
precipitates in assay wells interferes with absorption readings. Representative graph, n=2. 
  
 
In this instance, the iNOS treated with the L-NNA inhibitor showed an apparently higher 
level of enzyme activity than the untreated samples. This may have been due to the lack of 
uniformity between protein lysate samples, resulting in more non-specific protein in the 
treated sample than was present in the treated sample. A purple colour was observed in 
the untreated wells, while a less intense colour was seen in the treated wells. This suggests 
that the enzyme was functional and was being inhibited by the compound, but this could 
not be translated into reliable and reproducible absorbance readings due to the presence 
of large amounts of precipitates in both the treated and untreated wells.  
The lysates containing human eNOS and human iNOS were thought to be producing 
nitrites, suggesting that the enzymes were functional. However, the presence of large 
amounts of contaminating E. coli protein in the cell lysates cast doubt over the accuracy of 
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the absorbance readings. This observation agreed with what was seen when lysates were 
used in the nNOS assay system. The work to date had succeeded in recombinantly 
producing the three human nNOS isoforms, and all three were seen to be functional in the 
Griess assay, as evidenced by the appearance of a purple colour in the wells. However, only 
the affinity chromatography purified human nNOS produced reliable and robust results in 
the assay system, while the assays for the other two isoforms were less successful. 
 
4.15 Assay development conclusion 
 
The assay system was successfully developed for human nNOS which was the key target of 
this work. The assay was observed to function correctly using nNOS purified via affinity 
chromatography and was clearly inhibited by the known inhibitor, L-NNA. Despite 
manufacturer’s suggestions (personal communication), the Griess assay system employed 
here was not suitable for use with nNOS lysates as large amounts of precipitate in the assay 
wells caused the absorbances to give inaccurate readings. This was due to the non-specific 
proteins that were present in the lysate of the impure proteins.  
For iNOS and eNOS, the purification via Ni-NTA affinity chromatography was not possible 
due to poor interaction with the affinity column. Therefore, the enzymes were tested as 
crude lysates in the assay system. Similar to nNOS lysates, this proved to be ineffective due 
to the precipitates clouding the wells and interfering with the absorbance readings. It is 
suspected that the enzymes are functional as a purple colour develops for both isoforms 
upon treatment with the Griess reagents. This suspected activity could not be translated 
into a robust and reproducible assay system for iNOS and eNOS.  
The assay for human nNOS, which was the key target for this work, was functioning 
correctly. It was therefore decided to focus on the search for inhibitors of this target, and 
return to the development of the eNOS and iNOS assays at a later date. Future work may 
focus on development of the human eNOS and human iNOS assay using the successful 
expression protocols described above. 
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4.16 Compound testing 
 
The compounds derived from the various computational screens in chapter two were 
purchased, or synthesised as discussed in chapter three. The selected compounds have 
been subdivided into sections based on which computational method was used for their 
identification. All have been sequentially numbered and the structures of each compound 
are shown in the tables in chapter two. For each assay, the untreated human nNOS 
samples was designated as 100% active, and the inhibitory activities of the compounds 
were calculated relative to this. All assays included an L-NNA control. This known inhibitor 
was used at a concentration of 50 µM. A DMSO vehicle control was also included in every 
assay. All compounds for screening were dissolved in DMSO and used at a final 
concentration of 50 µM. The percentage of DMSO in each treated well, including the 
vehicle control, was 0.5%.  
All statistical analysis was carried out using Graphpad.130 Differences between the vehicle 
control and treated samples were tested for statistical significance using a two tailed t test, 
with a p value of less than 0.05 being deemed significant. Histograms and statistical 
analysis of all compounds tested are shown in the following sections. Each assay was 
carried out twice in duplicate to ensure that statistical analysis was robust.  
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4.16.1 Homology modelling flexible docking compounds 
U
nt
re
at
ed
 n
N
O
S
 
D
M
S
O
 V
eh
ic
le
 
M
 L
-N
N
A

50
 
C
om
po
un
d 
26
C
om
po
un
d 
27
C
om
po
un
d 
28
C
om
po
un
d 
29
C
om
po
un
d 
30
C
om
po
un
d 
31
C
om
po
un
d 
32
C
om
po
un
d 
33
C
om
po
un
d 
35
C
om
po
un
d 
36
0
50
100
150
Compounds
P
e
rc
e
n
ta
g
e
 a
c
ti
v
it
y
 
Figure 4.32. Biological evaluation of compounds 26-33, 35 and 36, identified via flexible docking of 
Maybridge compounds with human nNOS homology model. Two star significant difference between 
untreated nNOS and nNOS treated with 50 µM L-NNA (p=0.0076). One star significant difference 
between DMSO vehicle and compound 32 (p=0.0253). Representative graph, n=2.  
 
Compounds 26-33, 35 and 36 in Figure 4.32 are in silico hit compounds identified from 
docking of the Maybridge database with the 3PNF-HM. The structures of the compounds 
can be found in chapter two, Table 2.15. The known inhibitor, L-NNA, decreased activity as 
expected, but unfortunately, none of the evaluated compounds showed any inhibitory 
activity towards human nNOS. Interestingly, the wells treated with 32 showed an increase 
in nitrite concentration relative to the vehicle control, indicating that 32 may increase the 
activity levels of human nNOS. It is doubtful that 32 (Figure 4.33) provides a source of NO in 
a similar manner to arginine. This compound does not possess the guanidinium side chain 
which is necessary for NO formation via the proposed NOS catalytic cycle (Scheme 1.2). 
Therefore 32’s ability to enhance NO production may be based on an allosteric interaction 
with the nNOS enzyme. Compounds of this nature, which increase nNOS activity, have not 
been reported in the literature. While this was an interesting result, this project was 
Chapter Four                           NOS, Expression, Assay Development and Compound Evaluation 
 
221 
 
focused on identifying an nNOS inhibitor and so the exact mechanism of action of the 
compound was not explored.  
 
Figure 4.33. Compound 32 identified via screening of the Maybridge database with the 3PNF 
homology model.  
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Figure 4.34. Biological evaluation of 11-18 identified via flexible docking of Zinc compounds with 
human nNOS homology model. Two star significant difference between untreated nNOS and nNOS 
treated with 50 µM L-NNA (p=0.0014). Representative graph, n=2. 
 
Compounds 41-48 in Figure 4.34 were identified via flexible docking of the Zinc database 
using the 3PNF-HM. The structures of 41-48 are shown in Table 2.16. Again, the assay 
performed as expected with the known inhibitor acting to decrease nNOS activity levels. 
Unfortunately, this set of compounds showed no activity for human nNOS. Nitrite levels 
were not seen to increase or decrease for any of the compounds tested. This trend was 
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retained when the synthesied piperazine containing 37-40 were evaluated (synthesised in 
chapter three, section 3.2.1.3), with no decrease in nNOS activity observed (Figure 4.35). 
The data generated from the testing of these compounds was useful, despite the lack of an 
inhibitor. It provided a set of 21 experimentally validated inactive compounds for human 
nNOS. These types of compounds are not reported in the literature and provide a valuable 
resource for refinement of computational models.  
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Figure 4.35. Biological evaluation of synthesised 37-40 identified via flexible docking of Maybridge 
compounds with human nNOS homology model. Three star significant difference between untreated 
nNOS and nNOS treated with 50 µM L-NNA (p=0.0008). Representative graph, n=2. 
 
 
 
 
 
 
 
 
 
Chapter Four                           NOS, Expression, Assay Development and Compound Evaluation 
 
223 
 
4.16.2 Pharmacophore one compounds 
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Figure 4.36. Biological evaluation of 50-60 derived from pharmacophore one. One star significant 
difference between untreated nNOS and nNOS treated with 50 µM L-NNA (p=0.0134). 
Representative graph, n=2. 
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Figure 4.37. Biological evaluation of 61-70 derived from pharmacophore one. Two star significant 
difference between untreated nNOS and nNOS treated with 50 µM L-NNA (p=0.0134). 
Representative graph, n=2. 
 
The structures of 50-70 can be found in Table 2.21, chapter two. The results from their 
biological evaluation are shown in Figure 4.36 and Figure 4.37.  Similar to the homology 
model derived compounds, no novel human nNOS inhibitors were identified from this 
screen. The compounds which proved inactive were combined with the inactive 
compounds from section 4.16.1 and were used to further refine the pharmacophoric 
models as described in chapter two, section 2.8.3. This further increased the numbers of 
experimentally validated human nNOS inhibitors which were useful for this work.  
 
 
Chapter Four                           NOS, Expression, Assay Development and Compound Evaluation 
 
225 
 
4.16.3 Pharmacophore two compounds 
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Figure 4.38. Biological evaluation of 71-81 identified from pharmacophore two. Two star significant 
difference between untreated nNOS and nNOS treated with 50 µM L-NNA (p=0.0224). 
Representative graph, n=2. 
 
As demonstrated in Figure 4.38, 71-81 were seen to be inactive against human nNOS. 
While this was not ideal, the pool of experimentally validated inactives against human 
nNOS was further increased.  
The use of a pharmacophore to search for human nNOS inhibitors was a novel and logical 
approach, and represented a viable option for this project. The inabilities of this approach 
to identify a new class of inhibitors lead to the use of the human nNOS crystal structure for 
screening purposes.  
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4.16.4 Crystal structure docking compounds 
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Figure 4.39. Biological evaluation of 82-84, 86, 87, 89-93 identified via the crystal structure screen. 
Two star significant difference between untreated nNOS and nNOS treated with 50 µM L-NNA 
(p=0.0014). Representative graph, n=2. 
 
Docking of the human nNOS crystal structure with commercial datasets (Zinc and 
Maybridge) was conducted in the latter stages of the project as the first reports of 
crystallised human nNOS were released in early 2015.83 The use of high throughput 
computational screening with this structure has yet to be reported in the literature. 
Compounds 82-84, 86, 87, 89-93 (structures shown in chapter two, section 2.9.2) were 
chosen for biological evaluation from this computational screen. The results from this assay 
test are shown in Figure 4.39. 
A set of urea containing compounds were synthesised based on hits from the 
computational screen of the human nNOS crystal structure. The structures and synthesis of 
this family of compounds is outlined in chapter three, section 3.2.2. The results from the 
biological screening of these compounds are shown in Figure 4.40. 
Chapter Four                           NOS, Expression, Assay Development and Compound Evaluation 
 
227 
 
U
nt
re
at
ed
 n
N
O
S
 
D
M
SO
 V
eh
ic
le
 
M
 L
-N
N
A

50
 
C
om
po
un
d 
94
C
om
po
un
d 
95
C
om
po
un
d 
96
C
om
po
un
d 
97
0
50
100
150
Compounds
P
e
rc
e
n
ta
g
e
 a
c
ti
v
it
y
 
Figure 4.40. Biological evaluation of 94-97, derived from crystal structure screen and synthesised as 
per chapter four, section 3.2.2. Three star significant difference between untreated nNOS and nNOS 
treated with 50 µM L-NNA (p=0.0008). Representative graph, n=2. 
 
The assay results demonstrated that the compounds tested did not have any inhibitory 
effect on the recombinantly produced human nNOS. The inability of these compounds to 
inhibit the protein, along with the inactivity observed with the compounds derived from 
previous in silico screens confirmed that human nNOS is a difficult target to 
computationally model and target.  
 
4.16.5 Literature and other compounds 
 
During the course of this project, Xu et al. published a computational paper that contained 
a set of structures that they proposed as possible human nNOS inhibitors.62 This publication 
was purely computational and did not contain biological evaluation. Some of the 
compounds suggested by Xu et al. (Figure 4.41) were therefore acquired and biologically 
evaluated.  
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Figure 4.41. Additional literature compounds that were biologically evaluated, 107-110.
62
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Figure 4.42. Biological evaluation of compounds identified from literature sources.
62
 One star 
significant difference between untreated nNOS and nNOS treated with 50 µM L-NNA (p=0.0224). 
One star significant difference between DMSO vehicle and 107 (p=0.0483). Representative graph, 
n=2. 
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The results of the biological evaluation of compounds 107-110 are shown in Figure 4.42. 
These compounds proved inactive in the assay system. This added weight to the theory 
that human nNOS is a difficult target to model and predict as the computational work of 
two separate research projects had failed to identify a human nNOS inhibitor.  
Interestingly, compound 107 was seen to increase nNOS activity. Similar to 32, it is unlikely 
that 107 binds to nNOS in the same manner as arginine, the natural substrate. Compound 
107 does not have the necessary guanidinium group required for NO production, and 
therefore most likely causes the increase in enzyme activity via allosteric interactions with 
nNOS. A combined study on the precise binding modes of 107 and 32 may elucidate the 
exact nature of the process which causes increased NO production from nNOS. This type of 
study was not attempted during this project.  
 
4.16.6 Discussion on compound evaluation 
  
Although no human nNOS inhibitor had been identified in these screening trials, there were 
a number of very positive results generated. The use of a human nNOS homology model 
and pharmacophore to screen commercial databases is a novel approach, and the results 
shown above contribute to the overall field of human nNOS inhibition. The compounds 
tested proved to be inactive, but now represent the first set of experimentally validated 
human nNOS inactive compounds. These are useful for future computational and synthetic 
work. Compound 32 was seen to increase the activity of human nNOS. The exact 
mechanism of action of this compound is not clear. Further studies on the binding mode of 
32 may provide a valuable insight into the mechanism of human nNOS over activation.  
Compounds developed via in silico methods from other groups also proved to be inactive in 
the assay. This, coupled with the lack of activity of the computationally derived from this 
work, suggests that human nNOS is a challenging target. This theory is reinforced by the 
fact that there are no literature reports of successful human nNOS inhibitors that were 
generated by CADD. This also helps to explain why there are only two well explored classes 
of nNOS inhibitors, as new inhibitor classes seem to be difficult to identify.  
The assay system, based on recombinantly produced human nNOS, proved to be reliable, 
high throughput and reproducible. The routine use of human nNOS co-expressed with 
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calmodulin for compound evaluation is a unique feature of this project. The publication of 
the human nNOS crystal structure demonstrates that the field is moving towards a human 
isoform based system, rather than the traditional rat based systems. The assay system that 
was utilised in this project can therefore be considered to be at the “cutting edge” of the 
field, and ensures that future assay testing experiments will be relevant.  
The assay system is also high throughput. Compound screening can be achieved by one 
experienced operator, and represents a considerable strength of this assay system. Other 
assay systems, such as the radio labelled arginine assay for NOS activity, require expensive 
(and potentially hazardous) materials and cannot be used in a high throughput manner like 
the system developed in this work. Furthermore, alternate assay systems require the 
addition of calmodulin to ensure maximal nNOS activity. This is not necessary for the assay 
system described here as the human nNOS is co-expressed with human calmodulin. It is 
felt, therefore, that the procedures developed in this work represent an affordable, robust 
and rapid method of testing inhibitory compounds against human nNOS that has yet to be 
matched in the literature.   
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4.17 Conclusion 
 
This work focused on reproducible expression of all three human isoforms of the NOS 
proteins in E. coli cells. The conditions for expression, lysis and purification were optimised 
for human nNOS, the key target of this work. The resulting system, as outlined above, 
provides a fast, inexpensive and reproducible route to partially purified human nNOS. In 
addition, this system allows for the co-expression of human calmodulin with the nNOS 
protein. The two recombinant proteins stay complexed throughout the purification process 
and are both present in the elution fractions from a Ni-NTA column. This is a novel and 
potentially extremely useful system as the complexation of nNOS and calmodulin should 
result in a maximally efficient NOS enzyme.  
This purified complex was successfully utilised in a Griess assay system. Both a treated 
protein sample and a sample with the known NOS inhibitor, L-NNA, were trialled. A clear 
activity difference was observed between the treated and untreated samples, indicating 
that the nNOS was functional, and that its inhibition leads to a decrease in absorbance at 
540 nM. The IC50 of L-NNA in this system was calculated as 8.0 µM +/- 2.0 µM .DMSO was 
also identified as a suitable vehicle for the system as it did not interfere with readings when 
used at 0.5% of the total assay volume. A cost effective, in house system was therefore 
available for testing of the potential nNOS inhibitory compounds that had been identified 
from the in silico screen. 
Human iNOS and human eNOS were also successfully expressed from the E. coli cells. Both 
were co-expressed with human calmodulin. However, purification of these NOS isoforms 
via affinity chromatography proved problematic, with the histidine tag on the isoforms not 
binding well to the column resin. This may have been due to the folding of the iNOS and 
eNOS protein, which potentially results in the tag being unable to bind to the resin. Both 
the iNOS and eNOS constructs had the histidine tag on the C terminus, where the nNOS 
construct had the tag on the N terminus of the protein. As all three isoforms fold in a 
similar manner, movement of the tag from C to N terminus in the eNOS and iNOS 
constructs may result in less transient tag/resin binding.  
Despite the difficulties in the purification process, the identification of the iNOS and eNOS 
proteins in the crude lysates prompted testing of these samples in the Griess assay. 
Although a purple colour did develop in the wells for both isoforms, the formation of large 
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amounts of precipitated, non-specific protein resulted in inaccurate absorbance readings 
that could not be translated into nitrite concentrations.  
Although a working assay system was not developed for human iNOS and human eNOS, the 
expression of both isoforms was successful. In future work, an alternate purification 
method, such as size exclusion chromatography, may result in purified samples of iNOS and 
eNOS, which could then be used in the manner described for nNOS.  
The successfully developed assay for human nNOS was used to biologically evaluate a wide 
range of compounds, both purchased and synthesised. While none of the compounds 
proved active against human nNOS, the assay system proved itself to be high throughput 
and reproducible. The tested compounds provide a valuable resource for future 
computational screens, and the assay system which was developed represents a novel, 
useful and transferable method for evaluation of human nNOS inhibitors. Two compounds 
(32 and 107) were also observed to increase nNOS activity levels, potentially providing an 
additional avenue of research into the exact mechanisms of NOS over activation.  
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5 Materials and Methods
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5.1 Chemicals and reagents 
  
All chemicals, reagents and solvents were purchased from Sigma, Fischer or Lennox unless 
otherwise stated. Restriction enzymes were obtained from either Promega or Fermentas. 
Plasmid DNA isolation and purification kits were purchased from Invitrogen and Thermo 
Scientific. DNA size markers for agarose gels were supplied by Fermentas. 
Protein purification was carried out using Ni-NTA agarose purchased from Qiagen. SDS gels 
were made using acrylamide supplied by Promega. ECL Western blot substrate was 
purchased from Pierce. Molecular weight markers were purchased from Thermo Scientific. 
Blotting paper was supplied by Whatman purchased from GE Healthcare. PVDF membranes 
were also purchased from GE Healthcare.  Antibodies were obtained from Sigma (anti-
histidine) and Thermo Scientific (anti-iNOS, eNOS and nNOS). Anti-calmodulin antibody was 
obtained from Pierce. The Griess assay kit (part number NB 78) and necessary co-factors 
(part number NS70) were sourced from Oxford Biomedical Research.  
 
5.2 Biological Materials and Methods 
 
5.2.1 Vectors and host strains 
 
Human NOS DNA was gifted by Dr. Hartmut Kleinert (Johannes Gutenberg University of 
Mainz). The three isoforms were supplied in pQE30 vectors, incorporating a C terminus 
histidine tag for eNOS and iNOS and an N terminus histidine tag for nNOS. The vector also 
coded for ampicillin resistance and had an inducible T5 lac operon promoter, (Figure 5.1 to 
Figure 5.3). 
Expression was initially attempted with the NOS isoforms alone and then co-expression 
trials were conducted with calmodulin. The calmodulin DNA was gifted by Dr. Clinton 
Nishida, UCSF. This was supplied in a modified pACYC vector which coded for 
chloramphenicol resistance (Figure 5.4). 
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Figure 5.1. pQE30 Human eNOS construct. 
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Figure 5.2. pQE30 Human iNOS construct. 
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Figure 5.3. pQE30 Human nNOS construct. 
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Figure 5.4. pIRC Human calmodulin construct. 
 
DNA amplification was carried out using TOP10 E. coli cells, supplied by Invitrogen. 
Expression was conducted in BL21(DE3) E. coli cells supplied by Invitrogen.  
 
 
 
 
Chapter Five                                                                                                 Materials and Methods 
 
 
239 
 
5.2.2 DNA amplification and verification 
 
5.2.2.1 Transformation of competent E. coli 
 
TOP10 E. coli cells were used to amplify all DNA samples received from other labs. The 
transformation of these cells was carried out as per manufacturer’s instructions.  A 5 µL 
sample of the required DNA at a concentration of 5 ng/µL was pipetted into 50 µL of 
competent TOP10 cells which had been thawed on ice. The mixture was incubated on ice 
for 30 minutes before being heat shocked at 42 0C for 30 seconds. The cells were 
immediately placed back onto ice and 250 µL of pre warmed super optimal broth with 
catabolite repression (SOC) media was added (5% tryptone (w/v), 0.5% yeast extract (w/v),  
2.5 mM KCl,  10 mM MgCl2, 10 mM MgSO4, 20 mM glucose). Cells were incubated at 37 
0C 
for 1 hour with shaking, then plated on LB agar plates (1% tryptone (w/v), 0.5% yeast 
extract (w/v), 0.5% NaCl (w/v), 1% agar (w/v), pH 7) with 50 µg/µl of ampicillin (and 25 
µg/µl chloramphenicol when co-expressing calmodulin) for selection and left at 37 0C 
overnight.  
 
5.2.2.2 Miniprep and subsequent analysis 
 
Colonies that grew on selection agar plates were transferred into 3 mL LB media (1% 
tryptone (w/v), 0.5% yeast extract (w/v), 1% NaCl (w/v), pH 7). Colonies were incubated in 
media overnight at 37 0C. A 2 mL sample of each respective culture was spun at 6800 RCF 
for 2 minutes. DNA was then extracted from the bacteria using the plasmid purification kit 
supplied by Thermo Scientific (K0503), as per manufacturer’s instructions. A 5 μl sample of 
purified plasmid was then digested, using the appropriate restriction enzyme, to assess the 
presence of the desired insert (Table 5.1). 
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Table 5.1. Restriction digest mixtures. 
Component iNOS plasmid eNOS plasmid nNOS plasmid 
Calmodulin 
plasmid 
Miniprepped DNA 5 µL 5 µL 5 µL 5 µL 
Fast Digest buffer 2 µL 2 µL 2 µL 2 µL 
Restriction 
enzyme 1 
1 µL Hinc II 1 µL Hinc II 1 µL EcoR1 1 µL BamH1 
Restriction 
enzyme 2 
1 µL xbal 1 µL xbal 1 µL Not1 1 µL BamH1 
Water 11 µL 11 µL 11 µL 11 µL 
Expected Band 
size 1 
4041 bases 3803 bases 4386 bases 4224 
Expected Band 
size 2 
2840 bases 3221 bases 3381 bases 540 
 
5.2.2.3 Agarose gel analysis  
 
The DNA digests generated via the miniprep procedure were analysed via agarose gel to 
ensure that the NOS and calmodulin genes were present. A 0.8% agarose gel was used with 
SYBR Safe DNA gel stain supplied by Invitrogen (S33102) to visualize the DNA. Agarose (0.4 
g) was heated in 50 mL 1 x TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.4) until 
dissolution occurred. The solution was cooled and 5 µL of SYBR safe was added. Gels were 
poured and allowed to set at room temperature. DNA loading dye was supplied by Thermo 
Scientific and was used in a 1:10 dilution with the DNA sample. Gels were elctrophoresed at 
120 volts and visualised using UV light. GeneRuler 1 kb DNA ladder supplied by Thermo 
Scientific (SM0313) was used to assess the size of the eletrophoresed DNA. Samples 
containing inserts of the correct size were noted and used for midi preparations.  
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5.2.2.4 Midiprep culture of plasmid 
 
Samples which contained the plasmid of interest were propagated in 50 mL LB media with 
50 μg/ml of ampicillin and 25 μg/ml of chloramphenicol when co-expressing calmodulin.  
Media was inoculated with 1 mL of miniprep culture and grown at 37 0C for 48 hours. 
Plasmid was then purified using the S.N.A.P. Midiprep kit supplied by Invitrogen (K1910-
01), as per manufacturer’s instructions. DNA was eluted using 750 μL sterile Milli-Q water. 
DNA concentration was assessed by reading absorbance at 260 nm. DNA was then stored 
at -20 0C. 
 
5.2.2.5 Preparation of glycerol stocks 
 
For long term storage of plasmids, liquid cultures of E. coli transformed with the plasmid of 
interest were frozen at -80 0C. Briefly, 150 μl of a 50 ml culture of desired E. coli was 
combined with 850 μl of sterile glycerol and mixed thoroughly. Cells were then stored at -
80 0C. 
 
5.2.2.6 Gene sequencing  
 
All gene sequencing was performed by Eurofins labs, Germany. DNA samples (15 µL) with 
concentrations of 50 ng/µL were prepared for each of the four constructs from the 
Midiprep samples. The T5 promoter was used as a primer for the NOS genes. Also, due to 
the length of the NOS genes, internal primers were chosen every 300 base pairs. These 
internal primers were 20 base pairs long. For calmodulin gene sequencing the primer 
chosen was the first 20 base pairs of the calmodulin gene. Internal primers were not 
required. Results of gene sequencing were compared to the published sequences using the 
Clustal Omega alignment tool from the EMBL website. All alignments are provided in 
appendix. 
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5.2.3 Co-expression and isolation of NOS and calmodulin proteins 
 
5.2.3.1 Competent cells, their transformation and expression screening 
   
Expression studies were carried out in BL21(DE3)cells supplied by Invitrogen. These were 
supplied as “One Shot” fully competent cells. These were first transfected with the NOS 
constructs. NOS DNA was isolated from the TOP10 cells using Miniprep as previously 
described. This DNA was transformed into the BL21(DE3) cells using the same protocol as 
described in section 5.2.2.1. Cells were transfected using 2 µL of DNA construct at a DNA 
concentration of 5 ng/µL. The transfected cells were spread onto LB agar plates containing 
50 µg/µL of ampicillin and were incubated at 37 0C overnight.  
Individual colonies were chosen and grown in 5 mL of LB media containing 50 µg/µL of 
ampicillin (LB-amp) with shaking at 37 0C. The OD600 of the cultures was measured 
periodically using LB-amp media as a blank. When an OD600 of 0.600 was reached (after 
roughly four hours) protein expression was induced by addition of 1 mM IPTG. The cultures 
were grown overnight at 37 0C with shaking. The resulting cells (1 mL) were pelleted by 
centrifugation at 4000 x g. The supernatant was discarded and the pellets were 
resuspended in 100 µL of 5 x Laemmli sample buffer (300 mM Tris-HCl, 50% (v/v) glycerol, 
10% (w/v) SDS, 0.02% (w/v) bromophenol blue, 10% (v/v) β-mercaptoethanol, pH 6.8). 
These samples were loaded directly onto SDS gels and analysed via Western blot to confirm 
expression of NOS proteins. Glycerol stocks were made of the colonies which were 
observed to express well.  
BL21(DE3) cells were also used when calmodulin and NOS genes were to be co-expressed in 
the same cell. When transforming two constructs at once, 2 µL of each construct was used, 
each at a concentration of 5 ng/µL. The agar plates in this case contained 50 µg/µL of 
ampicillin and 25 µg/µL of chloramphenicol. 
Expression testing was conducted in the same manner as described above, however the LB 
media used for culture growth contained 50 µg/µL of ampicillin and 25 µg/µL of 
chloramphenicol (LB-amp/chlor). Expressing clones were identified via Western blot 
analysis and glycerol stocks prepared.  
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5.2.3.2 Large scale expression of NOS proteins and lysis of cells 
 
Glycerol stocks containing strongly expressing clones were streaked on LB agar plates 
containing the appropriate antibiotics. In the case of NOS expression alone the antibiotic 
used was ampicillin (50 µg/µL). When co-expressing NOS and calmodulin the antibiotics 
used were ampicillin (50 µg/µL) and chloramphenicol (25 µg/µL). The streaked plates were 
incubated overnight at 37 0C and individual colonies chosen. The individual colonies were 
grown in 50 mL of appropriate LB media (LB-amp or LB-amp/chlor) at 37 0C overnight with 
constant shaking.  The cultures were then diluted back to an OD600 of 0.65 in TB media 
(1.2% (w/v) tryptone, 2.4% (w/v) yeast, 0.4% (v/v) glycerol, 17 mM KH2PO4, 72 mM K2HPO4, 
pH 7.0). Fresh antibiotic was added to the media to final concentrations of 50 µg/µL and 25 
µg/µL for ampicillin and chloramphenicol respectively. Riboflavin and aminolevulinic acid 
were added to final concentrations of 2 µM and 1 mM respectively. IPTG was added to a 
final concentration of 1 mM to induce protein expression, and the cultures were left to 
shake (200-250 RPM) at room temperature for 12 hours.  
The cultures were centrifuged at 4,000 x g for 15 minutes using a Sorvall RC5C Plus 
ultracentrifuge with rotor SLA-3000 precooled to 4 0C. The resulting supernatant was 
discarded and the pellet resuspended in lysis buffer (3-5 mL per gram of wet cell pellet 
weight) containing the components outlined in Table 5.2. 
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Table 5.2. Lysis buffer components. 
a
 
Component Concentration 
Hepes 50 mM 
NaCl 500 mM 
β mercaptoethanol b 10 mM (140µL/100mL) 
Triton X-100 1% 
Sigma inhibitor cocktail b 1 tablet/100ml 
PMSF c 1 mM (0.0435g in 2.5ml IPA, 1mL/litre) 
Lysozyme 2 mg/ml 
Glycerol 20% 
Tetrahydrobiopterin 10 µM 
CaCl2 2 mM 
a pH adjusted to 8.0 @ 4 °C (for iNOS experiments the pH was adjusted to 7.5)  
b added just before use 
c
 a phenylmethylsulfonyl fluoride (PMSF) stock was first made up in isopropyl alcohol and 
an appropriate volume of this stock solution was added to the lysis buffer.  
The pellet was resuspended by vigorous vortexing and repeated pipetting. The culture was 
passed through an 18 gauge needle and was then incubated at 4 0C for an hour on a 
mechanical roller. The PMSF containing alcohol solution was re-added after 30 minutes, 
and again following the hour rolling.  
Following the hour incubation the suspensions were sonicated using a probe sonicator 
(Bandelin Electrical, UW2200, 20% power, with a cycle time of six, 30 seconds). This was 
repeated three times. The sonicated solutions were passed through a 25 gauge needle into 
appropriate sized centrifugation tubes. Centrifugation was then carried out at 14,000 x g 
for 20 minutes at 4 0C.  Pellet and cleared lysate were separated and the pellet was 
resuspended in PBS. This was retained for SDS-PAGE analysis. A small sample of cleared 
lysate was also retained for SDS-PAGE analysis with the majority taken forward for Ni-NTA 
purification.  
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5.2.3.3 Purification and storage of recombinant protein  
 
Ni-NTA resin (2 mL per 400 mL of original culture) was used for protein purification. The Ni-
NTA resin was first pre equilibrated with binding buffer (50 mM HEPES, 500 mM NaCl, 20% 
(v/v) glycerol, 10 µM BH4  and 2 mM CaCl2). For nNOS the binding buffer also contained 10 
mM imidazole. For eNOS and iNOS no imidazole was used in the binding buffer. Ni-NTA 
resin was centrifuged (700 x g, 4 0C) for one minute. The top layer was removed and 
replaced with an equal volume of binding buffer. The tube was mixed thoroughly and re-
centrifuged. This was repeated three times. The Ni-NTA resin was added to the cleared 
lysate samples and left mixing at 4 0C for 90 minutes.  
The resin was then collected using 5 mL plastic, disposable columns. For nNOS, the resin 
was washed once with 10 column volumes of binding buffer containing 40 mM imidazole. 
Bound protein was then eluted in one column volume of binding buffer with 250 mM 
imidazole. For eNOS and iNOS, washings were conducted using binding buffer with no 
imidazole present. Elution was carried out in the same manner as for nNOS.  
Dialysis was carried out to remove imidazole from protein samples. Each 1 mL of purified 
protein was dialysed against 500 mL of dialysis buffer (50 mM HEPES, 500 mM NaCl, 20% 
(v/v) glycerol, 2 mM CaCl2) for 2 hours at 4 
0C. This was repeated twice more to yield a final 
imidazole concentration of less than 2 x 10-9 M. The samples were then concentrated to 
half their original volume using centrifugal concentration (Amicon Ultra) with a molecular 
weight cut off of 10 kDa. The concentrated samples were added to an equal volume of ice 
cold, fresh dialysis buffer supplemented with 10 µM BH4 and were aliquoted in volumes of 
35 µL into pre cooled Eppendorf tubes. The samples were immediately frozen at -800C for 
use in future assay work.    
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5.2.4 Expression verification: One dimensional electrophoresis, Western blot 
and mass spectrometry 
 
5.2.4.1 Pierce protein assay  
 
A standard protein curve was prepared using BSA at 0, 50, 100, 200, 400, 600, 800, 1000, 
1250, 1500, 1750 and 2000 μg/ml. Samples were diluted as required and 10μl used for the 
assay in duplicate. 10μl of each standard or sample was used in duplicate in a 96 well plate 
along with 150 μl Pierce Protein Assay reagent (PN22660). The plate was incubated at room 
temperature for 5 minutes. The plate was then analysed using a BIO-TEK EL800 plate 
reader at 630nm. Protein concentration of the samples was deduced from the standard 
curve. 
 
5.2.4.2 SDS-PAGE Analysis 
 
Before electrophoresis samples were denatured in 1 x Laemmli sample buffer.  Separation 
of proteins on the basis of molecular weight was achieved using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). The gels used contained 8% acrylamide. 
The resolving portion of the gel was made by mixing 4.6 mL water, 2.7 mL acrylamide, 2.5 
mL TRIS base in water pH 8.8, 0.1 mL 10% SDS in water, 0.1 mL 10% ammonium 
persulphate in water and 0.006 mL of tetramethylethylenediamine (TEMED). The stacking 
portion of the gel was made by mixing 1.4 mL water, 0.33 mL acrylamide, 0.25 mL TRIS base 
in water pH 6.6, 0.02 mL 10% SDS in water, 0.02 mL 10% ammonium persulphate in water 
and 0.002 mL TEMED. The denatured samples were loaded and electrophoresed at 19 mA 
per gel for approximately two hours. The running buffer consisted of 0.1% (w/v) SDS, 25 
mM Tris-Base and 192 mM glycine, pH 8.3. A protein ladder supplied by Thermo Scientific 
(SM1811) was used to assess the molecular weight of electrophoresed proteins. 
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5.2.4.3 Coomassie staining 
 
SDS-PAGE gels were stained with Coomassie brilliant blue stain (Thermo Scientific 
PageBlue). Gels run in a reducing environment were first washed three times in deionised 
water for ten minutes. Gels were then covered with 20 mL of Coomassie brilliant blue and 
placed on a rocker for 60 minutes at room temperature. Gels were destained using 
deionised water. Three initial de staining steps were carried out for ten minutes each, 
followed by an overnight de stain. Further water washes were carried out if necessary, until 
gels with strongly contrasting bands were obtained.  
 
5.2.4.4 Western blot 
 
More sensitive and specific detection of protein was achieved using Western blot. Proteins 
were transferred from polyacrylamide gels to polyvinylidene fluoride (PVDF) in transfer 
buffer (10 mM CAPS, pH 11, 10% (v/v) methanol) for 90 minutes at a constant 140 mA, 
using a semi-dry transfer unit. The membranes were then blocked using 10% Marvel milk in 
PBST (10 mM NaH2PO4, 0.14 M NaCl, 3 mM KCL, 0.05% (v/v) Tween-20, pH 7.4) for two 
hours at room temperature or overnight at 4 0C. The antibody of choice was then 
introduced. Anti-histidine antibody was used at a 1:5000 concentration in PBST. Incubation 
was carried out for two hours at room temperature. The membrane was then washed five 
times, for five minutes, with PBST.  
NOS specific antibodies were used in 1:1000 concentration in PBST. The membrane was 
incubated with the primary antibody overnight at 4 0C. The membrane was washed three 
times for five minutes in PBST. The secondary antibody used was goat anti-rabbit. This was 
incubated with the membrane for one hour, at room temperature at a concentration of 
1:2000. The membrane was then washed five times for five minutes with PBST. Calmodulin 
specific antibody was used at 1:500 concentration in PBST. The secondary antibody used 
with the calmodulin antibody was rabbit anti-mouse, which was used in 1:1000 
concentration.   
The washed blots were developed by incubation of the membrane for three minutes with 
enhanced chemiluminescent (ECL) Western blot substrate (Pierce). Signals were detected 
Chapter Five                                                                                                 Materials and Methods 
 
 
248 
 
using photography film supplied by Kodak or Santa Cruz. Exposure times varied depending 
on what antibody was used. The preferred exposure time for anti-histidine antibody proved 
to be between 30 and 45 minutes. For the NOS specific antibodies exposure time was 15 
minutes. These films were developed and molecular weight markers were manually added 
using the PVDF membrane as a guide. 
 
5.2.4.5 Stripping and re-probing PVDF membranes 
 
In order to utilise different antibodies on the same PVDF membrane, the initial primary 
antibody used must be removed. PVDF membranes were stripped of antibody using 5mL of 
Restore Western blot Stripping Buffer (21059) supplied by Thermo Scientific and incubated 
with rotation for 5 minutes at room temperature. Residual stripping solution was removed 
by washing three times for five minutes with PBST. In order to ascertain if complete 
removal of the antibody had occurred, membranes were incubated with ECL and 
developed as described above. Where no signal was detected, complete removal of the 
enzyme conjugate could be assumed. Successfully stripped membranes were then re-
blocked with 10% (w/v) non-fat dried milk prepared in PBST for a minimum of 30 minutes 
at room temperature. Successfully stripped membranes could then be probed with 
alternative antibodies. Membranes were probed a maximum of three times.  
 
5.2.4.6 Mass spectrometry 
 
Successful expression of NOS and calmodulin proteins was confirmed via mass 
spectrometry analysis. Following Coomassie staining of gels the bands which were 
suspected to be NOS proteins were cut from the gel and prepared for analysis using the 
protocol of Shevchenko et al.131 Bands of interest were manually cut from the gel surface 
sliced into small cubes and placed into 500 μl Eppendorf tube. The gel fragments were 
incubated with 100 µL of 100 mM ammonium bicarbonate/acetonitrile for 30 minutes. 
Acetonitrile (500 µL) was added and incubation continued until destaining of the gel 
fragments was completed. 
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Trypsin digestion solution was prepared using 20 μg sequencing grade trypsin supplied by 
Promega (V511C). Trypsin (20 μg) was resuspended in 1.5 mL 10 mM ammonium 
bicarbonate containing 10% (v/v) acetonitrile. Each gel piece was incubated on ice with 50 
μL of the trypsin solution for two hours. Additional digestion solution was added to any gel 
pieces that were not saturated with solution. The gel pieces were prevented from drying 
out by addition of 10 μL of 10 mM ammonium bicarbonate in 10% acetonitrile to the top of 
each sample. The gel pieces were then incubated at 37 0C overnight. Protein was extracted 
from the gel plugs using 100 μL extraction buffer (1:2 (v/v) 5% formic acid: acetonitrile). 
Samples were incubated at 37 0C for 15 minutes with shaking. The solution containing 
extracted peptides was then removed from each sample and placed in a fresh Eppendorf 
tube. Samples were vacuum dried using an Eppendorf concentrator 5301 and stored at -20 
0C until mass spectrometry analysis. 
All peptide identifications were carried out using the Ion Trap 6340 LC/MS/MS system 
supplied by Agilent. Digested samples were resuspended in 20 μl 0.1% (v/v) trifluroacetic 
acid (TFA) in Milli-Q water. Samples were then filtered using spin filters supplied by Fisher 
(MPA-150-020W), pore size 0.22 µM. Trypsin digest (5 μL) was loaded onto a C18 chip 
(G4240-62006) supplied by Agilent at a rate of 0.6 μl/min in 0.1% formic acid (FA). The 
mobile phases were aqueous solutions of 0.1% (v/v) FA and an acetonitrile solution of 0.1% 
(v/v) FA. A 10 minute gradient was carried out to increase the acetonitrile concentration to 
100% linearly. Charged ions were generated using an electrospray ionisation source. Spray 
voltage was set to 2000 V.  
 
All peptides were submitted to the Mascot search engine to identify proteins and searched 
against the Swiss-Prot database.121 Trypsin was set as the digestion enzyme and up to two 
missed cleavages were allowed. Peptide mass tolerance was set at ± 2 for precursor ions 
and a tolerance of ± 1 for fragment ions. Variable modifications allowed for were 
carboxymethyl (C) and oxidation (M). Taxonomy was selected as Homo sapien. When using 
the Swiss-Prot, database individual ion scores >37 indicate protein identity or extensive 
homology (p<0.05). Only peptides matched with a score >37 were accepted as significant.  
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5.2.5 Griess assay 
 
The effectiveness of potential human nNOS inhibitors was tested using a Griess assay kit 
supplied by Oxford Biomedical research (NB78).  Also purchased from the same supplier 
was the nitric oxide synthase co-factor kit, (NS70). This co-factor kit contained 25 µM FAD,  
25 µM  and 2.5 µM  calmodulin. The Griess assay kit contained the following components 
(Table 5.3). 
 
Table 5.3. Griess assay kit components. 
Component Contents 
Reaction buffer 20 mM HEPES; 0.5 mM EDTA 
NADPH part A NADP+ , Glucose 6-Phosphate, L-arginine 
NAPDH part B Glucose 6-phosphate dehydrogenase 
Nitrate reductase Nitrate reductase 
Nitrate reductase Buffer Aqueous buffer 
Colour solution A Sulfanilamide in 3N HCl 
Colour solution B 
N-(1-Naphthyl) ethylenediamine 
dihydrochloride 
Nitrite standard 500 pmol / µL NaNO2 
 
 
5.2.5.1 Standard curve construction 
 
The manufacturer provided nitrite standard samples was used to produce a standard curve. 
The standard was diluted using MQ water to produce a series of solutions with nitrite 
concentrations ranging from 0 to 100 µM. The absorbance of these solutions was read at 
540 nM. Absorbance was plotted against nitrite concentration to generate a standard 
curve. 
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5.2.5.2 Sample testing 
 
Frozen protein samples prepared as described above (Section 5.2.3.3) were defrosted on 
ice for compound testing. Each vial of 35 µL allowed for one compound to be tested in 
duplicate. All compounds to be tested were made up in DMSO. Eppendorf tubes were 
labelled as required; each set of tests included a positive and a negative control, as well as 
a vehicle control.  The positive control was untreated NOS protein, the negative control 
was NOS protein treated with 50 µM of L-NNA and the vehicle control was treated with 
1.25 µL of DMSO. 
To each Eppendorf 200 µL of reaction buffer, 10 µL of NADPH A and 10 µL of NADPH B were 
added, along with 30 µL of purified NOS protein and 10 µL of NOS cofactor mix. 
Compounds to be tested were added to the appropriate tubes in 1.25 µL of DMSO to a final 
concentration of 50 µM. These tubes were shaken gently and then incubated at 37 0C for 
six hours.  
Following incubation the tubes were chilled on ice for five minutes before adding 10 µL of 
nitrate reductase. Following a brief vortex these were then left at room temperature for 20 
minutes and then centrifuged at 12,500 rpm for five minutes at 4 0C. A 100 µL aliquot from 
each tube was then added in duplicate to a 96 well plate. Colour solution A (50 µL) was 
added to each well, followed by 50 µL of colour solution B (Table 5.3). The plate was 
covered with a clear lid and left rocking gently for five minutes. The absorbance readings 
were measured at 540 nM. The absorbances were converted to concentration using the 
standard curve. The effectiveness of the compounds was compared to the vehicle for 
statistical significance using Graphpad.130 Differences between the vehicle control and 
treated samples were tested for statistical significance using a two tailed t test, with a p 
value of less than 0.05 being deemed significant. 
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5.3 Computational theory 
 
In silico drug design has proven to be a popular and productive tool for identification of 
small molecule inhibitors of various enzymes and binding sites.  There are many techniques 
which can be applied in this field. This work made use of a selection of these including 
docking, homology modelling, pharmacophore development and large database screening. 
Efforts were also made to predict various ADMET properties of computational hit 
compounds. The following section describes the theory behind these techniques. 
 
5.3.1 Molecular mechanical calculations 
 
The strength of ligand-enzyme interactions are of key importance for in silico design 
experiments. These interactions are scored based on how strongly the ligand is predicted 
to bind to the enzyme. Owing to the size and complexity of the molecules involved it is 
computationally difficult to examine all interactions at an atomistic level. Instead, 
approximations called force fields are used.132 These force fields also play a role in other 
processes such as energy minimization operations. They are therefore of fundamental 
importance and will be discussed in some detail.  
 
5.3.2 Force fields 
 
Force fields are a simplified method of predicting the overall energy of a given nuclear 
configuration, such as a ligand protein interaction. The total energy (Etot) can be written as 
a function of the nuclear coordinates.133 Electrons are not explicitly considered and the 
field they generate is not actually calculated, but rather represented by an “effective” 
potential treated by classical mechanics.133 Electrons can be explicitly considered by use of 
quantum mechanical calculations. These are extremely accurate and precise calculations 
but are resource intensive and so are not suitable for the types of virtual screening 
applications that were used in this project.  
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Different force fields calculate the total energy of the molecules in slightly different ways. A 
popular and widely used force field is Chemistry at HARvard Macromolecular mechanics, or 
CHARMm.134 This is incorporated into Biovia’s Discovery Studio suite of software. The force 
field equation for CHARMm is shown in Equation 2. 
 
Equation 2. CHARMm force field equation.
69
 
𝑈(𝑅)⃗⃗ ⃗⃗ ⃗⃗   = ∑  𝐾𝑏 (𝑏 − 𝑏0)
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2
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Each term of the equation represents a different parameter which needs to be considered 
for configuration energy. These terms can be loosely divided into bonding and non-bonding 
terms. The bonded terms are 𝑣(𝑏) bond stretching (Equation 3), 𝑣(𝜃) angle bending 
(Equation 4), 𝑣(𝜑) torsion potentials (Equation 5), and 𝑣(𝜔) improper torsions (Equation 
6). The energy contribution of all bonded terms is calculated by comparing the observed 
state of the molecule to an “ideal” value. The difference is then multiplied by a constant. 
Deviation away from the “ideal” value results in an energy penalty. The larger the 
deviation, the larger the penalty, the more energetic that particular state becomes. The 
non bonding interactions are accounted for by νnb(rij). The non bonded functions include 
Van der Waals forces and electrostatic interactions.133  
 
5.3.2.1 Bonded Functions 
 
EacHB in a molecule is assigned a reference length by the particular force field. Deviation of 
bond length away from this reference length results in an energy penalty for that particular 
version of the molecule. The energy penalty is calculated based on Hooke’s law as shown in 
Equation 3. 
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Equation 3. Bond length term of the CHARMm equation.
69
 
𝑣(𝑏) =  𝐾𝑏(𝑏 − 𝑏0)
2 
 
Where b0 is the reference bond length, b is the observed bond length and K is the force 
constant for bond stretching. This constant is unique to each particular bond type. The 
larger the deviation from the reference bond length the larger the energy penalty. 
The second bonded interaction is the angle bending term. This parameter is viewed in a 
similar manner to the bond stretching term already described. EacHB is assigned a 
reference angle and deviation from this angle results in an energy penalty proportional to 
the size of the deviation. This is quantified as shown in Equation 4.  
 
Equation 4. Bond angle term of the CHARMm equation.
69
 
𝑣(𝜃) =  𝐾𝜃(𝜃 − 𝜃0)
2 
 
Where θ is the observed angle, θ0 is the reference angle and, K is the force constant needed 
to bend the bond angle.  
BotHB stretching and angle bending are sometimes referred to as hard degrees of freedom, 
i.e. large amounts of energy are required to stretch or bend a bond. The majority of 
structure variation from bonded terms is due to torsional interactions of the molecule. As a 
bond is rotated 360 0 from its starting position, the energy associated with the bond will 
change. The energy will increase if the bond is forced into an unfavourable torsion and will 
decrease if the bond adopts a favourable torsion. Favoured and disfavoured torsions vary 
between bond types. The energy associated with particular torsions are calculated using a 
cosine series expansion as shown in Equation 5.  
 
Equation 5. Torsional potential term of the CHARMm equation.
69
 
𝑣(𝜑) =  𝐾𝜑 (1 + cos(𝑛𝜑 − 𝛿)) 
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Where v(ψ) is the torsion energy, Kφ is the barrier height, defining how much energy is 
needed to rotate the bond. This is constant and bond specific. The n term is the number of 
minimum energy points adopted during a full 360 0 rotation and finally δ is the phase 
factor, which is the torsional angle with the lowest energy. An example of the graphs 
generated using this function is shown in Figure 5.5.135 
 
 
Figure 5.5. Graph demonstrating the torsion energies possessed by bonds at various angles.
135
 The x-
axis represents the bond torsional angles, while the y-axis represents the energy at that torsional 
angle. 
The graph shows the energies of two different bonds. The bond represented by the dotted 
line adopts its minimum energy at three rotational points, 0 0, 180 0 and 360 0. The solid line 
also has three minimum energy points at 60 0,180 0 and 300 0. The energy barrier for this 
bond is lower than that of the dotted line, meaning that it will be easier for this bond to 
rotate out of its ideal torsional configuration.  
Improper torsions are used to define bond angle torsions in planar groups which have out 
of plane bending motions, such as sp2 hybridized carbons in carbonyl groups and in 
aromatic rings. A reference angle, ω, is assigned to motifs which commonly exhibit out of 
plane bending. This assigned value dictates to what degree the bond is expected to bend 
out of the plane. Deviation from this reference angle is assigned an energy penalty relative 
to the size of the deviation (Equation 6). 
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Equation 6. Improper torsions equation.
69
 
𝑣(𝜔) =   𝐾𝜔(𝜔 − 𝜔0)
2 
 
The final type of bonded interaction is a broad class called cross terms. This refers to how 
movement in one part of the molecule may result in a conformational change somewhere 
else.  For example, as a bond angle tightens the bonds which create this angle may stretch 
in an attempt to minimize the steric clash between the two bonded atoms. A diagram of 
such an interaction is shown in Figure 5.6. 
 
Figure 5.6. Illustration of cross terms. 
 
The “normal” species represents the bonding environment when there is no steric 
interference between atoms one and three. The “abnormal” species demonstrates how the 
bond length between atoms two and three and two and one can increase to mitigate steric 
interactions between atoms one and three. In Urey-Bradley force fields, such as CHARMm, 
the change in energy caused by these types of movements are represented by a harmonic 
function of the distance between the one and three atoms as shown in Equation 7.  
Equation 7. Energy change associated with a 1,3 cross term in a CHARMm.
69
 
𝑣(𝑠) =   𝐾𝑈𝐵(𝑆 − 𝑆0)
2 
 
K is the force constant and S0 is the “ideal” distance between the one and three atoms and 
S is the adopted distance between the one and three atoms. 
This can actually be classified as a non-bonded term as it examines the energy changes 
caused by the interactions of the two non-bonded atoms one and three as in Figure 5.6. 
The other two major non bonded terms considered in CHARMm are electrostatic 
interactions and Van der Waals forces which are discussed in Section 5.3.2.2.  
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5.3.2.2 Non bonded functions 
 
Electrostatic interactions are caused by permanent dipoles within molecules due to the 
differences in electronegativity between various atoms. These permanent dipoles result in 
attractive or repulsive forces between ligands and receptors. The unevenly distributed 
charges within a molecule are often represented mathematically by functional point 
charges. The electrostatic attraction or repulsion between two atoms/molecules can then 
be calculated as a sum of these point charges using a variation of Coulomb’s law as shown 
in Equation 8. 
 
Equation 8. CHARMm describing electrostatic interactions.
69
 
𝒒𝒊𝒒𝒋
𝟒𝝅𝜺𝟎𝜺𝒓𝒊𝒋
 
 
Where qi and qj are the magnitudes of the charge on each molecule, Ɛ0 is the permittivity of 
free space which is a constant. The Ɛ term is the permittivity of the solvent in which the 
molecules are immersed and  rij  is the distance between the two molecules.  
Van der Waals interactions are accounted for using a Lennard-Jones 12-6 potential which 
incorporates both attractive and repulsive interactions.136 The CHARMm term is shown in 
Equation 9. 
 
Equation 9. Lennard Jones term for CHARMm.
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 The R12 term describes the repulsive force that exists at short distances between atoms 
due to the overlapping electronic orbitals, while the R6 term describes the attractive force 
that exists between transient diploes. The two equations shown in Equation 8 and Equation 
9 are combined as one function in the CHARMm equation.  
Chapter Five                                                                                                 Materials and Methods 
 
 
258 
 
The final term in the CHARMm equation is known as the spline function (Equation 10).  
Equation 10. Spline function in CHARMm.
69
 
𝑣(𝑠) =   𝑈𝐶𝑀𝐴𝑃(𝜑, 𝜓) 
 
This function is used primarily for operations involving biomolecules, such as protein 
minimization calculations. It adds the energy associated with the backbone dihedral angles 
to the overall energy as represented in Equation 2. It also allows for correction of small 
errors in the protein backbone.69 
 
5.3.3 Protein minimizations 
 
Force fields are clearly an integral part of scoring interactions between targets and 
potential interactors. Force fields can also be applied to another vital computational 
process, energy minimization tasks.  
This project made use of Discovery Studio and it’s in built energy minimization algorithm 
which is based on the CHARMm force field. This program uses a combination of two 
minimization methods, steepest descent followed by conjugate gradient. The steepest 
descent method moves the atoms of the protein structure to cause the most rapid decline 
in energy possible. This allows the protein to adopt a local minimum. This can then be 
refined using a conjugate gradient to find the global minimum of the protein. This type of 
analysis is particularly important when examining areas of the protein which are highly 
flexible such as loops.  
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5.4 Other computational tools 
 
5.4.1 Clustering 
 
Clustering involves grouping molecules with similar properties into subsets, or clusters, so 
that each member of the set has similar properties, while molecules in different subsets are 
as dissimilar as possible. Similarity is assigned based on RMSD of the heavy atoms, or 
Tanimoto distances for fingerprints.167 Each cluster is assigned a cluster centre. This is a 
single molecule which best represents the properties of all the members of the set.  This 
type of analysis is useful as it allows a large dataset to be represented by a smaller, more 
manageable dataset. 168  
 
5.4.2 Pharmacokinetic predictions 
 
Discovery Studio can predict an array of ADMET properties for small molecule datasets. 
This allows for elimination of compounds with unfavourable pharmacokinetic profiles early 
in the drug development process. The ADMET predictions are derived from Bayesian 
models of experimentally validated compounds. Three of these properties were used in this 
work. The first of these was a prediction of how easily screened compounds would pass 
blood brain barrier (BBB) following oral administration. This is scored from zero to four and 
is based on the ratio of the concentration of compound in the brain to the concentration of 
compound in the blood (Table 5.4).169 
Table 5.4. BBB levels and descriptions. 
Level Value Description 
0 Very high 
Brain: Blood ratio greater than 
5:1 
1 High 
Brain: Blood ratio between 1:1 
and 5:1 
2 Medium 
Brain: Blood ratio between 
0.3:1 and 1:1 
3 Low 
Brain: Blood ratio less than 
0.3:1 
4 Undefined 
Outside 99 percent confidence 
ellipse 
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The absorption level property predicts human intestinal absorption after oral 
administration. This is defined by the percentage of the compound which is absorbed into 
the bloodstream. A compound is defined as well absorbed if at least 90% of it enters the 
bloodstream. A value of zero is good, one is moderate, two is low and three is very low 
absorption.170 
The solubility level descriptor predicts the aqueous solubility of a compound in water at 25 
0C. Compounds are assigned a solubility level from zero to six relative to a selection of 
known drugs (Table 5.5).169 
Table 5.5. Solubility descriptors from Discovery Studio. 
Level Description 
0 Extremely low solubility, lower than 95% of drugs 
1 Very low solubility, at border line of 95% of drugs 
2 Low solubility, at lower end of 95% of drugs 
3 Good, slight soluble to soluble 
4 Optimal solubility 
5 Very soluble, risks rapid elimination 
6 Unknown 
 
 
5.5  Computational Methods 
 
5.5.1 Structure based design 
 
5.5.1.1 Homology model construction 
 
Initial structure based screening trials were conducted using a human nNOS homology 
model. The templates used for this were rat nNOS crystal structures (PDB codes 3RQJ and 
3PNF, with resolution of 1.84 Å and 1.94 Å respectively).65,73 One homology models were 
developed from each template.  
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The human nNOS protein sequence was retrieved from the Uniprot database and aligned 
to the sequence of each template using Discovery Studio software from Biovia. One 
hundred homology models were then constructed using the default settings of Modeller.149 
Owing to the small, inflexible loops of nNOS no loop refinement was performed. The 
models were ranked using the DOPE scoring function and the top scoring model for the 
3PNF and the 3RQJ templates were taken. These were energy minimized to remove 
potential atom clashes and were then validated. The homology models are referred to as 
3PNF-HM and 3RQJ-HM.    
 
5.5.2 Homology model structural verification 
 
The structural robustness of the homology models was verified using a variety of tools on 
the UCLA website (http://services.mbi.ucla.edu/SAVES/). These included Verify 3-D, Errat 
and Procheck. For a full and detailed discussion of the functions of each of these tools 
please refer to section 2.2. 
 
 
 
5.5.3 Homology model functional verification 
 
The functionality of the models for virtual screening was tested using two main methods. 
Firstly, the templates used had been co-crystallized with inhibitors of rat nNOS. These 
inhibitors were removed and re docked into the binding site of the homology models. The 
ability of each docking function to re produce the original binding pose of the inhibitors 
was measured via RMSD.  
Secondly, the ability of the model to identify active nNOS inhibitors from a set of 1000 
molecules was tested. The set of 1000 molecules was termed a test set. The Chembl 
website was searched for compounds which inhibited human nNOS and the resulting list 
sorted based on IC50 values. Compounds with an IC50 of 10 µM or lower were chosen as 
Chapter Five                                                                                                 Materials and Methods 
 
 
262 
 
active inhibitors, while those with an IC50 above 30 µM were designated inactive, or decoys. 
This resulted in an active file with 520 compounds and an inactive file of 147 compounds. 
To have an active to decoy ratio of roughly 1:33 the active compounds were clustered into 
33 cluster centres and the centre of each cluster taken as representative of the cluster.139    
A total of 967 decoys were needed to make up the full 1000 molecules and to achieve the 
desired ratio. The first 147 of these were taken directly from Chembl. The remaining 820 
decoys were generated using the Chemdiv database and an nNOS like Bayesian filter. This 
filter was developed in Pipeline Pilot using the 520 active nNOS inhibitors taken from 
Chembl. The component learned what physio-chemical properties a molecule should have 
in order to be an nNOS inhibitor. The Chemdiv dataset was then passed through this filter 
and the top 820 compounds retained. These were combined with the 147 Chembl inactives 
to give a final total of 967 decoys. The active compounds were merged into this file to 
generate the final test set.  Note that while Chembl classes the compounds mentioned 
above as human nNOS inhibitors, detailed examination of the literature from which the 
compounds were sourced mentions very little testing carried out on the human isoform of 
nNOS. The test set was therefore made up almost wholly of rat nNOS active and inactive 
compounds. There are insufficient reports of compounds tested on human nNOS to allow 
for generation of a human only test set.  
Tautomers and stereoisomers of the test set were generated using Pipeline Pilot. 
Conformers were then generated with Omega.139 This molecule file was then docked into 
3PNF-HM and 3RQJ-HM using default FRED parameters. Both homology models were 
tested with and without water present. The docked lists from each of the seven FRED 
scoring functions each model were used to generate a set of ROCS curves. The overall best 
homology model and scoring function from this set of tests was chosen based on the 
verification results and taken forward for screening of commercial datasets. 
 
5.5.4 Database preparation and docking 
 
Two databases were screened for potential nNOS inhibitors using the 3PNF homology 
model. These were Maybridge (http://www.maybridge.com ) and a “drug like commercially 
available” subset of Zinc (http://zinc.docking.org/subsets/drugs-now ). Using Pipeline Pilot, 
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the largest fragment of each compound from both libraries was kept, thus removing salt 
counter ions which may interfere with binding. Duplicates were removed and a bump 
check filter was applied that removed molecules which were poorly drawn.  A poorly drawn 
molecule was defined as a compound in which two or more atoms are 0.1 Å or less apart. A 
Lipinski filter was also applied to both datasets to select for drug like molecules. A blood 
brain barrier filter also used. Finally tautomers, stereoisomers and conformers were 
generated.  
The binding site of the homology model was defined using the inhibitory ligand which the 
3PNF template had been co crystallized with. Docking was conducted using FRED and the 
compounds ranked using Chemscore. Following the docking the duplicates were removed 
and the top 1000 compounds from Maybridge and Zinc were retained. Predicted 
pharmacokinetic (PK) properties such as solubility, blood brain barrier permeability and 
absorption level were generated for these compounds.   
The same procedure was carried out using human iNOS and human eNOS crystal structures 
(PDB codes 3E7G and 1M9M and respectively). The top 1000 compounds from the rigid 
dock using the Chemscore function were retained for each isoform. 
 
5.5.5 Flexible docking 
 
The top 100 hits from Maybridge and Zinc rigid docking were flexibly docked into the 3PNF-
HM using CDocker in Discovery Studio. The residues as outlined in Table 2.1 were selected 
and allowed to be flexible. The hemeoglobin and the tetrahydrobiopterin adjacent to the 
binding site were also allowed to be flexible. The most promising candidates were chosen 
from this screen based on docking score, commercial availability, potential for chemical 
modification and PK properties. These were purchased in screening quantities for testing.    
The same procedure was repeated for the eNOS and iNOS crystal structures with the 
residues as outlined in Table 2.19 allowed to be flexible. 
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5.5.6 Key residue rotamers  
 
Several publications that have focused on rat nNOS have reported that a glutamic acid at 
position 592 in the binding pocket plays a key role in ligand receptor interactions via 
HBing.49,52,77 The rotameric states of the corresponding glutamic acid in the human 
homology model (Glu597) were explored. In an effort to improve the docking protocol 
performance, the seven “new” rotameric states were docked with the test set as before 
(section 5.5.3) and ROCS scores generated. The three rotamers of ASp602 in the human 
homology model were also examined in this way. The rotamers were enumerated in 
Discovery Studio using the Ponder and Richards rotamer library.171  
 
5.5.7 Crystal structures of iNOS and eNOS and their verification  
 
Docking experiments were also conducted using human iNOS and human eNOS. Crystal 
structures of the human isoforms of both of these proteins are available in the PDB so 
generation of homology models was not necessary. Two crystal structures for iNOS and two 
crystal structures for eNOS were chosen. The iNOS structures were 4NOS and 3E7G with 
resolutions of 2.25 Å and 2.2 Å respectively.79,80 The eNOS crystal structures were 1M9M 
and 3NOS with resolutions of 1.96 Å and 2.40 Å respectively.80,81 Structural integrity was 
verified using similar techniques as were used for the nNOS homology model, i.e. Verify 3-
D, Errat and Procheck. Functional tests were also performed by attempting to re dock the 
co-crystallised ligand into each of the protein crystal structures and by using test sets. 
For eNOS and iNOS the test sets were developed using similar techniques as were used to 
develop the nNOS HM test set. Actives and decoys were retrieved from Chembl and the 
actives clustered into 33 centres. A total of 635 actives and 187 decoys were available for 
iNOS, while 282 actives and 275 decoys were available for eNOS. The decoys available on 
Chembl were supplemented by screening the Chemdiv database with an iNOS or eNOS 
“like” Bayesian filter.  Tautomers, stereoisomers and conformers of the tests sets were 
generated and then docked into the appropriate crystal structure. The ability of the crystal 
structures and the docking program to differentiate between actives and decoys was 
evaluated using ROCS curves. The best performing scoring function and crystal structure 
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were chosen for eNOS and iNOS. These were taken forward for screening of commercial 
databases and analysis of the selectivity of the docking protocol for nNOS inhibitors over 
eNOS and iNOS inhibitors.  
  
5.5.8 Database preparation and docking of iNOS and eNOS 
 
Method as per Section 5.5.4. 
 
5.5.9 Published crystal structure docking 
 
In 2015 the first structure crystal structure of human nNOS was published.83 The structure 
was validated and rigid docking of Zinc and Maybridge was carried out using FRED 3.0.0. 
This new version of FRED was released during the course of this work. It returns only one 
scoring function, Chemgauss4.  
 
5.5.10 Pharmacophore construction 
 
Generation of an nNOS pharmacophore was accomplished using a training set. This was 
developed using the Chembl database. Compounds with IC50 values of 10 µM or less were 
defined as active nNOS inhibitors, while those with IC50 values of greater than 20 µM were 
defined as inactive. This set of parameters returned 550 active compounds from Chembl 
and 300 inactives. Actives and inactives were clustered separately into groups of 10 and 
copied into separate files. Tautomers and stereoisomers were generated. The actives were 
given the principal attribute of one, while the inactives were designated zero. Attempts to 
generate a pharmacophore from this training set failed. Therefore new actives were 
handpicked based on compound activity. This omitted extremely small and potentially 
unviable active compounds, such as small nitrogen heterocyclic compounds. Ten active 
compounds (with an IC50 of 10 µM or less) and ten inactive compounds (with an IC50 of 30 
µM or more) were chosen for pharmacophore generation (Table 5.6). Also included were 
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compounds that had proved inactive in the Griess assay (compounds 26-35). These 
compounds had been developed from the homology model screen and showed no activity 
in the Griess assay with human nNOS. Tautomers and stereoisomers were generated for all 
actives and inactives, and the set used to generate the first pharmacophore.  
 
Table 5.6. Chembl compounds used for first pharmacophore development. 
Training Set Active Compounds Chembl ID 
(Handpicked) 
Training Set Inactive Compounds Chembl ID 
(Cluster Centres) 
Chembl1944717 (2) Chembl114551 
Chembl1825174 Chembl101439 
Chembl397446 Chembl7889 
Chembl293212 Chembl100658 
Chembl162416 Chembl1800530 
Chembl43678 Chembl292690 
Chembl1955937 Chembl85525 
Chembl2203178 Chembl431417 
Chembl2011136 Chembl112246 
Chembl233655 Chembl86795 
 
Chembl1944717 was designated as most active for the pharmacophore generation. This 
compound is reported to have an IC50 of 12 nM for human nNOS.
84  This was one of the few 
Chembl compounds actually tested on human nNOS. The features which were permitted in 
the pharmacophore construction were H-bond donor and acceptor, hydrophobic, 
hydrophobic aromatic, positive ionisable, negative ionisable, positive charge, negative 
charge and ring aromatic. The minimum number of features was set to two and the 
maximum to six.  
Six parameter sets were used to determine the optimal settings for pharmacophore 
generation from the training set. These parameter sets altered the number of excluded 
volumes, the fitting method (rigid or flexible) and the number of features that could be 
omitted during the generation process. Ten pharmacophores were generated with the 
parameter sets to give a total of 60 pharmacophores (Table 5.7). Pharmacophore 
generation was conducted using Catalyst in Discovery Studio.  
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Table 5.7. Pharmacophore development parameters. 
Parameter set Excluded Volumes Rigid or Flexible Max Omit Feature 
1 0 Rigid 0 
2 0 Rigid 1 
3 50 Rigid 0 
4 50 Flexible 1 
5 0 Flexible 0 
6 50 Flexible 0 
 
 
5.5.11 Pharmacophore validation 
 
Validation of the pharmacophore models was conducted using training sets. This validation 
was conducted as part of the pharmacophore generation protocol. The test set was used 
was the Bayesian haystack that had been developed for the structure based design. 
Following ROCS analysis the most successful pharmacophore was taken forward for 
screening of commercial databases.  
 
5.5.12 Screening commercial databases with pharmacophores 
 
The commercial databases were prepared as previously described (section 5.5.4). They 
were then both screened using the best pharmacophore. The returned compound lists had 
duplicates removed, PK properties calculated and were then compiled into a ranked table. 
 
5.5.13 Pharmacophore evolution 
 
Experimental evaluation of pharmacophore one in silico derived hits allowed for addition of 
new compounds to the generation set for the second pharmacophore. All inactive 
compounds (compound 50-70) were added to the inactive portion of the training set and 
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new models generated. All new pharmacophore models were tested with the test set as 
described before. The actives used for the generation of pharmacophore one were used for 
generation of pharmacophore two, as was an active compound that had not appeared in 
Chembl on the original search (Figure 5.7).45 The best performing pharmacophores were 
again used to screen commercial databases.  
 
 
Figure 5.7. Extra active used for the generation of pharmacophore 2.
45
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5.6 Chemical Materials and Methods 
 
5.6.1 Instrumentation 
 
Reagents and reactants were purchased from Aldrich or Alfa Aesar and used as received 
unless otherwise stated. DCM was distilled over CaH2 and THF over Na wire and 
benzophenone. Anhydrous DMF was purchased from Sigma Aldrich. Toluene was dried 
over 4 Å molecular sieves.  
All NMR spectra were recorded on a Bruker Avance spectrometer at a probe temperature 
of 25 °C, unless otherwise stated, operating at 500 MHz for the 1H nucleus and 126 MHz for 
the 13C nucleus. Proton and carbon signals were assigned with the aid of 2D NMR 
experiments (COSY, HSQC) and DEPT experiments for novel compounds. Spectra were 
recorded in CDCl3 unless otherwise stated, with Me4Si used as internal standard. Chemical 
shifts are given in ppm downfield form the internal standard and coupling constants are 
given in Hz. 13C NMR spectra were recorded with complete proton decoupling. 
Melting point analyses were carried out using a Stewart Scientific SMP11 melting point 
apparatus and are uncorrected. 
High resolution mass spectra (HR-MS) were performed on an Agilent-L 1200 Series coupled 
to a 6210 Agilent Time-of-Flight (TOF) mass spectrometer equipped with an both a positive 
and negative electron spray source. Infrared spectra were obtained in the region 4000-400 
cm-1 on a Nicolet Impact 400D spectrophotometer or using a Perkin Elmer 2000 FTIR 
spectrometer.  
Flash column chromatography was performed using silica gel 60 (Merck, 0.040-0.063 mm). 
Analytical thin layer chromatography was carried out on aluminium sheets pre-coated with 
Merck TLC Silica gel 60 F254. Developed sheets were visualised using a portable UVltec CV-
006 lamp (λ = 254, 365 nm) or the appropriate stain. 
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5.6.2 Synthesis of 1-(4-(5-chloro-2-methylphenyl)piperazin-1-yl)-3-(m-
tolyloxy)propan-2-ol, compound 41 85  
 
Using a Gilson pipette, 1-(5-chloro-2-methylphenyl)-piperazine was mixed with 2-[(3-
methylphenoxy)methyl] oxirane in a 1:1 ratio and stirred briefly. The stir bar was removed 
and the reaction left to stand overnight. The resulting solution was a clear, viscous liquid. 
Purified via column chromatography (3:2 petroleum ether: EtOAc) to give a viscous, dark 
red oil. Yield 56%  
1H NMR: (500 MHz, CDCl3) δ 7.18 (app t, J = 7.8 Hz, 1H, H6), 7.09 (d, J = 8.0 Hz, 1H, H19), 
6.99-6.95 (m, 2H, H18, H19), 6.81 – 6.73 (m, 3H, H3, H5, H7), 4.15 (m, 1H, H9), 4.01 (m, 
2H,H8), 2.95 (dd, J = 8.5, 5.5 Hz, 4H, H13, H14), 2.87 – 2.82 (m, 2H, H10), 2.64 (dd, J = 12.3, 
8.2 Hz, 4H, H11, H12), 2.34 (s, 3H, H21), 2.26 (s, 3H, H1). 13C NMR: (126 MHz, CDCl3) δ 158.9 
(C4), 152.5 (C15), 139.7 (C2/C17), 132.1 (C17/C2), 131.9 (C19), 130.9 (C20), 129.3 (C6), 
123.2 (C16), 122.00 (Aryl C), 119.7 (C18), 115.6 (Aryl C), 111.6 (Aryl C), 70.3 (C8), 65.8 (C9), 
60.8 (C11, C12), 51.7 (C13, C14), 21.7 (C21), 17.6 (C1). Rf: 0.55 (3:2 petroleum ether: EtOAc)  
HR-MS: calcd for C21H28ClN2O2 m/z: [M+H]
+, 376.1861; found: 375.1861 [Diff (ppm) = -1.5].  
IR (Neat): 3422 (OH), 2944 (N-H), 1260 (C-Cl), 1049 (C-N), cm-1.  
 
5.6.3 Synthesis of tert-butyl (6-aminopyridin-2-yl)carbamate 
 
 
In a stirring flask of THF 1g (0.00458 moles) of ditertbutyl dicarbonate was mixed with 0.5 g 
(0.00458 moles) of 2,6 diaminopyridine. This was heated to 60 0C and stirred overnight. The 
THF was removed under reduced pressure to give a dark brown oil. This was dissolved in 
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DCM and purified using flash column chromatography. The product was eluted with 7:3 
EtOAc: petroleum ether. The product appeared as a light yellow solid. Yield 47%. 
 1H NMR: (500 MHz, CDCl3); δ 8.17 (s, 1H, H1), 7.39 (t, J = 8.0 Hz, 1H, H3), 7.20 (d, J = 7.9 Hz, 
1H, H4), 6.15 (d, J = 7.9 Hz, 1H, H2), 4.55 (s, 2H, H6), 1.51 (s, 9H, H9). 13C NMR: (126 MHz, 
CDCl3) δ 157.4 (C5), 152.7 (C7), 150.8 (C10), 139.9 (C3), 102.9 (C2), 101.9 (C4), 80.8 (C8), 
28.3 (C9). Rf: 0.88 (7:3 EtOAc: petroleum ether). IR (KBr): 2944 (N-H), 1675 (C=O)  cm-1. MP 
122-124 0C. Matches literature data.172 
 
5.6.4 Synthesis of 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium 
chloride (DMTMM), Compound 101 92 
 
 
Into 10 mL of freshly dried THF was placed 0.50 g (3 mmol) of 2-chloro-4,6-dimethoxy-
1,3,5-triazine (CDMT). 0.52 mL (3.2 mmol) of N-methylmorpholine (NMM) was added and 
the solution stirred in an open flask for 30 minutes. A white precipitate formed as the 
reaction progressed. The reaction was filtered through sintered glass and the white 
precipitate was collected. The solid was recrystallized from hot methanol and diethyl ether. 
The purified DMTMM appeared as a white solid and was stored at 4 0C to ensure stability. 
Yield 75%.  
1H NMR: (500 MHz, D2O) δ 4.67 – 4.62 (m, 2H), 4.17 (s, 6H), 4.16 – 4.13 (m, 2H), 3.96 – 3.82 
(m, 4H), 3.55 (s, 3H). 13C NMR: (126 MHz, D2O) δ 173.9 (C3,C4), 63.9 (ring C), 62.0 (ring C), 
60.0 (ring C), 57.1 (C1, C2), 55.8 (C6), 53.2 (ring C). IR (KBr): 1623, 1541, 1375, 1130 cm-1. 
MP: 114-118 0C. Matches literature data.92 
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5.6.5 Synthesis of triprotected aminoguanidinium, Compound 102 
 
 
Into a dry two necked round bottom under a flow of N2 was placed 0.125 g (2.37*10
-4 mols, 
1 eq) of Nα-Boc-Nω-(2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl)-L-arginine (Boc-
Arg-(Pbf)-OH), 0.075 g (2.37*10-4 mols, 1 eq ) of TBTU, 0.040 g of HOBt (2.61*10-4 mols, 1.1 
eq) and 0.65 ml (5*10-3 mols ) of NEt3. These were dissolved in dry DMF and stirred at room 
temperature for 15 minutes. 0.051 g (2.41*10-4 mols, 1 eq) of tert-butyl (6-aminopyridin-2-
yl)carbamate (AC002) was then added and the resulting solution stirred overnight at 50 0C. 
The solvent was removed under reduced pressure and the mixture purified via column 
chromatography using 7:3 petroleum ether: EtOAc as the solvent. The product appeared as 
a yellow oil. Yield 90% 
1H NMR: (500 MHz, CDCl3); 
1H NMR (500 MHz, CDCl3) δ 9.42 (s, 1H, NH), 7.86 (s, 1H, NH), 
7.66 (s, 1H, NH), 7.36 (app t, J = 8.0 Hz, 1H, H28), 7.19 (d, J = 8.0 Hz, 1H, H27), 6.13 (d, J = 
7.9 Hz, 1H, H29), 5.34 (d, J = 7.0 Hz, 1H, NH), 4.56-4.41 (m, 2H, NH, CH (H16)), 4.35 (s, 1H, 
H19), 3.36 (m, 1H, H16), 2.94 (s, 2H, H3), 2.55 (s, 3H, CH3), 2.50 (s, 3H, CH3), 2.38 (m, 1H, 
H18), 2.08 (s, 3H, CH3), 1.90 – 1.76 (m, 2H, H17), 1.60 – 1.51 (m, 1H, H18), 1.48 (s, 9H, BOC), 
1.44 (s, 6H, CH3 x 2), 1.43 (s, 9H, BOC). 
13C NMR (126 MHz, CDCl3) δ 175.2 (C24), 158.3 
(C14), 156.3 (C=O), 154.5 (C=O), 153.0 (Aryl C), 151.5 (Aryl C), 149.5 (Aryl C), 138.9 (C28), 
137.9 (Aryl C), 131.8 (Aryl C), 130.7 (Aryl C), 123.8 (Aryl C), 116.7 (Aryl C), 102.0 (C29), 100.6 
(C27), 85.7 (C2), 79.7 (C-Boc), 79.1 (C-Boc), 51.3 (C19), 42.1 (C3), 40.9 (C16) 28.0 (BOC CH3), 
27.6 (C1), 27.7 (BOC CH3), 24.3 (C18), 20.0 (C17), 18.2 (CH3), 17.0 (CH3), 11.4 (CH3). Rf: 0.46 
(7:3 petroleum ether: EtOAc) HR-MS: calcd for  C34H52N7O8S m/z: [M+H]
+ 718.3593; found: 
718.3583 [Diff (ppm) = -1.28 ppm]. IR (Neat): 3392 (N-H), 1696 (C=O), 1616 (C=O), 1369 
(S=O).  
Chapter Five                                                                                                 Materials and Methods 
 
 
273 
 
5.6.6 Synthesis of N-(3-chlorophenyl)-4-(naphthalen-1-ylmethyl)piperazine-1-
carboxamide, Compound 37 
 
Under a flow of nitrogen, 0.23 g (1 mmol) of 1-(naphthalen-1-ylmethyl)piperazine was 
mixed with 0.15 g (1 mmol) of 1-chloro-3-isocyanatobenzene in a sealed round bottom. To 
this was added dry DCM and the solution was stirred at room temperature. The reaction 
progress was monitored by TLC. After five hours the starting material was consumed. The 
DCM was removed under reduced pressure to yield the crude product. This was purified via 
column chromatography using 1:1 EtOAc:Pet Ether to elute the product as a white solid. 
Yield 81%. 
1H NMR: (500 MHz, CDCl3) δ 8.29 (d, 1H, J = 7.9 Hz, Napthyl H), 7.88 – 7.85 (m, 1H, Napthyl 
H), 7.82 – 7.78 (m, 1H, Napthyl H), 7.51-7.48 (m, 2H, Napthyl H), 7.44-7.39 (m, 2H, Napthyl 
H), 7.30 (d, J = 8.9,  2H, H20, H22), 7.23 (d, J = 8.9 Hz, 2H, H19, H23), 6.30 (s, 1H, H17), 3.95 
(s, 2H, H11), 3.50 – 3.45 (m, 4H, H14, H15), 2.60 – 2.52 (m, 4H, H12, H13). 13C NMR: (126 
MHz, CDCl3) δ 183.2 (C16), 137.4 (C18), 133.9 (Napthyl C6/C1), 133.2 (Napthyl C6/C1) 132.5 
(C10), 129.9 (C21), 128.8 (C20, C22), 128.4 (Napthyl C), 128.2 (Napthyl C), 127.5 (Napthyl 
C), 125.8 (Napthyl C), 125.7 (Napthyl C), 125.1 (Napthyl C), 124.6 (Napthyl C), 121.0 (C19, 
C23), 61.1 (C11), 52.8 (C12, C13), 44.1 (C14,C15). HR-MS: calcd for C22H23ClN3O m/z: 
[M+H]+; 380.1524 found: 380.1533  [Diff (ppm) = 2.1]. IR (KBr): 2937 (N-H), 1635 (C=O), 
820.9 (C-Cl) cm-1 MP: 205-206 0C 
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5.6.7 Synthesis of 4-(naphthalen-1-ylmethyl)-N-phenylpiperazine-1-
carboxamide, Compound 38 
 
Under a flow of nitrogen, 0.23 g (1 mmol) of 1-(naphthalen-1-ylmethyl)piperazine was 
mixed with 0.12 g (1 mmol) of isocyanatobenzene in a sealed round bottom. To this was 
added dry DCM and the solution was stirred at room temperature. The reaction progress 
was monitored by TLC. the starting material was consumed. The DCM was removed under 
reduced pressure to yield the crude product. This was redissolved in EtOAc and purified via 
column chromatography (50:50 EtOAc:Pet Ether) to yield the pure product as a 
yellow/orange solid. Yield 66%. 
 
1H NMR (500 MHz, CDCl3) δ 8.30 (d, J = 8.1 Hz, Napthyl H), 7.88 – 7.85 (m, Napthyl H), 7.80 
(m, 1H, Napthyl H), 7.51 (m, 2H, Napthyl H), 7.44 – 7.40 (m, 2H, Napthyl H), 7.34 (dd, J = 
8.5, 1.0 Hz, 2H, H20, H22), 7.30 – 7.27 (m, 2H, H19, H23), 7.03 (m, 1H, H21), 6.30 (s, 
1H,H17), 3.95 (s, 2H, H11), 3.51 – 3.47 (m, 4H, H14, H15), 2.59 – 2.54 (m, 4H, H12, H13). 13C 
NMR (126 MHz, CDCl3) δ 182.2 (C16), 138.9 (C18), 133.9 (Napthyl C6/C1), 133.2 (Napthyl 
C6/C1), 132.5 (C10), 128.9 (C19,C23), 128.5 (Napthyl C), 128.3 (Napthyl), 127.6 (Napthyl C), 
125.9 (Napthyl C), 125.7 (Napthyl C), 125.1 (Napthyl C), 124.7 (Napthyl C), 123.1 (C21), 
119.9 (C20, C22), 61.2 (C11), 52.9 (C12, C13), 44.2 (C14, C15). HR-MS: calcd for C22H24N3O 
m/z: [M+H]+; 346.1914  found: 346.1923 [Diff (ppm) = 2.64]. IR (KBr): 2951 (N-H), 1638 
(C=O) cm-1. MP: 158-160 0C 
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5.6.8 Synthesis of 4-(naphthalen-1-ylmethyl)-N-phenylpiperazine-1-
carbothioamide, Compound 39 
 
 
Under a flow of nitrogen, 0.23 g (1 mmol) of 1-(naphthalen-1-ylmethyl)piperazine was 
mixed with 0.14 g (1 mmol) of isothiocyanatobenzene in a sealed round bottom. To this 
was added dry DCM and the solution was stirred at room temperature. The reaction 
progress was monitored by TLC. After five hours the starting material was consumed. The 
DCM was removed under reduced pressure to yield the crude product. This was purified via 
column chromatography (95:5 DCM:MeOH) to yield the pure product as a white solid. Yield 
58%.  
 
1H NMR (500 MHz, CDCl3) δ 8.26 (d, J = 8.1 Hz 1H, Napthyl H), 7.87 – 7.84 (m, 2H, Napthyl 
H), 7.80 – 7.77 (m, 1H, Napthyl H), 7.54 – 7.47 (m, 2H, Napthyl H), 7.41 – 7.38 (m, 2H, 
Napthyl H), 7.33-7.29 (m, 2H, H20, H22), 7.16 (s, 1H, H17), 7.12 (m, 1H, H21), 7.08 (d, J = 7.6 
Hz, 2H, H19, H23), 3.93 (s, 2H, H11), 3.83 – 3.78 (m, 4H, H14, H15), 2.60 – 2.54 (m, 4H, H12, 
H13). 13C NMR (126 MHz, CDCl3) δ 183.3 (C16), 140.1 (C18), 133.9 (Napthyl C1/C6), 133.2 
(Napthyl C1/C6), 132.5 (C10), 129.2 (C20, C22), 128.5 (Napthyl C), 128.3 (Napthyl C), 127.6 
(Napthyl C), 125.9 (Napthyl C), 125.8 (Napthyl C), 125.1 (Napthyl C), 125.0 (C21), 124.7 
(Napthyl C), 122.6 (C19, C23), 60.9 (C11), 52.5 (C12, C13), 49.8 (C14, C15). HR-MS: calcd for 
C22H24N3S m/z: [M+H]+; 362.1685  found: 362.1694 [Diff (ppm) = 2.42]. IR (KBr): 2943 (N-
H), 1533 (C=S) cm-1. MP: 150-154 0C 
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5.6.9 Synthesis of N-(3-chlorophenyl)-4-(naphthalen-1-ylmethyl)piperazine-1-
carbothioamide, Compound 40 
 
Under a flow of nitrogen, 0.23 g (1 mmol) of 1-(naphthalen-1-ylmethyl)piperazine was 
mixed with 0.17 g (1 mmol) of 1-chloro-3-isothiocyanatobenzene in a sealed round bottom 
under a flow of nitrogen. To this was added dry DCM and the solution was stirred at room 
temperature. The reaction progress was monitored by TLC. After five hours the starting 
material was consumed. The DCM was removed under reduced pressure to yield the crude 
product. This was purified via column chromatography (4:1 petroleum ether: EtOAc) to 
yield the pure product as a white solid. Yield 76%. 
1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 8.1 Hz, 1H, Napthyl H), 7.89 – 7.84 (m, 1H, Napthyl 
H), 7.82 – 7.78 (m, 1H, Napthyl H), 7.51 (m, 2H, Napthyl H), 7.40 (m, 2H, Napthyl H), 7.28 (d, 
J = 8.7 Hz, 2H, H20, H22), 7.07 (d, J = 8.6 Hz, 2H, H19, H23), 3.94 (s, 2H, H11), 3.85 – 3.79 
(m, 4H, H14,H15), 2.61 – 2.54 (m, 4H, H12, H13). 13C NMR (126 MHz, CDCl3) δ 182.9 (C16), 
138.5 (C18), 133.9 (C1/C6), 133.2 (C1/C6), 132.4 (C10), 130.5 (C21), 129.2 (C20, C22), 128.5 
(Napthyl C), 128.3 (Napthyl C), 127.7 (Napthyl C), 125.9 (Napthyl C), 125.8 (Napthyl C), 
125.1 (Napthyl C), 124.7 (Napthyl C), 124.5 (C19, C23), 60.9 (C11), 52.5 (C12, C13), 49.5 
(C14, C15). HR-MS: calcd for C22H23ClN3S m/z: [M+H]
+; 396.1213  found: 396.1227  [Diff 
(ppm) = 3.5]. IR (KBr): 2939 (N-H), 1531 (C=S), 862 (C-Cl) cm-1. MP: 190-192 0C 
 
5.6.10 Synthesis of tert-butyl (2-aminoethyl)carbamate 173 
 
Ethylenediamine (28 mL, 400 mmol) was mixed in 300 mL of CH3Cl. This was stirred on ice. 
Di-tert butyl dicarbonate (8.74 g, 40 mmol) was dissolved in 10 mL of CH3Cl. This was added 
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via syringe pump at 20 µL/min. This took approximately 3.5 hours. Once all of the di-tert 
butyl dicarbonate was added the flask was stoppered and stirred overnight at room 
temperature. The reaction turned cloudy white as it progressed. Following the overnight 
stir the reaction mixture was washed with 6 x 100 mL of brine and 100 mL of deionised 
water. Following drying with MgSO4, the solvent was removed to yield the product as a 
clear oil. Yield: 85% 
1H NMR (500 MHz, CDCl3) δ 5.60 (s, 1H, H4), 2.85 (d, J = 5.4 Hz, 2H, H3), 2.47 (t, J = 5.9 Hz, 
2H, H2), 1.14 (s, 9H, H7), 1.08 (s, 2H, H1). 13C NMR (126 MHz, CDCl3) δ 156.3 (C5), 79.3 (C6), 
43.4 (C2), 41.9 (C3), 28.5 (C7). IR (Neat): 2928 (N-H), 1687 (C=O) cm-1. Matches literature 
data.173 
 
5.6.11 Synthesis of tert-butyl (2-(4-fluorobenzamido)ethyl)carbamate 
 
AC009 (5 ml (1 eq, 0.032 mols)) was dissolved in 40 ml of dry DCM. 4.56 mL (1 eq, 0.032 
mols) of NEt3 was added and the flask was cooled on ice. 4.66 ml (1.5 eq, 0.048 mols) of 4-
flourobenzyl chloride was added slowly to the stirring mixture. This was then removed 
from the ice and stirred overnight at room temperature. The reaction mixture became 
yellow and an insoluble material precipitated out. In the morning the reaction mixture was 
diluted with DCM to solubilize the precipitate. The organic layer was washed with 3x40 mL 
of deionised water and dried with MgSO4.The solvent was then removed under reduced 
pressure to yield a yellow/white solid. This was purified via column chromatography (1:1 
EtOAc:Pet ether). Yield 74% 
1H NMR (500 MHz, CDCl3) δ 7.84 (dd, J = 8.6, 5.4 Hz, 2H, H3, H5), 7.30 (s, 1H, H8), 7.11 – 
7.06 (m, 2H, H2, H6), 5.06 (s, 1H, H11), 3.58 – 3.50 (m, 2H, H9), 3.41 (dd, J = 10.9, 5.8 Hz, 
H10), 1.42 (s, 9H, H14). 13C NMR (126 MHz, CDCl3) δ 166.7 (C7), 164.7 (d, J = 251.6 Hz, C1), 
157.8 (C12), 130.3 (d, J = 3.1 Hz, C4), 129.4 (d, J = 8.9 Hz, C3, C5), 115.5 (d, J = 21.8 Hz, C2, 
C6), 80.1 (C13), 42.4 (C9), 39.9 (C10), 28.3 (C14). Rf: 0.23 (1:1 EtOAc : petroleum ether) HR-
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MS: calcd for C14H19FN2O3Na m/z: [M+Na]
+; 305.1272  found: 305.1283  [Diff (ppm) = 3.71]. 
IR (KBr): 2985 (N-H Boc), 2942 (N-H, aryl), 1635 (C=O, BOC) 1606 (C=O, aryl) cm-1. MP: 
121-123 0C 
 
5.6.12 Synthesis of N-(2-aminoethyl)-4-fluorobenzamide 
 
AC010 was dissolved in 1:1 mixture of DCM:TFA and stirred at room temperature for 4 
hours, monitoring by TLC. When all AC009 had been consumed the solvent was removed 
under reduced pressure to afford a yellow oil. This was redissolved in EtOAC and petroleum 
ether was added slowly to crash out the product as a white solid. Yield 54%. 
 
1H NMR (500 MHz, MeOD) δ 7.89 (dd, J = 8.6, 5.4 Hz, 2H, H3. H5), 7.06 (t, J = 8.7 Hz, 2H, 
H2,H6), 3.66 (t, J = 5.3 Hz, 2H, H9), 3.16 (m, 2H, H10). 13C NMR (126 MHz, MeOD) δ 169.8 
(C7),166.1 (d, J = 250.9, C1), 131.1 (C4), 131.0 (d, J = 9.0 Hz, C3, C5), 116.2 (d, J = 22.1 Hz, 
C2, C6), 40.8 (C9), 39.0 (C10). HR-MS: calcd for C9H12N2OF m/z: [M+H]
+; 183.0928  found: 
183.0930  [Diff (ppm) = 1.1]. IR (KBr): 3010 (N-H Boc), 2938 (N-H, aryl), 1606 (C=O) cm-1.  
 
5.6.13 Synthesis of 1-(isocyanatomethyl)-3-(trifluoromethyl)benzene, 
Compound 99 
 
Into dry toluene under a flow of N2 was placed 0.715 g (3.5*10
-3 mols, 1 eq) of 2-(3-
(trifluoromethyl)phenyl)acetic acid. To this was added 0.74 ml (5.25*10-3 mols, 1.5 eq) of 
triethylamine. 1.12 ml (5.25*10-3 mols, 1.5 eq ) of diphenylphosphoryl azide was added 
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dropwise over the course of three hours at room temperature with constant stirring. Once 
addition was completed the reaction was left to stir for a further 3 hours at room 
temperature. It was then heated to 85 0C overnight.  
The resulting orange liquid was carried straight through to the next step without further 
purification. Confirmation of product formation was accomplished by withdrawal of an 
aliquot of the reaction mixture for NMR analysis.  
1H NMR (500 MHz, CDCl3) δ 7.50 – 7.45 (m, 2H), 7.41-7.39 (m, 2H), 4.48 (s, 2H, H5). 
 
5.6.14 Synthesis of 4-fluoro-N-(2-(3-(3-
(trifluoromethyl)benzyl)ureido)ethyl)benzamide, Compound 94 
 
 
To a stirring solution of AC012 was added 0.49 mls (3.5*10-3 mols, 1 eq) of NEt3 and 0.638 g 
(3.5*10-3 mols, 1 eq) of AC010 dissolved in dry toluene. The reaction was stirred under N2 
overnight at 85 0C. The solvent was removed in vacuo and the product isolated as a white 
solid via column chromatography (1:1 EtOAc: petroleum ether). Yield 37%. 
 
1H NMR (500 MHz, DMSO) δ 9.49 (s, 1H, NH), 8.62 (s, 1H, NH), 7.90 (dd, 2H, J = 8.6, 5.6 Hz, 
H4, H5), 7.62 – 7.52 (m, 5H, Aryl H), 7.31 (t, J = 8.8 Hz, 1H, H17), 6.73 (s, 1H, NH) 4.33 (m, 
2H, H14), 3.45 – 3.35 (m, 4H, H9, H10). 13C NMR: (126 MHz, DMSO) δ 166.0 (C7), 164.3 (d, J 
= 248.2 Hz, C1), 158.6 (q, J = 36.0 Hz, C19), 157.0 (C12), 143.1 (C15), 130.6 (q, J = 240.7 Hz, 
C21), 131.4 (d, J = 2.9 Hz, C6), 130.3 (d, J = 8.0 Hz, C4, C5), 123.7 (d, J = 3.6 Hz, C6), 119.8 
(C16), 117.5 (C17), 115.6 (d, J = 21.7 Hz, C2, C3), 115.3 (m, C18, C20), 43.0 (C14), 40.7 (C9), 
38.7 (C10). Rf: 0.45 (1:1 EtOAc: petroleum ether). HR-MS: calcd for C18H17N3O2F4Na m/z: 
[M+Na]+; 407.118  found: 407.1187  [Diff (ppm) = 1.77]. IR (KBr): 2947 (N-H), 1644 (C=O), 
1327 (C-F) cm-1. M.P: 142-144 0C. 
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5.6.15 Synthesis of tert-butyl (2-benzamidoethyl)carbamate 
 
 
 
Prepared as per AC010 with benzoyl chloride used in place of 4-flourobenzyl chloride. Yield 
42% 
1H NMR (500 MHz, DMSO) δ 8.48 (t, J = 4.8 Hz, 1H, H8), 7.88 (d, J = 7.4 Hz, 2H, H3, H5), 7.56 
(t, J = 7.3 Hz, 1H, H1), 7.49 (t, J = 7.5 Hz, 2H, H2, H6), 6.93 (t, J = 5.4 Hz, 1H, H11), 3.35 (dd, J 
= 12.3, 6.3 Hz, 2H, H9), 3.16 (dd, J = 12.3, 6.2 Hz, 2H, H10), 2.03 (s, 9H, H14). 13C NMR (126 
MHz, DMSO) δ 166.9 (C7), 156.2 (C12), 135.0 (C2), 131.5 (C1), 128.6 (C2, C6), 127.6 (C3, 
C5), 78.1 (C13), 28.7 (C9), 21.1 (10), 14.5 (C14). HR-MS: calcd for C14H20N2O3Na m/z: 
[M+Na]+; 287.1366  found: 287.1377  [Diff (ppm) = 3.88]. IR (KBr) 2924 (N-H), 1663 (C=O), 
cm-1. 
 
5.6.16 Synthesis of N-(2-aminoethyl)benzamide 
 
 
Prepared  as per AC011, dissolving AC014 in a 1:1 mixture of DCM:TFA and stirring at room 
temperature. Yield 42%.  
1H NMR (500 MHz, D2O) δ 7.74 (d, J = 7.3 Hz, 2H, H3, H5), 7.57 (t, J = 7.4 Hz, 1H, H1), 7.47 (t, 
J = 7.7 Hz, 2H, H2, H6), 3.65 (t, J = 5.8 Hz, 2H, H9), 3.20 (t, J = 5.5 Hz, 2H, H10). 13C NMR (126 
MHz, D2O) δ 171.7 (C7), 132.5 (C1), 128.8 (C2, C6), 127.1 (C3, C5), 39.3 (C10), 37.3 (C9). 
Matches literature data. 174 
Chapter Five                                                                                                 Materials and Methods 
 
 
281 
 
 
5.6.17 Synthesis of N-(2-(3-(3-(trifluoromethyl)benzyl)ureido)ethyl)benzamide, 
Compound 95 
 
 
Prepared as per 94 by combing AC015 and AC012. Isolated as a white solid. Yield 41%. 
 
1H NMR (500 MHz, DMSO): δ 9.49 (s, 1H, NH), 8.59 (t, J = 4.9 Hz, 1H, NH), 7.83 (d, J = 7.2 Hz, 
2H, H4, H5), 7.63 – 7.50 (m, 6H, Aryl H), 7.47 (t, J = 7.5 Hz, 1H, H1), 6.72 (t, J = 6.1 Hz, 1H, 
H13), 4.33 (m, 2H, H14), 3.45 – 3.35 (m, 4H, H9/H10). 13C NMR: (126 MHz, DMSO) δ 167.1 
(C7), 158.4 (q, J = 36.0 Hz, C19), 157.1 (C12), 143.1 (C15), 134.9 (C6) 131.5 (C4, C5), 130.6 
(q, J = 270.0 Hz, C21), 128.7 (C1), 127.7 (C2,C3)  123.7 (C16), 123.7 (m, C17), 115.8 (q, J = 
3.9 Hz, C20) 115.7 (q, J = 3.7 Hz, C18), 42.7 (C14), 40.7 (C9), 38.6 (C10). Rf: 0.42 (1:1 
EtOAc:petroleum ether). HR-MS: calcd for C18H18N3O2F3Na m/z: [M+Na]
+; 388.1243  found: 
388.1254  [Diff (ppm) = 3.71] IR (KBr): 2938 (N-H), 1634 (C=O), 1320 (C-F) cm-1 MP: 136-138 
0C 
 
5.6.18 Synthesis of 4-fluoro-N-(2-(3-(3-(trifluoromethyl)phenyl)ureido) 
ethyl)benzamide, Compound 96 
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Prepared as per 94 by combining AC011 and 1-isocyanato-3-(trifluoromethyl)benzene. Yield 
39%. 
1H NMR: (500 MHz, DMSO) δ 8.95 (s, 1H, H13), 8.58 (t, J = 5.1 Hz, 1H, H18), 7.97 (s, 1H, 
H20), 7.94 (d, J = 8.6, 2H, H4, H5), 7.51 (d, J = 8.2 Hz, 1H, H15), 7.45 (t, J = 8.3 Hz, 1H, H16), 
7.29 (d, J = 8.5 Hz, 2H, H2, H3), 7.22 (d, J = 7.6 Hz, 1H, H17), 6.40 (t, J = 5.5 Hz, 1H, H11), 
3.38 (dd, J = 11.5, 5.7 Hz, 2H, H9), 3.32 – 3.28 (m, 2H, H10). 13C NMR (126 MHz, DMSO) δ 
165.9 (C7), 164.3 (d, J = 248.3 Hz, C1), 155.7 (C12), 141.8 (C14), 131.4 (d, J = 2.9 Hz, C6) 
130.3 (d, J = 8.0 Hz, C4, C5), 129.9 (q, J = 31.3 Hz, C18), 128.7 (C16), 124.8 (q, J = 272.3 Hz, 
C19), 121.6 (C15), 117.7 (q, J = 3.7 Hz, C17), 115.6 (d, J = 21.7 Hz, C2, C3), 114.1 (q, J = 3.4 
Hz, C20), 40.4 (C9), 39.5 (C10).Rf: 0.38 (1:1 EtOAc:petroleum ether) HR-MS: calcd for 
C17H15N3O2F4Na m/z: [M+Na]
+; 392.0993  found: 392.1003  [Diff (ppm) = 2.64] IR (KBr): 
2946 (N-H), 1647 (C=O), 1325 (C-F) cm-1  M.P 186-188 0C 
 
5.6.19 Synthesis of N-(2-(3-(3-(trifluoromethyl)phenyl)ureido)ethyl)benzamide, 
Compound 97 
 
 
Prepared as per 94 by combining AC015 and 1-isocyanato-3-(trifluoromethyl)benzene. 
Isolated as a white solid. Yield 36%. 
1H NMR (500 MHz, DMSO): δ 8.96 (s, 1H, H13), 8.54 (t, J = 4.8 Hz, 1H, H8), 7.96 (s, 1H, H20), 
7.86-7.83 (d, J = 7.3 Hz, 2H, H4, H5), 7.51 (m, 2H, H1, H15), 7.48-7.41 (m, 3H, H2, H3, H16), 
7.21 (d, J = 7.5 Hz, 1H, H17), 6.40 (t, J = 5.5 Hz, 1H, H11), 3.37 (m, 2H, H9), 3.33-3.27 (m, 2H, 
H10). 13C NMR (126 MHz, DMSO) δ 166.7 (C7), 155.4 (C12), 141.4 (C14), 134.4 (C6), 131.2 
(C1), 129.8 (C16), 129.5 (q, J = 31.2 Hz, C18), 128.3 (C2/C3), 127.2 (C4/C5), 124.3 (q, J = 
272.2 Hz, C19), 121.2 (C15), 117.3 (q, J =  4.1 Hz, C17), 113.7 (q, J = 3.9 Hz, C20) 39.5 (C9), 
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38.7 (C10). HR-MS: calcd for C34H32N6O4F6Na m/z: [2M+Na]
+; 725.2281  found: 725.2312  
[Diff (ppm) = 4.19] IR (KBr): 2951 (N-H), 1639 (C=O), 1335 (C-F) cm-1 M.P 174-176 0C 
 
5.6.20 Synthesis of 2-(2-(phenylthio)ethyl)isoindoline-1,3-dione 
 
 
 
Into a flask of dry DMF under a continuous flow of N2 was placed 0.19 g (1.76 *10 
-3 mols, 1 
eq) of thiophenol and 0.32 mls (1.76 *10 -3 mols, 1 eq) of a 30% solution of NaOMe. This 
was stirred for 40 minutes at room temperature. 0.55 g (2.64 * 10 -3 mols, 1.5 eq) of 2-(2-
chloroethyl)isoindoline-1,3-dione was dissolved in 2 mL dry DMF in a separate flask under 
inert atmosphere. This was added via cannula to the stirring thiophenol mixture over the 
course of 15 minutes. The combined solution was stirred at room temperature overnight. 
The DMF was removed under reduced pressure and the residue taken up in ethyl acetate. 
This was washed with 3 equivalents each of 1 M HCl, brine and water. The ethyl acetate 
was removed and the resulting yellow oil purified via column chromatography, eluting with 
17:3 petroleum ether: ethyl acetate. The product was isolated as a yellow oil. Yield 86%. 
 1H NMR (500 MHz, CDCl3) δ 7.60 – 7.56 (m, 2H, H1, H2), 7.52 – 7.48 (m, 2H, H3, H4), 7.20 
(d, J = 7.5 Hz, 2H, H12, H16), 7.05 (t, J = 7.7 Hz, 2H, H13, H15), 6.92 (t, J = 7.4 Hz, 1H, H14), 
3.72 (t, J = 7.1 Hz, 2H, H9), 3.05 (t, J = 7.1 Hz, 2H, H10). 13C NMR (126 MHz, CDCl3) δ 167.7 
(C7, C8), 134.9 (C5, C6), 133.9 (C3, C5), 131.8 (C11), 129.3 (C12, C16), 128.9 (C13, C15), 
126.1 (C14), 123.0 (C1, C2), 37.4 (C9), 31.3 (C10). Rf: 0.40 (17:3 petroleum ether: EtOAc). 
HR-MS: calcd for C16H14NO2S m/z: [M+H]
+; 284.074  found: 284.0739  [Diff (ppm) = -0.14]. 
IR (Neat): 1650 (C=O), 697 (C-S).  
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5.6.21 Synthesis of (phenylthio)methanamine 
 
 
AC019 (0.72 g , 2.54*10-3 mols, 1 eq) was dissolved in methanol. To this was added 0.29 ml 
(5.08*10-3 mols, 2 eq) of glacial acetic acid and 0.05 ml (0.01 mols, 4 eq) of hydrazine 
monohydrate. This was stirred for 4 hours at 65 0C. The resulting white solution was filtered 
to remove insoluble material. The filtrate was collected and the solvent removed under 
reduced pressure. The white solid was re dissolved in 500 ml ethyl acetate. An extraction 
was carried out with 150 mL of 2 M HCl. The aqueous layer was adjusted to pH 14 with 
NaOH and washed with ethyl acetate. The organic layer was dried with Na2SO4 and the 
solvent removed to yield the product as yellow oil which turned to a white solid on 
standing. Yield 77%.  
1H NMR (500 MHz, CDCl3) δ 7.27 (d, J = 7.2 Hz, 2H, H4, H5), 7.18 (t, J = 7.7 Hz, 2H, H6, H7), 
7.09 (t, J = 7.4 Hz, 1H, H8), 2.90 (t, J = 6.4 Hz, 2H, H3), 2.80 (t, J = 6.3 Hz, 2H, H2), 1.49 (s, 2H, 
H1). 13C NMR (126 MHz, CDCl3) δ 135.8 (C9), 129.7 (C4, C5), 129.0 (C6, C7), 126.2 (C8), 40.9 
(C2), 38.0 (C3). MP: 66-68 0C. Matches literature data.175 
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6.1  Conclusion 
 
Human nNOS is an enzyme of key biological importance. It produces NO which is involved 
in a plethora of neuronal signalling events. Over production of the free radical NO has been 
implicated in a number of serious neurological diseases. Partial inhibition of over active 
nNOS offers a potential therapeutic avenue for treatment of these debilitating conditions. 
The aim of this project was to make use of a range in silico techniques to identify novel 
human nNOS inhibitors. There is an over reliance on two key scaffolds for nNOS inhibition, 
namely modified arginines and 2-aminopyridines. The field is also overly focused on the use 
of rat nNOS for inhibition studies. This project aimed to move away from these scaffolds 
and from the rat isoform of the enzyme, and also aimed to be the first to use high 
throughput in silico screening methodologies for human nNOS inhibition. The project also 
attempted to co-express human calmodulin with human nNOS in E. coli cells, an approach 
not yet reported in the literature.  
A human nNOS homology model was successfully constructed and validated, and was then 
used to flexibly dock large commercial databases for potential inhibitory compounds. The 
binding poses of the top hit from this screen was examined in detail. The interactions which 
it formed with the human nNOS homology model binding site were largely in agreement 
with literature precedent. Some of the top hits from this screen were purchased, while 
others were synthesised. 
The synthesised compounds from the homology model screen were all novel, and 
contained a piperazine core. These were synthesised using epoxide ring opening, and 
nucleophilic attack on isocyanates and isothiocyanates. All targets from this class of 
compounds were successfully synthesised and were progressed for biological evaluation.     
The structure based design approach was complimented with a ligand based design 
approach. A pharmacophore was developed using the Chembl database. This 
pharmacophore was validated and used to screen commercial databases. Following assay 
testing of the initial pharmacophore hits, a second pharmacophore was generated. This 
included the experimentally validated inactive human nNOS inhibitors, identified from the 
initial pharmacophore and homology model, in the generation set. These represent one of 
the only reported sets of experimentally validated inactive human nNOS inhibitors. The 
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second pharmacophore was successfully validated and again used for commercial database 
screening. A range of compounds were purchased for biological evaluation from this 
screen. 
The publication of the human nNOS crystal structure late in this project’s life cycle allowed 
for comparisons to be drawn between the human nNOS homology model and the crystal 
structure. The homology model was found to be an accurate representation of the human 
nNOS binding site. The crystal structure was then used to screen commercial databases as 
before. A number of compounds from this screen were purchased, while others were 
synthesised. 
The synthetic targets from the nNOS crystal structure screen all contained a common urea 
motif. Synthesis of this motif was achieved via amine attack on isocyanates. The required 
isocyanate intermediates were synthesised via azide formation and Curtius’ 
rearrangement. Again, all synthetic targets were isolated and characterised and were taken 
forward for biological evaluation.   
Further compounds were designed by examination of the two most commonly reported 
structural motifs used in rat nNOS inhibition. A compound was designed that combined 
these two popular scaffolds, namely arginines and aminopyridines.  This was done in an 
attempt to exploit the inhibitor properties of both scaffolds, while retaining the selectivity 
of the 2-aminopyridine for the nNOS isoform. 
An assay system was established requiring the recombinant production of the three human 
NOS isoforms. The common literature approach to NOS inhibitor testing involves using rat 
NOS, bovine eNOS and murine iNOS. The establishment of an all human assay system 
would therefore be of great benefit to the field. The publication of the human nNOS crystal 
structure indicates that the field is moving in that direction, so the approach of this project 
was at the forefront of human nNOS inhibitor discovery.  
The DNA sequences of the three human NOS proteins were verified and E. coli cells were 
transformed with the DNA containing plasmids. Following extensive optimisation 
experiments for the expression of human nNOS, a new strategy was employed that aimed 
to co-express the human NOS enzymes with human calmodulin, a key co-factor for NOS 
function. Human nNOS was successfully co-expressed with human calmodulin, and the two 
were purified via affinity chromatography. Human eNOS and human iNOS were also 
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expressed with calmodulin, although their purification via affinity chromatography proved 
more challenging.  
An assay system was then established using the recombinant proteins. The recombinantly 
expressed human nNOS, the principle target of this work, was found to be active in the 
Griess assay. This assay system quantifies NOS activity by measuring the levels of nitrites 
which the enzyme produces. Treatment of active protein with Griess reagents resulted in 
the development of an intense purple colour, proving that the nNOS enzyme was active. 
The untreated protein produced higher levels of nitrites than the sample treated with the 
known NOS inhibitor, L-NNA. DMSO was also successfully identified as a suitable vehicle for 
compound delivery to the assay system. A dose response curve was constructed using the 
recombinantly produced human nNOS and L-NNA. The protein was seen to be inhibited 
more fully in the presence of higher L-NNA concentrations, and an IC50 value of 8.0 µM was 
determined.  
The assay system was then trialled using lysates containing human eNOS and human iNOS. 
While the proteins were seen to be functional, as evidenced by the appearance of a purple 
colour in the wells, the presence of large amounts of precipitated non-specific E. coli 
proteins interfered with the absorbance readings. This meant that the assay system could 
not accurately distinguish between treated and untreated eNOS and iNOS samples. 
In all, 72 compounds, some synthesised and others purchased, were evaluated for their 
inhibitory activity against human nNOS in the Griess assay. No in vitro hits were identified 
which emphasizes the challenging nature of this project, as does the fact that the literature 
is dominated by just two inhibitor classes. Several positive outcomes were achieved that 
will make a significant contribution to the field of nNOS inhibition. We now have, for the 
first time, a set of experimentally validated compounds that can be used as human nNOS 
inactives in future computational studies. This will allow for the development of more 
accurate models for nNOS inhibition. In addition, the first co-expression system for human 
nNOS with human calmodulin in E. coli cells has been developed. The use of E. coli as a host 
for this process is significant as it allows for rapid, inexpensive production of active human 
nNOS. The combination of this co-expression system with the Griess assay technology has 
resulted in the first high throughput co-expression/assay system for human nNOS inhibitor 
discovery.  
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6.2 Future work 
 
The computational models developed throughout this project are among the first of their 
kind for human nNOS. Further refinement of these models with the experimentally 
validated inactives would therefore be a potentially fruitful endeavour. The experimentally 
validated inactive human nNOS compounds are particularly useful for future 
pharmacophore studies.  
Development of a high throughput expression and assay system for of human iNOS and 
human eNOS would also be of benefit to the field. Both proteins have been expressed in 
this work and are functional, but the purification protocols require further optimisation. 
Potentially, size exclusion chromatography could be used to purify this isoforms. This could 
then result in an all human NOS assay system. Alternatively, the His-tags of eNOS and iNOS 
could be moved to their N termini to try and improve the performance of affinity 
chromatography purification with these isoforms. The size exclusion could also be applied 
to human nNOS so as to obtain 100% pure protein. This could then be used for 
crystallisation trails.  
Compounds 37 and 102 were seen to increase the level of NO production in human nNOS. 
Although this was not the aim of this project, these compounds may provide a mechanism 
for the study of nNOS over activation. The exact binding mode of these compounds with 
human nNOS could be elucidated by crystallization of human nNOS with compounds 37 
and 102 in situ.  
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8.1 Amino acids 
 
Table 8.1. Amino acid three letter and one letter codes. 
Amino Acid Three letter code One letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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Figure 8.1. Amino acid side chains. 
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8.2 Rat nNOS aligned with human nNOS 
 
Rat   MEENTFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA 
Human MEDHMFGVQQIQPNVISVRLFKRKVGGLGFLVKERVSKPPVIISDLIRGGAAEQSGLIQA 
      **:. ******************************************************* 
 
Rat   GDIILAVNDRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI 
Human GDIILAVNGRPLVDLSYDSALEVLRGIASETHVVLILRGPEGFTTHLETTFTGDGTPKTI 
      ******** *************************************************** 
 
Rat   RVTQPLGPPTKAVDLSHQPSASKDQSLAVDRVTGLGNGPQHAQGHGQGAGSVSQANGVAI 
Human RVTQPLGPPTKAVDLSHQPPAGKEQPLAVDGASGPGNGPQHAYDDGQEAGSLPHANGLAP 
      ******************* *.*:* **** .:* *******  .** ***: :***:*  
 
Rat   D-----PTMKSTKANLQDIGEHDELLKEIEPVLSILNSGSKATNRGGPAKAEMKDTGIQV 
Human RPPGQDPAKKATRVSLQGRGENNELLKEIEPVLSLLTSGSRGVKGGAPAKAEMKDMGIQV 
      *: *:*:..**  **.:***********:*.***:..: *.******** **** 
 
Rat   DRDLDGKSHKAPPLGGDNDRVFNDLWGKDNVPVILNNPYSEKEQSPTSGKQSPTKNGSPS 
Human DRDLDGKSHKPLPLGVENDRVFNDLWGKGNVPVVLNNPYSEKEQPPTSGKQSPTKNGSPS 
      **********  *** :*********** ****:********** *************** 
 
Rat   RCPRFLKVKNWETDVVLTDTLHLKSTLETGCTEHICMGSIMLPSQHTRKPEDVRTKDQLF 
Human KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF 
      :************:*******************:******* ****:*:******* *** 
 
Rat   PLAKEFLDQYYSSIKRFGSKAHMDRLEEVNKEIESTSTYQLKDTELIYGAKHAWRNASRC 
Human PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC 
      ******:****************:*********::************************* 
 
Rat   VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW 
Human VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW 
      ************************************************************ 
 
Rat   NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKAPRGRFDVLPLLLQANGNDPELFQ 
Human NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ 
      ************************************ *********************** 
 
Rat   IPPELVLEVPIRHPKFDWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV 
Human IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV 
      ****************:******************************************* 
 
Rat   RDYCDNSRYNILEEVAKKMDLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT 
Human RDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSAT 
      *******************:**************************************** 
 
Rat   ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV 
Human ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV 
      ************************************************************ 
 
 
 
Rat   WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE 
Human WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE 
      ************************************************************ 
 
Rat   IFKHAFDAKAMSMEEYDIVHLEHEALVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ 
Human IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ 
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      *********.**************:*********************************** 
 
Rat   EERKSYKVRFNSVSSYSDSRKSSGDGPDLRDNFESTGPLANVRFSVFGLGSRAYPHFCAF 
Human EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF 
      *******************:***************:************************ 
 
Rat   GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKPNN 
Human GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN 
      ********************************************************* ** 
 
Rat   SLISNDRSWKRNKFRLTYVAEAPDLTQGLSNVHKKRVSAARLLSRQNLQSPKFSRSTIFV 
Human SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV 
      *****************:*****:**************************** ******* 
 
Rat   RLHTNGNQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPANHVVKVEMLEERNTALGV 
Human RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV 
      ******.**********************************.*::****:********** 
 
Rat   ISNWKDESRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATNEKEKQRLLVLSKGLQEY 
Human ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY 
      ****.** **********************************.***************** 
 
Rat   EEWKWGKNPTMVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV 
Human EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV 
      **********:************************************************* 
 
Rat   SYHTRDGEGPVHHGVCSSWLNRIQADDVVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP 
Human SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP 
      **:*******:***************::******************************** 
 
Rat   FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE 
Human FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE 
      ************************************************************ 
 
Rat   PDRPKKYVQDVLQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSEE 
Human PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE 
      **:*******:*********************************************** * 
 
Rat   DAGVFISRLRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDADEVFSS 
Human DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS 
      ********:**************************************:****** 
 
8.3 Human nNOS construct aligned with published human nNOS sequence 
 
pQE30 forward primer; 
 
 
nNOS  FHTEFIKEEKLTMRGSHHHHHHGSACELGTMEDHMFGVQQIQPNVISVRLFKRKVGGLGF 60 
Pub   ------------------------------MEDHMFGVQQIQPNVISVRLFKRKVGGLGF 30 
                                    ****************************** 
 
nNOS  LVKERVSKPPVIISDLIRGGAAEQSGLIQAGDIILAVNGRPLVDLSYDSALEVLRGIASE 120 
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Pub   LVKERVSKPPVIISDLIRGGAAEQSGLIQAGDIILAVNGRPLVDLSYDSALEVLRGIASE 90 
      ************************************************************ 
 
nNOS  THVVLILRGPEGFTTHLETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPPAGKEQPLAVD 180 
Pub   THVVLILRGPEGFTTHLETTFTGDGTPKTIRVTQPLGPPTKAVDLSHQPPAGKEQPLAVD 150 
      ************************************************************ 
 
nNOS  GASGPGNGPQHAYDDGQEAGSLPHANGLAPRPPGQDPAKKATRVSLQGRGENNELLKEIE 240 
Pub   GASGPGNGPQHAYDDGQEAGSLPHANGLAPRPPGQDPAKKATRVSLQGRGENNELLKEIE 210 
      ************************************************************ 
 
nNOS  PVLSLLTSGSRGVKGGAPAKAEMKDMGIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGN 300 
Pub   PVLSLLTSGSRGVKGGAPAKAEMKDMGIQVDRDLDGKSHKPLPLGVENDRVFNDLWGKGN 270 
      ************************************************************ 
 
nNOS  VPVVLNNPYSEK------------------------------------------------ 312 
Pub   VPVVLNNPYSEKEQPPTSGKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETG 330 
      ************ 
 
 
Internal primer 1; 
nNOS   CPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF 59 
Pub   KCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVRTKGQLF 360 
      *********************************************************** 
 
nNOS  PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC 119 
Pub   PLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRC 420 
      ************************************************************ 
 
nNOS  VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW 179 
Pub   VGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVW 480 
      ************************************************************ 
 
nNOS  NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ 239 
Pub   NSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQ 540 
      ************************************************************ 
 
nNOS  IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLSSAP-------------- 285 
Pub   IPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGV 600 
      ****************************************** 
 
Internal primer 2; 
nNOS   ------------------------------SITPVFHQEMLNYRLTPSFEYQPDPWNTHV 30 
Pub    ESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHV 720 
                                     ****************************** 
 
nNOS   WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE 90 
Pub    WKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATETGKSQAYAKTLCE 780 
       ************************************************************ 
 
nNOS   IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ 150 
Pub    IFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGCALMEMRHPNSVQ 840 
       ************************************************************ 
 
nNOS   EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF 210 
Pub    EERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFGLGSRAYPHFCAF 900 
       ************************************************************ 
 
nNOS   GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN 270 
Pub    GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN 960 
       ************************************************************ 
 
nNOS   SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLL----------------- 313 
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Pub    SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV 1020 
       ******************************************* 
 
Internal primer 3; 
nNOS   ----------------------------GEAFRTWAKKVFKAACDVFCVGDDVNIEKANN 32 
Pub    GHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFCVGDDVNIEKANN 960 
                                    ******************************* 
 
nNOS   SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV 92 
Pub    SLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNLQSPKSSRSTIFV 1020 
       ************************************************************ 
 
nNOS   RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV 152 
Pub    RLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKVELLEERNTALGV 1080 
       ************************************************************ 
 
nNOS   ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY 212 
Pub    ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY 1140 
       ************************************************************ 
 
nNOS   EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV 272 
Pub    EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV 1200 
       ************************************************************ 
 
nNOS   SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGP------ 326 
Pub    SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP 1260 
       ****************************************************** 
 
pQE30 reverse primer; 
nNOS   --------------------------------------------KEKQRLLVLSKGLQEY 16 
Pub    ISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQRLLVLSKGLQEY 1140 
                                                   **************** 
 
nNOS   EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV 76 
Pub    EEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDMYPDEVHLTVAIV 1200 
       ************************************************************ 
 
nNOS   SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP 136 
Pub    SYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVPCILVGPGTGIAP 1260 
       ************************************************************ 
 
nNOS   FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYSEETLQAKNKGVFRELYTAYSRE 196 
Pub    FRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKGVFRELYTAYSRE 1320 
       ************************************* ********************** 
 
nNOS   PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE 256 
Pub    PDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQRIMTQQGKLSAE 1380 
       ************************************************************ 
 
nNOS   DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS 310 
Pub    DAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDTDEVFSS 1434 
       ****************************************************** 
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8.4 Human eNOS construct aligned with published human eNOS sequence 
 
pQE30 forward primer; 
eNOS   --------------------------MFTYICNHIKYATNRGNLRSAITVFPQRCPGRGD 34 
Pub    APRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGD 240 
                                 ********************************** 
 
eNOS   FRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPP 94 
Pub    FRIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPP 300 
       ************************************************************ 
 
eNOS   ELFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMST 154 
Pub    ELFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMST 360 
       ************************************************************ 
 
eNOS   EIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDH 214 
Pub    EIGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDH 420 
       ************************************************************ 
 
eNOS   HAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPW 274 
Pub    HAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPW 480 
       ************************************************************ 
 
eNOS   KGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVK--------------------- 313 
Pub    KGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGR 540 
       ***************************************        
 
Internal primer 1; 
eNOS    ------------------------------------TPVFHQEMVNYFLSPAFRYQPDPW 24 
Pub     HAATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPW 480 
                                            ************************ 
 
eNOS    KGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGR 84 
Pub     KGSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGR 540 
        ************************************************************ 
 
eNOS    LFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSS 144 
Pub     LFRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSS 600 
        ************************************************************ 
 
eNOS    PRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHF 204 
Pub     PRPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHF 660 
        ************************************************************ 
 
eNOS    CAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAA 264 
Pub     CAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAA 720 
        ************************************************************ 
 
eNOS    RDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMF--------------------- 303 
Pub     RDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATIL 780 
        *************************************** 
 
 
Internal primer 2; 
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eNOS    -----------GGLGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAA 49 
Pub     CAFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAA 720 
                   ************************************************* 
 
 
eNOS   RDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATIL 109 
Pub    RDIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATIL 780 
       ************************************************************ 
 
eNOS   VRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGP 169 
Pub    VRLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGP 840 
       ************************************************************ 
 
eNOS   PPGWVRDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRY 229 
Pub    PPGWVRDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRY 900 
       ************************************************************ 
 
 
 
eNOS   EEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVL 289 
Pub    EEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVL 960 
       ************************************************************ 
 
eNOS   AYRTHDGLGPLHYGVCSTWLSQLKPGRP-------------------------------- 317 
Pub    AYRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAP 1020 
       **** ********************* * 
 
Internal primer 3; 
eNOS   ---------TLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVL 51 
Pub    EEWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVL 960 
                *************************************************** 
 
eNOS   AYRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAP 111 
Pub    AYRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAP 1020 
       ************************************************************ 
 
eNOS   FRGFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSRE 171 
Pub    FRGFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSRE 1080 
       ************************************************************ 
 
eNOS   PDNPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELD 231 
Pub    PDNPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELD 1140 
       ************************************************************ 
 
eNOS   EAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDT 291 
Pub    EAGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDT 1200 
       ************************************************************ 
 
eNOS   NSPHHHHHH 300 
Pub    NSP------ 1203 
       ***       
 
8.5 Human iNOS construct aligned with published human iNOS sequence 
 
pQE30 forward primer; 
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iNOS   ADNNYNRFNCERITISHRIDLEMACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSP 60 
Pub    ----------------------MACPWKFLFKTKFHQYAMNGEKDINNNVEKAPCATSSP 38 
                             ************************************** 
iNOS   VTQDDLQYHNLSKQQNESPQPLVETGKKSPESLVKLDATPLSSPRHVRIKNWGSGMTFQD 120 
Pub    VTQDDLQYHNLSKQQNESPQPLVETGKKSPESLVKLDATPLSSPRHVRIKNWGSGMTFQD 98 
       ************************************************************ 
iNOS   TLHHKAKGILTCRSKSCLGSIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAK 180 
Pub    TLHHKAKGILTCRSKSCLGSIMTPKSLTRGPRDKPTPPDELLPQAIEFVNQYYGSFKEAK 158 
       ************************************************************ 
iNOS   IEEHLARVEAVTKEIETTGTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCS 240 
Pub    IEEHLARVEAVTKEIETTGTYQLTGDELIFATKQAWRNAPRCIGRIQWSNLQVFDARSCS 218 
       ************************************************************ 
iNOS   TAREMFEHICRHVRYSTNNGNIRSAII--------------------------------- 267 
Pub    TAREMFEHICRHVRYSTNNGNIRSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIR 278 
       ************************** 
 
Internal primer 1; 
 
iNOS  ------------WQHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWKPKYG 48 
Pub   RSAITVFPQRSDGKHDFRVWNAQLIRYAGYQMPDGSIRGDPANVEFTQLCIDLGWKPKYG 300 
                    ********************************************** 
 
iNOS  RFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVG 108 
Pub   RFDVVPLVLQANGRDPELFEIPPDLVLEVAMEHPKYEWFRELELKWYALPAVANMLLEVG 360 
      ************************************************************ 
 
iNOS  GLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINI 168 
Pub   GLEFPGCPFNGWYMGTEIGVRDFCDVQRYNILEEVGRRMGLETHKLASLWKDQAVVEINI 420 
      ************************************************************ 
 
iNOS  AVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGCPADWIWLVPPMSGSITPVFHQEM 228 
Pub   AVLHSFQKQNVTIMDHHSAAESFMKYMQNEYRSRGGCPADWIWLVPPMSGSITPVFHQEM 480 
      ************************************************************ 
 
iNOS  LNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVRVT 288 
Pub   LNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVRVT 540 
      ************************************************************ 
 
iNOS  ILFATETGKSEALAWGPGGLIQLCLQPQ---------GCLHG------------------ 321 
Pub   ILFATETGKSEALAWDLGALFSCAFNPKVVCMDKYRLSCLEEERLLLVVTSTFGNGDCPG 600 
      *************** 
 
Internal primer 2; 
 
iNOS  ------------------------------------SLGQAVLFACMLMRKTMASRVRVT 24 
Pub   LNYVLSPFYYYQVEAWKTHVWQDEKRRPKRREIPLKVLVKAVLFACMLMRKTMASRVRVT 540 
                                              ******************** 
 
iNOS  ILFATETGKSEALAWDLGALFSCAFNPKVVCMDKYRLSCLEEERLLLVVTSTFGNGDCPG 84 
Pub   ILFATETGKSEALAWDLGALFSCAFNPKVVCMDKYRLSCLEEERLLLVVTSTFGNGDCPG 600 
      ************************************************************ 
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iNOS  NGEKLKKSLFMLKELNNKFRYAVFGLGSSMYPRFCAFAHDIDQKLSHLGASQLTPMGEGD 144 
Pub   NGEKLKKSLFMLKELNNKFRYAVFGLGSSMYPRFCAFAHDIDQKLSHLGASQLTPMGEGD 660 
      ************************************************************ 
 
 
 
iNOS  ELSGQEDAFRSWAVQTFKAACETFDVRGKQHIQIPKLYTSNVTWDPHHYRLVQDSQPLDL 204 
Pub   ELSGQEDAFRSWAVQTFKAACETFDVRGKQHIQIPKLYTSNVTWDPHHYRLVQDSQPLDL 720 
      ************************************************************ 
 
iNOS  SKALSSMHAKNVFTMRLKSRQNLQSPTSSRATILVELSCEDGQGLNYLPGEHLGVCPGNQ 264 
Pub   SKALSSMHAKNVFTMRLKSRQNLQSPTSSRATILVELSCEDGQGLNYLPGEHLGVCPGNQ 780 
      ************************************************************ 
 
iNOS  PALVQGILS--------------------------------------------------- 279 
Pub   PALVQGILERVVDGPTPHQTVRLEALDESGSYWVSDKRLPPCSLSQALTYFLDITTPPTQ 840 
      ******** 
 
pQE30 reverse primer; 
iNOS   ------------------LEALCQPSEYSKWKFTNSPTFLEVLEEFPSLRVSAGFLLSQL 42 
Pub    LLLQKLAQVATEEPERQRLEALCQPSEYSKWKFTNSPTFLEVLEEFPSLRVSAGFLLSQL 900 
                         ****************************************** 
 
iNOS   PILKPRFYSISSSRDHTPTEIHLTVAVVTYHTRDGQGPLHHGVCSTWLNSLKPQDPVPCF 102 
Pub    PILKPRFYSISSSRDHTPTEIHLTVAVVTYHTRDGQGPLHHGVCSTWLNSLKPQDPVPCF 960 
       ************************************************************ 
 
iNOS   VRNASGFHLPEDPSHPCILIGPGTGIAPFRSFWQQRLHDSQHKGVRGGRMTLVFGCRRPD 162 
Pub    VRNASGFHLPEDPSHPCILIGPGTGIAPFRSFWQQRLHDSQHKGVRGGRMTLVFGCRRPD 1020 
       ************************************************************ 
 
iNOS   EDHIYQEEMLEMAQKGVLHAVHTAYSRLPGKPKVYVQDILRQQLASEVLRVLHKEPGHLY 222 
Pub    EDHIYQEEMLEMAQKGVLHAVHTAYSRLPGKPKVYVQDILRQQLASEVLRVLHKEPGHLY 1080 
       ************************************************************ 
 
iNOS   VCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSQKRYHEDIFGAVFPYEAKKDR 282 
Pub    VCGDVRMARDVAHTLKQLVAAKLKLNEEQVEDYFFQLKSQKRYHEDIFGAVFPYEAKKDR 1140 
       ************************************************************ 
 
iNOS   VAVQPSSLEMSALHHHHHH 301 
Pub    VAVQPSSLEMSAL------ 1153 
       *************       
 
8.6 Human calmodulin construct aligned with published human calmodulin 
sequence 
 
T7 promotor primer; 
CaM   MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADG 
Pub   MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADG 
      ************************************************************ 
 
CaM   NGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDE 
Pub   NGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDE 
      ************************************************************ 
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CaM   EVDEMIREADIDGDGQVNYEEFVQMMTAK 
Pub   EVDEMIREADIDGDGQVNYEEFVQMMTAK 
      ***************************** 
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